US20160220417A1 - Methods and devices for increasing aqueous humor outflow - Google Patents
Methods and devices for increasing aqueous humor outflow Download PDFInfo
- Publication number
- US20160220417A1 US20160220417A1 US15/012,544 US201615012544A US2016220417A1 US 20160220417 A1 US20160220417 A1 US 20160220417A1 US 201615012544 A US201615012544 A US 201615012544A US 2016220417 A1 US2016220417 A1 US 2016220417A1
- Authority
- US
- United States
- Prior art keywords
- canal
- implant
- schlemm
- ocular implant
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000001742 aqueous humor Anatomy 0.000 title claims description 61
- 238000000034 method Methods 0.000 title claims description 42
- 239000007943 implant Substances 0.000 claims abstract description 468
- 210000002159 anterior chamber Anatomy 0.000 claims abstract description 61
- 239000012530 fluid Substances 0.000 claims description 47
- 238000004891 communication Methods 0.000 claims description 30
- 210000001519 tissue Anatomy 0.000 claims description 21
- 208000010412 Glaucoma Diseases 0.000 claims description 18
- 210000001747 pupil Anatomy 0.000 claims description 14
- 238000002513 implantation Methods 0.000 claims description 9
- 230000004323 axial length Effects 0.000 claims description 4
- 210000001508 eye Anatomy 0.000 description 127
- 210000001585 trabecular meshwork Anatomy 0.000 description 31
- 238000005452 bending Methods 0.000 description 24
- 210000004087 cornea Anatomy 0.000 description 21
- 230000004410 intraocular pressure Effects 0.000 description 20
- 230000010339 dilation Effects 0.000 description 13
- 238000004088 simulation Methods 0.000 description 13
- 210000004240 ciliary body Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- -1 poly(vinylpyrrolidone) Polymers 0.000 description 6
- 239000002699 waste material Substances 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000000284 resting effect Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000013178 mathematical model Methods 0.000 description 4
- 229910001000 nickel titanium Inorganic materials 0.000 description 4
- 210000003786 sclera Anatomy 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 210000004127 vitreous body Anatomy 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009998 heat setting Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 2
- 206010052114 Conjunctival bleb Diseases 0.000 description 2
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 2
- 229910045601 alloy Inorganic materials 0.000 description 2
- 239000000956 alloy Substances 0.000 description 2
- 230000001384 anti-glaucoma Effects 0.000 description 2
- 230000001886 ciliary effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
- 238000003698 laser cutting Methods 0.000 description 2
- 239000007769 metal material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 229920001515 polyalkylene glycol Polymers 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229910010380 TiNi Inorganic materials 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- HZEWFHLRYVTOIW-UHFFFAOYSA-N [Ti].[Ni] Chemical compound [Ti].[Ni] HZEWFHLRYVTOIW-UHFFFAOYSA-N 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000005043 peripheral vision Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000012781 shape memory material Substances 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
Definitions
- the present invention relates generally to devices that are implanted within the eye. More particularly, the present invention relates to devices that facilitate the transfer of fluid from within one area of the eye to another area of the eye.
- glaucoma is now the leading cause of irreversible blindness worldwide and the second leading cause of blindness, behind cataract, in the world.
- NHIH National Eye Institute
- Glaucoma researchers have found a strong correlation between high intraocular pressure and glaucoma. For this reason, eye care professionals routinely screen patients for glaucoma by measuring intraocular pressure using a device known as a tonometer. Many modern tonometers make this measurement by blowing a sudden puff of air against the outer surface of the eye.
- the eye can be conceptualized as a ball filled with fluid.
- fluid There are two types of fluid inside the eye.
- the cavity behind the lens is filled with a viscous fluid known as vitreous humor.
- the cavities in front of the lens are filled with a fluid know as aqueous humor. Whenever a person views an object, he or she is viewing that object through both the vitreous humor and the aqueous humor.
- the cornea and the lens can include no blood vessels. Accordingly, no blood flows through the cornea and the lens to provide nutrition to these tissues and to remove wastes from these tissues. Instead, these functions are performed by the aqueous humor.
- a continuous flow of aqueous humor through the eye provides nutrition to portions of the eye (e.g., the cornea and the lens) that have no blood vessels. This flow of aqueous humor also removes waste from these tissues.
- Aqueous humor is produced by an organ known as the ciliary body.
- the ciliary body includes epithelial cells that continuously secrete aqueous humor.
- a stream of aqueous humor flows out of the anterior chamber of the eye through the trabecular meshwork and into Schlemm's canal as new aqueous humor is secreted by the epithelial cells of the ciliary body.
- This excess aqueous humor enters the venous blood stream from Schlemm's canal and is carried along with the venous blood leaving the eye.
- shunts were implanted to direct aqueous humor from the anterior chamber to the extraocular vein (Lee and Scheppens, “Aqueous-venous shunt and intraocular pressure,” Investigative Ophthalmology (February 1966)).
- Other early glaucoma treatment implants led from the anterior chamber to a sub-conjunctival bleb (e.g., U.S. Pat. No. 4,968,296 and U.S. Pat. No. 5,180,362).
- an ocular implant comprising a longitudinally extending body having an inlet portion and a Schlemm's canal portion distal to the inlet portion, the inlet portion being configured to extend into and be in fluid communication with an anterior chamber of a human eye and the Schlemm's canal portion being configured to be inserted into Schlemm's canal adjacent to collector channels of the eye, a plurality of alternating spines and frames positioned longitudinally along at least a portion of the Schlemm's canal portion wherein the plurality of alternating spines and frames define a central channel extending therethrough, with the central channel being in fluid communication with the inlet portion, each of the spines having edges partially defining an opening across from the central channel and in fluid communication with the central channel, and each of the frames including first and second struts, the first and second struts each having an edge contiguous with an edge of an adjacent spine, the edges defining the opening in fluid communication with the central channel, wherein the ocular implant is configured to provide at least a 121% increase in average out
- the implant comprises at least three openings across from the central channel.
- the average outflow facility comprises 0.438 ⁇ l/min/mmHg.
- a peak circumferential flow rate through the ocular implant comprises 3.2 ⁇ l/min.
- the implant comprises at least six openings across from the central channel.
- the average outflow facility comprises 0.638 ⁇ l/min/mmHg.
- a peak circumferential flow rate through the ocular implant comprises 5.7 ⁇ l/min.
- the average outflow facility of the eye prior to implantation of the ocular implant comprises 0.138 ⁇ l/min/mmHg.
- An ocular implant adapted to reside at least partially in a portion of Schlemm's canal of an eye adjacent to collector channels of the eye
- the implant comprising a longitudinally extending curved body including a proximal portion and a distal portion, the distal portion of the curved body defining a longitudinal channel including a channel opening, and the curved body being adapted and configured such that the distal portion of the curved body resides in Schlemm's canal and the proximal portion extends into the anterior space of the eye while the ocular implant assumes an orientation in which the channel opening is adjacent a major side of Schlemm's canal when the ocular implant is implanted, wherein the ocular implant is configured to provide a 121%-222% increase in average outflow facility of aqueous humor from the anterior chamber through the collector channels of the eye.
- the implant comprises at least three openings across from the central channel.
- the average outflow facility comprises 0.438 ⁇ l/min/mmHg.
- a peak circumferential flow rate through the ocular implant comprises 3.2 ⁇ l/min.
- the implant comprises at least six openings across from the central channel.
- the average outflow facility comprises 0.638 ⁇ l/min/mmHg.
- a peak circumferential flow rate through the ocular implant comprises 5.7 ⁇ l/min.
- the average outflow facility of the eye prior to implantation of the ocular implant comprises 0.138 ⁇ l/min/mmHg.
- the distal portion of the curved body occupies up to 20% of Schlemm's canal but accounts for up to 54.5% of total outflow in the eye.
- the distal portion of the curved body occupies up to 40% of Schlemm's canal but accounts for up to 74.6% of total outflow in the eye.
- An ocular implant comprising an inlet portion and a Schlemm's canal portion distal to the inlet portion, the inlet portion being disposed at a proximal end of the implant and sized and configured to be placed within an anterior chamber of a human eye, the inlet portion having an inlet adapted to be in fluid communication with the anterior chamber, the Schlemm's canal portion comprising a central channel in fluid communication with the inlet, the central channel extending longitudinally in the Schlemm's canal portion, a first element disposed along the central channel, a second element disposed along the central channel distal to the first element, a third element disposed along the central channel distal to the first element and proximal to the second, a fourth element disposed along the central channel distal to the second element, the first, second, third and fourth elements each comprising two edges partially defining an elongate opening in fluid communication with the central channel, each of the first, second, third and fourth elements having circumferential extents less than 360 degrees so that the elongate opening extends
- the implant comprises at least three openings across from the central channel.
- the average outflow facility comprises 0.438 ⁇ l/min/mmHg.
- a peak circumferential flow rate through the ocular implant comprises 3.2 ⁇ l/min.
- the implant comprises at least six openings across from the central channel.
- the average outflow facility comprises 0.638 ⁇ l/min/mmHg.
- a peak circumferential flow rate through the ocular implant comprises 5.7 ⁇ l/min.
- the average outflow facility of the eye prior to implantation of the ocular implant comprises 0.138 ⁇ l/min/mmHg.
- the distal portion of the curved body occupies up to 20% of Schlemm's canal but accounts for up to 54.5% of total outflow in the eye.
- the distal portion of the curved body occupies up to 40% of Schlemm's canal but accounts for up to 74.6% of total outflow in the eye.
- a method of treating glaucoma comprising supporting tissue forming Schlemm's canal in an eye with an implant extending at least partially in the canal along an axial length within the canal, contacting with the implant less than 50% of the tissue forming the canal along the axial length, disposing an inlet portion of the implant in an anterior chamber of the eye, and providing fluid communication between the anterior chamber and the canal axially through the inlet into a channel of the implant such that an average outflow facility between the anterior chamber and the canal is increased by 121%-222%, and wherein the implant comprises open areas separated by spine areas along a first longitudinal section, the spine areas partially defining the channel, the supporting step comprising orienting the first longitudinal section openings towards a trabecular mesh portion of the canal.
- An ocular implant adapted to reside at least partially in a portion of Schlemm's canal of a human eye
- the implant comprising a body configured to extend within Schlemm's canal in a curved volume having a large radius side and a short radius side, the body having a circumferential extent within the curved volume that varies along the length of the body between sections having a lesser circumferential extent and sections having a greater circumferential extent, wherein the body defines a channel extending longitudinally through the body, the channel having a substantially open side disposed on the large radius side at one of the sections of lesser circumferential extent and an adjacent section of greater circumferential extent and a plurality of openings along the length of the body on the short radius side, the openings being in fluid communication with the channel, and an inlet portion configured to be disposed in an anterior chamber of the eye when the body is in Schlemm's canal, the inlet portion disposed on a proximal end of the body in fluid communication with the channel, the inlet portion defining one or more openings
- An ocular implant adapted to reside at least partially in a portion of Schlemm's canal of an eye, the eye having an iris defining a pupil
- the implant comprising a longitudinally extending curved body including a proximal portion and a distal portion, the distal portion of the curved body having a central longitudinal axis defined by a radius of curvature and a lateral cross section having a first lateral extent and a second lateral extent, an aspect ratio of the first lateral extent to the second lateral extent being greater than or equal to about two, the distal portion of the curved body defining a longitudinal channel including a channel opening, the channel opening included in defining the first lateral extent, the curved body being adapted and configured such that the distal portion of the curved body resides in Schlemm's canal and the proximal portion extends into the anterior space of the eye while the ocular implant assumes an orientation in which the channel opening is adjacent a major side of Schlemm's canal when the ocular implant is implanted
- FIG. 1 is a stylized perspective view depicting a portion of a human eye and a portion of an ocular implant disposed in Schlemm's canal.
- FIG. 2 is an enlarged perspective view showing a portion of the implant of FIG. 1 .
- FIG. 3 is a perspective view showing a volume defined by the body of the ocular implant of FIGS. 1 and 2 .
- FIG. 4 is a perspective view showing a first plane intersecting the body of an ocular implant.
- FIG. 5 is a perspective view showing a bending moment being applied to an ocular implant.
- FIG. 6 is a plan view of the implant shown in FIG. 5 but in the absence of any bending moment.
- FIG. 7A is a lateral cross-sectional view of the ocular implant of FIG. 6 taken along section line A-A of FIG. 6 .
- FIG. 7B is a lateral cross-sectional view of the ocular implant of FIG. 6 taken along section line B-B of FIG. 6 .
- FIG. 8 is an enlarged cross-sectional view of the ocular implant of FIG. 6 taken along section line B-B of FIG. 6 .
- FIG. 9 is an enlarged cross-sectional view of the ocular implant of FIG. 6 taken along section line A-A of FIG. 6 .
- FIG. 10 is a plan view showing an ocular implant according to another embodiment of the invention having a longitudinal radius of curvature that varies along its length.
- FIG. 11 is a perspective view showing an ocular implant according to yet another embodiment of the invention that has substantially no radius of curvature.
- FIG. 12 is a stylized representation of a medical procedure in accordance with this detailed description.
- FIG. 13A is a perspective view further illustrating a delivery system 100 used in the medical procedure shown in the previous Figure.
- FIG. 13B is an enlarged detail view further illustrating a cannula of the delivery system shown in the previous Figure.
- FIG. 14 is a stylized perspective view illustrating the anatomy of an eye.
- FIG. 15 is a stylized perspective view showing Schlemm's canal and an iris of the eye shown in the previous Figure.
- FIG. 16 is an enlarged cross-sectional view further illustrating Schlemm's canal SC shown in the previous Figure.
- FIG. 17 is a perspective view showing an ocular implant in accordance with this detailed description.
- FIG. 18A and FIG. 18B are section views showing an ocular implant disposed in Schlemm's canal of an eye.
- FIG. 19A , FIG. 19B and FIG. 19C are multiple plan views illustrating an implant in accordance with the present detailed description.
- FIG. 20 is a lateral cross-sectional view of an ocular implant taken along section line A-A shown in the previous Figure.
- FIG. 21A is a perspective view of an ocular implant and FIG. 21B is a stylized perspective view showing Schlemm's canal SC encircling an iris.
- FIG. 22A is a perspective view showing a delivery system 12100 that may be used to advance an ocular implant into Schlemm's canal of an eye.
- FIG. 22B is an enlarged detail view illustrating a cannula portion of the delivery system.
- FIG. 23 is an enlarged perspective view of an assembly including a cannula, an ocular implant, and a sheath.
- FIG. 24 is an additional perspective view of the assembly shown in the previous Figure.
- FIG. 25 is another perspective view of an assembly including a cannula, an ocular implant, and a sheath.
- FIG. 26 is an additional perspective view of the assembly shown in the previous Figure.
- FIG. 27A and FIG. 27B are perspective views showing a sheath in accordance with the present detailed description.
- FIG. 28 is a perspective view of an assembly including the sheath shown in the previous Figure.
- FIG. 29A and FIG. 29B are simplified plan views showing a sheath in accordance with the present detailed description.
- FIG. 30A , FIG. 30B and FIG. 30C are plan views showing an implant in accordance with the present detailed description.
- FIG. 31 is a lateral cross-sectional view of an ocular implant taken along section line A-A shown in the previous Figure.
- FIG. 32 is a plan view showing an implant in accordance with the present detailed description.
- FIG. 33A , FIG. 33B and FIG. 33C are plan views showing an additional implant in accordance with the present detailed description.
- FIG. 34 is a lateral cross-sectional view of an ocular implant taken along section line B-B shown in the previous Figure.
- FIG. 35 is a plan view showing an implant in accordance with the present detailed description.
- FIG. 36A through FIG. 36D are a series of plan views illustrating a method in accordance with the present detailed description.
- FIG. 37A through FIG. 37D are a series of section views illustrating a method in accordance with the present detailed description.
- FIG. 38A and FIG. 38B are simplified plan views showing a sheath in accordance with the present detailed description.
- FIG. 39 is a diagram showing the results of mathematical simulations of 8 mm and 16 mm ocular implants.
- FIG. 40 is a diagram showing circumferential flow rates for 8 mm and 16 mm ocular implants.
- FIG. 1 is a stylized perspective view depicting a portion of a human eye 20 .
- Eye 20 can be conceptualized as a fluid filled ball having two chambers.
- Sclera 22 of eye 20 surrounds a posterior chamber 24 filled with a viscous fluid known as vitreous humor.
- Cornea 26 of eye 20 encloses an anterior chamber 30 that is filled with a fluid know as aqueous humor.
- the cornea 26 meets the sclera 22 at a limbus 28 of eye 20 .
- a lens 32 of eye 20 is located between anterior chamber 30 and posterior chamber 24 . Lens 32 is held in place by a number of ciliary zonules 34 .
- the cornea and the lens can include no blood vessels. Accordingly, no blood flows through the cornea and the lens to provide nutrition to these tissues and to remove wastes from these tissues. Instead, these functions are performed by the aqueous humor.
- a continuous flow of aqueous humor through the eye provides nutrition to portions of the eye (e.g., the cornea and the lens) that have no blood vessels. This flow of aqueous humor also removes waste from these tissues.
- Aqueous humor is produced by an organ known as the ciliary body.
- the ciliary body includes epithelial cells that continuously secrete aqueous humor.
- a stream of aqueous humor flows out of the eye as new aqueous humor is secreted by the epithelial cells of the ciliary body. This excess aqueous humor enters the blood stream and is carried away by venous blood leaving the eye.
- aqueous humor flows out of the anterior chamber 30 through the trabecular meshwork 36 and into Schlemm's canal 38 , located at the outer edge of the iris 42 .
- Aqueous humor exits Schlemm's canal 38 by flowing through a number of outlets 40 . After leaving Schlemm's canal 38 , aqueous humor is absorbed into the venous blood stream.
- an ocular implant 100 is disposed in Schlemm's canal 38 of eye 20 .
- Ocular implant 100 has a body 102 including a plurality of tissue supporting frames 104 and a plurality of spines 106 .
- Body 102 also includes a first edge 120 and a second edge 122 that define a first opening 124 .
- First opening 124 is formed as a slot and fluidly communicates with an elongate channel 126 defined by an inner surface 128 of body 102 .
- first opening 124 is disposed on an outer side 130 of body 102 . Accordingly, channel 126 opens in a radially outward direction 132 via first opening 124 .
- Ocular implant 100 may be inserted into Schlemm's canal of a human eye to facilitate the flow of aqueous humor out of the anterior chamber. This flow may include axial flow along Schlemm's canal, flow from the anterior chamber into Schlemm's canal, and flow leaving Schlemm's canal via outlets communicating with Schlemm's canal.
- ocular implant 100 When in place within the eye, ocular implant 100 will support trabecular mesh tissue and Schlemm's canal tissue and will provide for improved communication between the anterior chamber and Schlemm's canal (via the trabecular meshwork) and between pockets or compartments along Schlemm's canal. As shown in FIG. 1 , the implant is preferably oriented so that the first opening 124 is disposed radially outwardly within Schlemm's canal.
- FIG. 2 is an enlarged perspective view showing a portion of ocular implant 100 shown in the previous figure.
- Ocular implant 100 has a body 102 that extends along a generally curved longitudinal axis 134 .
- Body 102 has a plurality of tissue supporting frames 104 and a plurality of spines 106 . As shown in FIG. 2 , these spines 106 and frames 104 are arranged in a repeating AB pattern in which each A is a tissue supporting frame and each B is a spine. In the embodiment of FIG. 2 , one spine extends between each adjacent pair of frames 104
- the frames 104 of body 102 include a first frame 136 of ocular implant 100 that is disposed between a first spine 140 and a second spine 142 .
- first frame 136 is formed as a first strut 144 that extends between first spine 140 and second spine 142 .
- First frame 136 also includes a second strut 146 extending between first spine 140 and second spine 142 .
- each strut undulates in a circumferential direction as it extends longitudinally between first spine 140 and second spine 142 .
- body 102 has a longitudinal radius 150 and a lateral radius 148 .
- Body 102 of ocular implant 100 includes a first edge 120 and a second edge 122 that define a first opening 124 .
- First opening 124 fluidly communicates with an elongate channel 126 defined by an inner surface 128 of body 102 .
- a second opening 138 is defined by a second edge 122 A of a first strut 144 and a second edge 122 B of a second strut 146 .
- First opening 124 , second opening 138 and additional openings defined by ocular implant 100 allow aqueous humor to flow laterally across and/or laterally through ocular implant 100 .
- the outer surfaces of body 102 define a volume 152 .
- FIG. 3 is an additional perspective view showing volume 152 defined by the body of the ocular implant shown in the previous figure.
- volume 152 extends along a generally curved longitudinal axis 134 .
- Volume 152 has a longitudinal radius 150 , a lateral radius 148 , and a generally circular lateral cross section 153 .
- FIG. 4 is a perspective view showing a first plane 154 and a second plane 155 that both intersect ocular implant 100 .
- first plane 154 is delineated with hatch marks.
- spines 106 of body 102 are generally aligned with one another and that first plane 154 intersects all spines 106 shown in FIG. 4 .
- body 102 of ocular implant 100 is generally symmetric about first plane 154 .
- the flexibility of body 102 is at a maximum when body 102 is bending along first plane 154 , and body 102 has less flexibility when bending along a plane other than first plane 154 (e.g., a plane that intersects first plane 154 ).
- body 102 has a second flexibility when bending along second plane 155 that is less than the first flexibility that body 102 has when bending along first plane 154 .
- the bending modulus of body 102 is at a minimum when body 102 is bent along first plane 154 .
- Body 102 has a first bending modulus when bent along first plane 154 and a greater bending modulus when bent along a plane other than first plane 154 (e.g., a plane that intersects first plane 154 ).
- body 102 has a second bending modulus when bent along second plane 155 that is greater than the first bending modulus that body 102 has when bent along first plane 154 .
- FIG. 5 is an enlarged perspective view showing a portion of ocular implant 100 shown in the previous figure.
- a bending moment M is being applied to body 102 of ocular implant 100 .
- Bending moment M acts about a first axis 156 that is generally orthogonal to first plane 154 .
- a second axis 158 and a third axis 160 are also shown in FIG. 5 .
- Second axis 158 is generally perpendicular to first axis 156 .
- Third axis 160 is skewed relative to first axis 156 .
- Body 102 of ocular implant 100 includes a first edge 120 and a second edge 123 that define a first opening 124 .
- Channel 126 of ocular implant 100 fluidly communicates with first opening 124 .
- a second opening 138 is defined by a second edge 122 A of a first strut 144 and a second edge 122 B of a second strut 146 .
- First opening 124 , second opening 138 and additional openings defined by ocular implant 100 allow aqueous humor to flow laterally across and/or laterally through ocular implant 100 .
- ocular implant 100 has a first spine 140 and a second spine 142 .
- First strut 144 and a second strut 146 form a first frame 136 of ocular implant 100 that extends between first spine 140 and second spine 142 .
- each strut undulates in a circumferential direction as it extends longitudinally between first spine 140 and second spine 142 .
- the flexibility of body 102 is at a maximum when body 102 is bent by a moment acting about first axis 156 , and body 102 has less flexibility when bent by a moment acting about an axis other than first axis 156 (e.g., second axis 158 and third axis 160 ).
- the bending modulus of body 102 is at a minimum when body 102 is bent by a moment acting about first axis 156 , and body 102 has a greater bending modulus when bent by a moment acting about an axis other than first axis 156 (e.g., second axis 158 and third axis 160 ).
- FIG. 6 is a plan view showing ocular implant 100 shown in the previous figure.
- body 102 defines a first opening 124 that is disposed on an outer side 130 of body 102 .
- a channel 126 is defined by the inner surface of body 102 and opens in a radially outward direction 132 via first opening 124 .
- Section lines A-A and B-B are visible in FIG. 6 .
- Section line A-A intersects a first frame 136 of ocular implant 100 .
- Section line B-B intersects a first spine 140 of ocular implant 100 .
- FIG. 7A is a lateral cross-sectional view of ocular implant 100 taken along section line A-A shown in the previous figure.
- Section line A-A intersects a first strut 144 and a second strut 146 of first frame 136 at the point where the circumferential undulation of these struts is at its maximum.
- Body 102 of ocular implant 100 has a longitudinal radius 150 and a lateral radius 148 .
- An inner surface 128 of body 102 defines a channel 126 .
- a first opening 124 fluidly communicates with channel 126 .
- first opening 124 in body 102 can be seen extending between first edge 120 A of first strut 144 and a first edge 120 B of second strut 146 .
- second strut 146 has a shape that is a mirror image of the shape of first strut 144 .
- FIG. 7B is a lateral cross-sectional view of ocular implant 100 taken along section line B-B shown in the previous figure. Section line B-B intersects first spine 140 of ocular implant 100 .
- Body 102 has a longitudinal radius 150 and a lateral radius 148 .
- the center 159 of lateral radius 148 and the center 163 of longitudinal radius 150 are disposed on opposite sides of first spine 140 .
- the center 159 of lateral radius 148 is disposed on a first side of first spine 140 .
- the center 163 of longitudinal radius 150 is disposed on a second side of second spine 142 .
- FIG. 8 is an enlarged cross-sectional view of ocular implant 100 taken along section line B-B of FIG. 6 .
- First spine 140 includes a first major side 160 , a second major side 162 , a first minor side 164 , and second minor side 166 .
- first major side 160 comprises a concave surface 168 .
- Second major side 162 is opposite first major side 160 .
- second major side 162 comprises a convex surface 170 .
- first spine 140 has a thickness T 1 extending between first major side 160 and second major side 162 . Also in the embodiment of FIG. 8 , first spine 140 has a width W 1 extending between first minor side 164 and second minor side 166 .
- the spine of an ocular implant in accordance with this detailed description has an aspect ratio of width W 1 to thickness T 1 greater than about 2. In some particularly useful embodiments, the spine of an ocular implant in accordance with this detailed description has an aspect ratio of width W 1 to thickness T 1 greater than about 4. In one useful embodiment, the ocular implant has a spine with an aspect ratio of width W 1 to thickness T 1 of about 5.2.
- a first axis 156 , a second axis 158 and a third axis 160 are shown in FIG. 8 .
- Second axis 158 is generally perpendicular to first axis 156 .
- Third axis 160 is skewed relative to first axis 156 .
- first spine 140 is at a maximum when first spine 140 is bent by a moment acting about first axis 156 .
- First spine 140 has a first flexibility when bent by a moment acting about first axis 156 and less flexibility when bent by a moment acting about an axis other than first axis 156 (e.g., second axis 158 and third axis 160 ).
- first spine 140 has a second flexibility when bent by a moment acting about second axis 158 shown in FIG. 8 . This second flexibility is less than the first flexibility that first spine 140 has when bent by a moment acting about first axis 156 .
- first spine 140 has a first bending modulus when bent by a moment acting about first axis 156 and a greater bending modulus when bent by a moment acting about an axis other than first axis 156 (e.g., second axis 158 and third axis 160 ).
- first spine 140 has a second bending modulus when bent by a moment acting about second axis 158 shown in FIG. 8 . This second bending modulus is greater than the first bending modulus that first spine 140 has when bent by a moment acting about first axis 156 .
- FIG. 9 is an enlarged cross-sectional view of ocular implant 100 taken along section line A-A of FIG. 6 .
- Section line A-A intersects first strut 144 and second strut 146 at the point where the circumferential undulation of these struts is at its maximum.
- Each strut shown in FIG. 9 includes a first major side 160 , a second major side 162 , a first minor side 164 , and second minor side 166 .
- first major side 160 comprises a concave surface 168
- second major side 162 comprises a convex surface 170 .
- each strut has a thickness T 2 extending between first major side 160 and second major side 162 . Also in the embodiment of FIG. 9 , each strut has a width W 2 extending between first minor side 164 and second minor side 166 .
- an ocular implant in accordance with this detailed description includes spines having a width W 1 that is greater than the width W 2 of the struts of the ocular implant.
- the struts of an ocular implant in accordance with this detailed description have an aspect ratio of width W 2 to thickness T 2 greater than about 2. In some particularly useful embodiments, the struts of an ocular implant in accordance with this detailed description have an aspect ratio of width W 2 to thickness T 2 greater than about 4.
- One exemplary ocular implant has struts with an aspect ratio of width W 2 to thickness T 2 of about 4.4.
- Body 102 of ocular implant 100 has a longitudinal radius 150 and a lateral radius 148 .
- an ocular implant in accordance with this detailed description is sufficiently flexible to assume a shape matching the longitudinal curvature of Schlemm's canal when the ocular implant advanced into the eye.
- a length of the ocular implant is selected so that the implant will extend across a pre-selected angular span when the implant is positioned in Schlemm's canal. Examples of pre-selected angular spans that may be suitable in some applications include 60°, 90°, 150° and 180°.
- the diameter of an ocular implant in accordance with this detailed description may be selected so that the ocular implant is dimensioned to lie within and support Schlemm's canal.
- the diameter of the ocular implant ranges between about 0.005 inches and about 0.04 inches. In some particularly useful embodiments, the diameter of the ocular implant ranges between about 0.005 inches and about 0.02 inches.
- an ocular implant in accordance with the present detailed description may be straight or curved. If the ocular implant is curved, it may have a substantially uniform longitudinal radius throughout its length, or the longitudinal radius of the ocular implant may vary along its length.
- FIG. 6 shows one example of an ocular implant having a substantially uniform radius of curvature.
- FIG. 10 shows one example of an ocular implant having a longitudinal radius of curvature that varies along the length of the ocular implant.
- An example of a substantially straight ocular implant is shown in FIG. 11 .
- FIG. 10 is a plan view showing an ocular implant 200 having a radius of curvature that varies along its length.
- ocular implant 200 has an at rest shape that is generally curved. This at rest shape can be established, for example, using a heat-setting process.
- the ocular implant shape shown in FIG. 10 includes a distal radius RA, a proximal radius RC, and an intermediate radius RB.
- distal radius RA is larger than both intermediate radius RB and proximal radius RC.
- intermediate radius RB is larger than proximal radius RC and smaller than distal radius RA.
- distal radius RA is about 0.320 inches
- intermediate radius RB is about 0.225 inches
- proximal radius RC is about 0.205 inches.
- a distal portion of the ocular implant follows an arc extending across an angle AA.
- a proximal portion of the ocular implant follows an arc extending across an angle AC.
- An intermediate portion of the ocular implant is disposed between the proximal portion and the distal portion. The intermediate portion extends across an angle AB.
- angle AA is about 55 degrees
- angle AB is about 79 degrees
- angle AC is about 60 degrees.
- Ocular implant 200 may be used in conjunction with a method of treating the eye of a human patient for a disease and/or disorder (e.g., glaucoma). Some such methods may include the step of inserting a core member into a lumen defined by ocular implant 200 .
- the core member may comprise, for example, a wire or tube.
- the distal end of the ocular implant may be inserted into Schlemm's canal.
- the ocular implant and the core member may then be advanced into Schlemm's canal until the ocular implant has reached a desired position.
- an inlet portion of the implant may be disposed in the anterior chamber of eye while the remainder of the implant extends through the trabecular mesh into Schlemm's canal.
- the core member may then be withdrawn from the ocular implant, leaving the implant in place to support tissue forming Schlemm's canal. Further details of ocular implant delivery systems may be found in U.S. application Ser. No. 11/943,289, filed Nov. 20, 2007, now U.S. Pat. No. 8,512,404, the disclosure of which is incorporated herein by reference.
- FIG. 1 shows the desired orientation of opening 124 when the implant 100 is disposed in Schlemm's canal. As shown, opening 124 faces radially outward.
- the implant 100 is therefore designed so that it is maximally flexible when bent along a plane defined by the longitudinal axis of implant 100 as shown in FIG. 1 , and less flexible when bent in other planes, thereby enabling the curved shape of Schlemm's canal to help place the implant in this orientation automatically if the implant is initially placed in Schlemm's canal in a different orientation.
- FIG. 11 is a perspective view showing an ocular implant 300 in accordance with an additional embodiment in accordance with the present detailed description.
- ocular implant 300 has a resting (i.e., unstressed) shape that is generally straight.
- Ocular implant 300 extends along a longitudinal axis 334 that is generally straight.
- ocular implant 300 is sufficiently flexible to assume a curved shape when advanced into Schlemm's canal of an eye.
- Ocular implant 300 comprises a body 302 .
- body 302 comprises a plurality of tissue supporting frames 304 and a plurality of spines 306 . As shown in FIG. 11 , these spines 306 and frames 304 are arranged in an alternating pattern in which one spine extends between each adjacent pair of frames 304 .
- the frames 304 of body 302 include a first frame 336 of ocular implant 300 is disposed between a first spine 340 and a second spine 342 .
- first frame 336 comprises a first strut 344 that extends between first spine 340 and second spine 342 .
- a second strut 346 of first frame also extends between first spine 340 and second spine 342 . Each strut undulates in a circumferential direction as it extends longitudinally between first spine 340 and second spine 342 .
- Body 302 of ocular implant 300 includes a first edge 320 and a second edge 322 that define a first opening 324 .
- Channel 326 of ocular implant 300 fluidly communicates with first opening 324 .
- First strut 344 of first frame 336 comprises a first edge 325 A.
- Second strut 346 has a first edge 325 B.
- first opening 324 in body 302 can be seen extending between first edge 325 A of first strut 344 and a first edge 325 B of second strut 346 .
- a first axis 356 , a second axis 358 and a third axis 360 are shown in FIG. 11 .
- Second axis 358 is generally perpendicular to first axis 356 .
- Third axis 360 is generally skewed relative to first axis 356 .
- the flexibility of body 302 is at a maximum when body 302 is bent by a moment acting about first axis 356 , and body 302 has less flexibility when bent by a moment acting about an axis other than first axis 356 (e.g., second axis 358 and third axis 360 ). Stated another way, in the embodiment of FIG.
- the bending modulus of body 302 is at a minimum when body 302 is bent by a moment acting about first axis 356 , and body 302 has a greater bending modulus when bent by a moment acting about an axis other than first axis 356 (e.g., second axis 358 and third axis 360 ).
- FIG. 6 Many of the figures illustrating embodiments of the invention show only portions of the ocular implant. It should be understood that many embodiments of the invention include an inlet portion (such as inlet 101 in FIG. 6 and inlet 201 in FIG. 10 ) that can be placed within the anterior chamber to provide communication of aqueous humor from the anterior chamber through the trabecular mesh into Schlemm's canal via the ocular implant. Further details of the inlet feature may be found in U.S. application Ser. No. 11/860,318.
- FIG. 12 is a stylized representation of a medical procedure in accordance with this detailed description.
- a physician is treating an eye 1220 of a patient P.
- the physician is holding a delivery system 12100 in his or her right hand RH.
- the physician's left hand (not shown) may be used to hold the handle H of a gonio lens 1223 . It will be appreciated that some physician's may prefer holding the delivery system handle in the left hand and the gonio lens handle H in the right hand RH.
- the physician may view the interior of the anterior chamber using gonio lens 1223 and a microscope 1225 .
- Detail A of FIG. 12 is a stylized simulation of the image viewed by the physician.
- a distal portion of a cannula 12102 is visible in Detail A.
- a shadow-like line indicates the location of Schlemm's canal SC which is lying under various tissue (e.g., the trabecular meshwork) that surround the anterior chamber.
- a distal opening 12104 of cannula 12102 is positioned near Schlemm's canal SC of eye 1220 .
- distal opening 12104 of cannula 12102 is placed in fluid communication with Schlemm's canal SC.
- an ocular implant may be advanced through distal opening 12104 and into Schlemm's canal SC.
- FIG. 13A is a perspective view further illustrating delivery system 12100 and eye 1220 shown in the previous Figure.
- cannula 12102 of delivery system 12100 is shown extending through a cornea 1240 of eye 1220 .
- a distal portion of cannula 12102 is disposed inside the anterior chamber defined by cornea 1240 of eye 1220 .
- cannula 12102 is configured so that a distal opening 12104 of cannula 12102 can be placed in fluid communication with Schlemm's canal.
- an ocular implant is disposed in a lumen defined by cannula 12102 .
- Delivery system 12100 includes a mechanism that is capable of advancing and retracting the ocular implant along the length of cannula 12102 .
- the ocular implant may be placed in Schlemm's canal of eye 1220 by advancing the ocular implant through distal opening 12104 of cannula 12102 while distal opening 12104 is in fluid communication with Schlemm's canal.
- FIG. 13B is an enlarged detail view further illustrating cannula 12102 of delivery system 12100 .
- an ocular implant 12126 has been advanced through distal opening 12104 of cannula 12102 .
- Cannula 12102 of FIG. 13B defines a passageway 12124 that fluidly communicates with distal opening 12104 .
- Ocular implant 12126 may be moved along passageway 12124 and through distal opening by delivery system 12100 .
- Delivery system 12100 includes a mechanism capable of performing this function.
- FIG. 14 is a stylized perspective view illustrating a portion of eye 1220 discussed above.
- Eye 1220 includes an iris 1230 defining a pupil 1232 .
- eye 1220 is shown as a cross-sectional view created by a cutting plane passing through the center of pupil 1232 .
- Eye 1220 can be conceptualized as a fluid filled ball having two chambers.
- Sclera 1234 of eye 1220 surrounds a posterior chamber PC filled with a viscous fluid known as vitreous humor.
- Cornea 1236 of eye 1220 encloses an anterior chamber AC that is filled with a fluid known as aqueous humor.
- the cornea 1236 meets the sclera 1234 at a limbus 1238 of eye 1220 .
- a lens 1240 of eye 1220 is located between anterior chamber AC and posterior chamber PC. Lens 1240 is held in place by a number of ciliary zonules 1242 .
- the cornea and the lens can include no blood vessels. Accordingly, no blood flows through the cornea and the lens to provide nutrition to these tissues and to remove wastes from these tissues. Instead, these functions are performed by the aqueous humor.
- a continuous flow of aqueous humor through the eye provides nutrition to portions of the eye (e.g., the cornea and the lens) that have no blood vessels. This flow of aqueous humor also removes waste from these tissues.
- Aqueous humor is produced by an organ known as the ciliary body.
- the ciliary body includes epithelial cells that continuously secrete aqueous humor.
- a stream of aqueous humor flows out of the eye as new aqueous humor is secreted by the epithelial cells of the ciliary body. This excess aqueous humor enters the blood stream and is carried away by venous blood leaving the eye.
- Schlemm's canal SC is a tube-like structure that encircles iris 1230 . Two laterally cut ends of Schlemm's canal SC are visible in the cross-sectional view of FIG. 14 .
- aqueous humor flows out of anterior chamber AC and into Schlemm's canal SC.
- Aqueous humor exits Schlemm's canal SC and flows into a number of collector channels.
- aqueous humor is absorbed into the venous blood stream and carried out of the eye.
- FIG. 15 is a stylized perspective view showing Schlemm's canal SC and iris 1230 of eye 1220 shown in the previous Figure.
- Schlemm's canal SC is shown encircling iris 1230 .
- Iris 1230 defines a pupil 1232 .
- Schlemm's canal SC and iris 1230 are shown in cross-section, with a cutting plane passing through the center of pupil 1232 .
- Schlemm's canal SC is somewhat irregular, and can vary from patient to patient.
- the shape of Schlemm's canal SC may be conceptualized as a cylindrical-tube that has been partially flattened. With reference to FIG. 15 , it will be appreciated that Schlemm's canal SC has a first major side 1250 , a second major side 1252 , a first minor side 1254 , and a second minor side 1256 .
- Schlemm's canal SC forms a ring around iris 1230 with pupil 1232 disposed in the center of that ring.
- first major side 1250 is on the outside of the ring formed by Schlemm's canal SC and second major side 1252 is on the inside of the ring formed by Schlemm's canal SC. Accordingly, first major side 1250 may be referred to as an outer major side of Schlemm's canal SC and second major side 1252 may be referred to as an inner major side of Schlemm's canal SC.
- first major side 1250 is further from pupil 1232 than second major side 1252 .
- FIG. 16 is an enlarged cross-sectional view further illustrating Schlemm's canal SC shown in the previous Figure.
- Schlemm's canal SC comprises a wall W defining a lumen 1258 .
- the shape of Schlemm's canal SC is somewhat irregular, and can vary from patient to patient.
- the shape of Schlemm's canal SC may be conceptualized as a cylindrical-tube that has been partially flattened.
- the cross-sectional shape of lumen 1258 may be compared to the shape of an ellipse.
- a major axis 1260 and a minor axis 1262 of lumen 1258 are illustrated with dashed lines in FIG. 16 .
- the length of major axis 1260 and minor axis 1262 can vary from patient to patient.
- the length of minor axis 1262 is between one and thirty micrometers in most patients.
- the length of major axis 1260 is between one hundred and fifty micrometers and three hundred and fifty micrometers in most patients.
- Schlemm's canal SC comprises a first major side 1250 , a second major side 1252 , a first minor side 1254 , and a second minor side 1256 .
- first major side 1250 is longer than both first minor side 1254 and second minor side 1256 .
- second major side 1252 is longer than both first minor side 1254 and second minor side 1256 .
- FIG. 17 is a perspective view showing an ocular implant in accordance with this detailed description.
- Ocular implant 12126 of FIG. 17 comprises a body 12128 that extends along a generally curved longitudinal central axis 12148 .
- body 12128 has a radius of curvature R that is represented with an arrow extending between a lateral central axis 12176 and body 12128 .
- Body 12128 of ocular implant 12126 has a first major surface 12130 and a second major surface 12132 .
- body 12128 is curved about longitudinal central axis 12148 so that first major surface 12130 comprises a concave surface 12136 and second major surface 12132 comprises a convex surface 12134 .
- the curvature of body 12128 can be pre-sized and configured to align with the curvature of Schlemm's canal in a patient's eye.
- a distal portion of body 12128 defines a longitudinal channel 12138 including a channel opening 12139 .
- Channel opening 12139 is disposed diametrically opposite a central portion 12135 of concave surface 12136 . Because of the curvature of the body 12128 , an outer diameter of the implant defined by the channel opening 12139 will be greater than an inner diameter of the implant defined by surface 12132 .
- the body is pre-biased to assume a configuration in which the channel opening 12139 is disposed along an outer diameter of the body, ensuring that the channel opening can be positioned adjacent to the first major side 1250 of Schlemm's canal.
- central portion 12135 of concave surface 12136 defines a plurality of apertures 12137 .
- Each aperture 12137 fluidly communicates with channel 12138 .
- body 12128 is adapted and configured such that ocular implant 12126 assumes an orientation in which channel opening 12139 is adjacent a major side of Schlemm's canal when ocular implant 12126 is disposed in Schlemm's canal.
- Ocular implant 12126 can be made, for example, by laser cutting body 12128 from a length of metal or a shape memory material (e.g., nitinol or stainless steel) tubing.
- FIG. 18A and FIG. 18B are section views showing an ocular implant 12126 disposed in Schlemm's canal SC of an eye.
- FIG. 18A and FIG. 18B may be collectively referred to as FIG. 18 .
- the eye of FIG. 18 includes an iris 1230 .
- a central portion of iris 1230 defines a pupil 1232 .
- Schlemm's canal SC is disposed near an outer edge of iris 1230 .
- the trabecular meshwork TM extends up from the iris of overlays Schlemm's canal SC.
- the picture plane of FIG. 18 extends laterally across Schlemm's canal SC and the trabecular meshwork TM.
- Schlemm's canal SC forms a ring around iris 1230 with pupil 1232 disposed in the center of that ring.
- Schlemm's canal SC has a first major side 1250 , a second major side 1252 , a first minor side 1254 , and a second minor side 1256 .
- first major side 1250 is further from pupil 1232 than second major side 1252 .
- first major side 1250 is an outer major side of Schlemm's canal SC and second major side 1252 is an inner major side of Schlemm's canal SC.
- a distal portion of ocular implant 12126 is shown resting in Schlemm's canal SC.
- a proximal portion of ocular implant 12126 is shown extending out of Schlemm's canal SC, through trebecular meshwork TM and into anterior chamber AC.
- Ocular implant 12126 of FIG. 18 comprises a body having a first major surface 12130 and a second major surface 12132 .
- first major surface 12130 comprises a concave surface
- second major surface 12132 comprises a convex surface.
- a distal portion of ocular implant 12126 defines a longitudinal channel 12138 including a channel opening 12139 .
- Channel opening 12139 is disposed diametrically opposite a central portion 12135 of first major surface 12130 .
- ocular implant 12126 is assuming an orientation in which channel opening 12139 is adjacent and open to first major side 50 of Schlemm's canal.
- ocular implant 12126 is assuming an orientation in which channel opening 12139 is adjacent and open to second major side 1252 of Schlemm's canal.
- FIG. 19A , FIG. 19B and FIG. 19C illustrate multiple plan views of an implant 12126 in accordance with the present detailed description.
- FIG. 19A , FIG. 19B and FIG. 19C may be referred to collectively as FIG. 19 . It is customary to refer to multi-view projections using terms such as front view, top view, and side view.
- FIG. 19A may be referred to as a top view of implant 12126
- FIG. 19B may be referred to as a side view of implant 12126
- FIG. 19C may be referred to as a bottom view of implant 12126 .
- the terms top view, side view, and bottom view are used herein as a convenient method for differentiating between the views shown in FIG. 19 .
- FIG. 8 may assume various orientations without deviating from the spirit and scope of this detailed description. Accordingly, the terms top view, side view, and bottom view should not be interpreted to limit the scope of the invention recited in the attached claims.
- Ocular implant 12126 of FIG. 19 comprises a body 12128 that extends along a longitudinal central axis 12148 .
- Body 12128 of ocular implant 12126 has a first major surface 12130 and a second major surface 12132 .
- body 12128 is curved about longitudinal central axis 12148 so that first major surface 12130 comprises a concave surface 12136 and second major surface 12132 comprises a convex surface 12134 .
- a distal portion of body 12128 defines a longitudinal channel 12138 including a channel opening 12139 .
- Channel opening 12139 is disposed diametrically opposite a central portion 12135 of concave surface 12136 .
- central portion 12135 of concave surface 12136 defines a plurality of apertures 12137 .
- Each aperture 12137 fluidly communicates with channel 12138 .
- body 12128 is adapted and configured such that ocular implant 12126 assumes an orientation in which channel opening 12139 is adjacent a major side of Schlemm's canal when ocular implant 12126 is disposed in Schlemm's canal.
- FIG. 20 is a lateral cross-sectional view of ocular implant 12126 taken along section line A-A shown in the previous Figure.
- Ocular implant 12126 comprises a body 12128 having a first major surface 12130 and a second major surface 12132 .
- body 12128 curves around a longitudinal central axis 12148 so that first major surface 12130 comprises a concave surface 12136 and second major surface 12132 comprises a convex surface 12134 .
- the concave surface 12136 of body 12128 defines a longitudinal channel 12138 having a channel opening 12139 .
- channel 12138 has a width WD and a depth DP.
- Body 12128 of ocular implant 12126 has a first lateral extent EF and a second lateral extent ES.
- body 12128 is adapted and configured such that ocular implant 12126 automatically assumes an orientation in which the channel opening is adjacent a major side of Schlemm's canal when ocular implant 12126 is disposed in Schlemm's canal.
- an aspect ratio of first lateral extent EF to second lateral extent ES is greater than about one. In some particularly useful embodiments, the aspect ratio of first lateral extent EF to second lateral extent ES is about two.
- the aspect ratio of first lateral extent EF to second lateral extent ES is greater than about two. In some useful embodiments, an aspect ratio of channel width WD to channel depth DP is greater than about one. In some particularly useful embodiments, the aspect ratio of channel width WD to channel depth DP is about two. In some useful embodiments, the aspect ratio of channel width WD to channel depth DP is greater than about two.
- FIG. 21A is a perspective view of an ocular implant 12126 and FIG. 21B is a stylized perspective view showing Schlemm's canal SC encircling an iris 1230 .
- FIG. 21A and FIG. 21B may be collectively referred to as FIG. 21 .
- Schlemm's canal SC may overhang iris 1230 slightly.
- Iris 1230 defines a pupil 1232 .
- Schlemm's canal SC forms a ring around iris 1230 with pupil 1232 disposed in the center of that ring.
- first major side 1250 is further from pupil 1232 than second major side 1252 .
- first major side 1250 is an outer major side of Schlemm's canal SC and second major side 1252 is an inner major side of Schlemm's canal SC.
- a window 1270 is cut through first major side 1250 of Schlemm's canal SC in FIG. 21B .
- an ocular implant 12126 can be seen residing in a lumen defined by Schlemm's canal.
- Ocular implant 12126 of FIG. 21 comprises a body 12128 having a first major surface 12130 .
- First major surface 12130 of body 12128 comprises a concave surface 12136 .
- Body 12128 defines a longitudinal channel 12138 including a channel opening 12139 .
- Channel opening 12139 is disposed diametrically opposite a central portion 12135 of concave surface 12136 .
- ocular implant 12126 is assuming an orientation in which channel opening 12139 is adjacent first major side 1250 of Schlemm's canal.
- FIG. 22A is a perspective view showing a delivery system 12100 that may be used to advance an ocular implant 12126 into Schlemm's canal of an eye.
- Delivery system 12100 includes a cannula 12102 that is coupled to a handle H.
- Cannula 12102 defines a distal opening 21104 .
- the distal portion of cannula 21102 of delivery system 12100 is configured and adapted to be inserted into the anterior chamber of a human subject's eye so that distal opening 12104 is positioned near Schlemm's canal of the eye.
- Cannula 12102 is sized and configured so that the distal end of cannula 21102 can be advanced through the trabecular meshwork of the eye and into Schlemm's canal. Positioning cannula 12102 in this way places distal opening 12104 in fluid communication with Schlemm's canal.
- an ocular implant is disposed in a passageway defined by cannula 12102 .
- Delivery system 12100 includes a mechanism that is capable of advancing and retracting the ocular implant along the length of cannula 12102 .
- the ocular implant may be placed in Schlemm's canal of eye 1220 by advancing the ocular implant through distal opening 12104 of cannula 12102 while distal opening 12104 is in fluid communication with Schlemm's canal.
- FIG. 22B is an enlarged detail view further illustrating cannula 12102 of delivery system 12100 .
- cannula 12102 comprises a tubular member defining a distal opening 12104 , a proximal opening 12105 , and a passageway 12124 extending between proximal opening 12105 and distal opening 12104 .
- cannula 12102 includes a curved portion 12107 disposed between distal opening 12104 and proximal opening 12105 .
- an ocular implant 12126 is disposed in passageway 12124 defined by cannula 12102 .
- Ocular implant 12126 of FIG. 22B comprises a body 12128 that extends along a generally curved longitudinal central axis 12148 .
- Body 12128 of ocular implant 12126 has a first major surface 12130 and a second major surface 12132 .
- first major surface 12130 defines a longitudinal channel 12138
- second major surface 12132 comprises a convex surface 12134 .
- Longitudinal channel 12138 includes a channel opening 12139 .
- Ocular implant 12126 is orient relative to delivery cannula 12102 such that longitudinal channel 12138 of ocular implant 12126 opens in a radially outward direction RD when ocular implant 12126 is disposed in curved portion 12107 .
- Radially outward direction RD is illustrated using an arrow in FIG. 22B .
- Distal opening 12104 of cannula 12102 may be placed in fluid communication with Schlemm's canal of an eye.
- Implant 12126 may be advanced through distal opening 12104 and into Schlemm's canal while assuming the orientation shown in FIG. 22B .
- ocular implant 12126 may be oriented such that channel opening 12139 is adjacent an outer major side of Schlemm's canal when ocular implant 12126 is disposed in Schlemm's canal.
- FIG. 23 is an enlarged perspective view of an assembly 12106 including an ocular implant 12126 , a sheath 12120 , and a cannula 12102 .
- cannula 12102 is cross-sectionally illustrated in FIG. 23 .
- a sheath 12120 is shown extending into a passageway 12124 defined by cannula 12102 .
- sheath 12120 is illustrated in a transparent manner with a pattern of dots indicating the presence of sheath 12120 .
- an implant 12126 is disposed in a lumen 12122 defined by sheath 12120 .
- Implant 12126 comprises a body 12128 having a first major surface 12130 and a second major surface 12132 .
- body 12128 curves around a longitudinal central axis so that first major surface 12130 comprises a concave surface and second major surface 12132 comprises a convex surface 12134 .
- the concave surface of body 12128 defines a longitudinal channel 12138 .
- a core 12166 is shown extending through longitudinal channel 12138 .
- Body 12128 of ocular implant 12126 defines a plurality of openings 12140 .
- sheath 12120 is covering openings 12140 .
- sheath 12120 comprises a proximal portion 12150 defining a lumen 12122 and a distal portion 12152 defining a distal aperture 12154 .
- Core 12166 is shown extending through distal aperture 12154 in FIG. 23 .
- distal portion 12152 of sheath 12120 has a generally tapered shape.
- FIG. 24 is an additional perspective view of assembly 12106 shown in the previous Figure.
- core 12166 , sheath 12120 , and implant 12126 are shown extending through a distal port 12104 of cannula 12102 .
- Core 12166 , sheath 12120 , and implant 12126 have been moved in a distal direction relative to the position of those elements shown in the previous Figure.
- a push tube 12180 is visible in FIG. 24 .
- a distal end of push tube 12180 is shown contacting a proximal end of implant 12126 .
- push tube 12180 is disposed in a lumen 12122 defined by sheath 12120 .
- Sheath 12120 comprises a proximal portion 12150 defining a passageway 12124 and a distal portion 12152 defining a distal aperture 12154 .
- Implant 12126 is disposed in lumen 12122 defined by sheath 12120 .
- core 12166 is shown extending through a channel 12138 defined by implant 12126 and a distal aperture 12154 defined by distal portion 12152 of sheath 12120 .
- FIG. 25 is an additional perspective view showing assembly 12106 shown in the previous Figure. With reference to FIG. 25 , it will be appreciated that implant 12126 is disposed outside of cannula 12102 . In the embodiment of FIG. 25 , core 12166 , sheath 12120 , and push tube 12180 have been advanced further so that implant 12126 is in a position outside of cannula 12102 .
- Methods in accordance with the present invention can be used to deliver an implant into Schlemm's canal of an eye.
- a distal portion of core 12166 and sheath 12120 may be advanced out of the distal port of cannula 12102 and into Schlemm's canal.
- Ocular implant 12126 may be disposed inside sheath 12120 while the distal portion of the sheath 12120 is advanced into Schlemm's canal.
- Sheath 12120 and core 12166 may then be retracted while push tube 12180 prevents implant 12126 from being pulled proximally.
- FIG. 26 is an additional perspective view showing the assembly 12106 shown in the previous Figure.
- core 12166 and sheath 12120 have been moved in a proximal direction relative to implant 12126 .
- implant 12126 is now disposed outside of sheath 12120 .
- Some methods in accordance with the present detailed description include the step of applying a proximally directed force to sheath 12120 and core 12166 while providing a distally directed reactionary force on implant 12126 to prevent implant 12126 from moving proximally.
- implant 12126 may pass through distal aperture 12154 of sheath 12120 as sheath 12120 is retracted over implant 12126 .
- distal portion 12152 of sheath 12120 comprises a first region 12156 and a second region 12158 .
- the frangible connection between first region 12156 and second region 12158 has been broken in the embodiment of FIG. 26 .
- This frangible connection may be selectively broken, for example, when sheath 12120 is moved in a proximal direction relative to implant 12126 due to the larger diameter of implant 12126 with respect to the diameters of distal portion 12152 and opening 12154 of sheath 12120 .
- the width of distal aperture 12154 becomes larger when the frangible connection is broken.
- a method in accordance with the present detailed description may include the step of advancing a distal end of a cannula through a cornea of the eye so that a distal portion of the cannula is disposed in the anterior chamber of the eye.
- the cannula may be used to access Schlemm's canal, for example, by piercing the wall of Schlemm's canal with a distal portion of the cannula.
- a distal portion of a sheath may be advanced out of a distal port of the cannula and into Schlemm's canal.
- An ocular implant may be disposed inside the sheath while the distal portion of the sheath is advanced into Schlemm's canal.
- the ocular implant comprises a body defining a plurality of apertures and the method includes the step of covering the apertures with a sheath.
- the distal portion of the implant may be advanced into Schlemm's canal while the apertures are covered by the sheath. Covering the apertures as the implant is advanced into Schlemm's canal may reduce the trauma inflicted on Schlemm's canal by the procedure.
- the apertures may be uncovered, for example, after the implant has reached a desired location (e.g., inside Schlemm's canal).
- the apertures of the implant may be uncovered, for example, by moving the sheath in a proximal direction relative to the implant. In some applications, this may be accomplished by applying a proximal directed force to the sheath while holding the implant stationary.
- the implant may be held stationary, for example, by applying a distally directed reaction force on the implant. In one embodiment, a distally directed reaction force is provided by pushing on a proximal end of the implant with a push tube.
- Some methods include the step of ceasing advancement of the sheath into Schlemm's canal when a proximal portion of the implant remains in an anterior chamber of the eye and a distal portion of the implant lies in Schlemm's canal. When this is the case, only a distal portion of the implant is advanced into Schlemm's canal.
- the portion of the implant extending out of Schlemm's canal and into the anterior chamber may provide a path for fluid flow between the anterior chamber and Schlemm's canal.
- An assembly may be created by placing a core in a channel defined by the ocular implant.
- a sheath may be placed around the implant and the core.
- the core and the implant may then be inserted into the lumen of a sheath.
- the sheath may be slipped over the implant and the core.
- the core may be withdrawn from the channel defined by the ocular implant, for example, after the implant has been delivered to a desired location.
- the core may be withdrawn from the channel, for example, by moving the core in a proximal direction relative to the implant. In some applications, this may be accomplished by applying a proximal directed force to the core while holding the implant stationary.
- the implant may be held stationary, for example, by applying a distally directed reaction force on the implant. In one embodiment, a distally directed reaction force is provided by pushing on a proximal end of the implant with a push tube.
- the core, the implant, and the sheath may be advanced into Schlemm's canal together. Once the implant is in a desired location, the core and the sheath may be withdrawn from the Schlemm's canal leaving the implant in the desired location. In some methods, the core and the sheath are withdrawn from Schlemm's canal simultaneously.
- FIG. 27A and FIG. 27B are perspective views showing a sheath 12120 in accordance with the present detailed description.
- FIG. 27A and FIG. 27B may be referred to collectively as FIG. 27 .
- Sheath 12120 of FIG. 27 comprises a proximal portion 12150 defining a lumen 12122 and a distal portion 12152 defining a distal aperture 12154 .
- lumen 12122 is generally larger than distal aperture 12154 .
- distal portion 12152 of sheath 12120 comprises a first region 12156 , a second region 12158 , and a frangible connection 12160 between first region 12156 and second region 12158 .
- a slit 12164 defined by distal portion 12152 is shown disposed between first region 12156 and second region 12158 .
- frangible connection 12160 comprises a bridge 12162 extending across slit 12164 .
- frangible connection 12160 has been broken.
- Frangible connection 12160 may be selectively broken, for example, by moving sheath 12120 in a proximal direction relative to an implant disposed in lumen 12122 having a diameter larger than the diameters of distal opening 12154 and distal portion 12152 of sheath 12120 .
- distal aperture 12154 becomes larger when frangible connection 12160 is broken.
- distal portion 12152 may comprise various elements that create a localized line of weakness without deviating from the spirit and scope of the present detailed description. Examples of possible elements include: a skive cut extending partially through the wall of distal portion 12120 , a series of holes extending through the wall of distal portion 12120 , a perf cut, a crease, and a score cut.
- FIG. 28 is a perspective view of an assembly including sheath 12120 shown in the previous Figure.
- an implant 12126 is shown extending through distal aperture 12154 defined by distal portion 12152 of sheath 12120 .
- Implant 12126 defines a channel 12138 .
- a core 12166 can be seen resting in channel 12138 .
- Implant 12126 and core 12166 extend proximally into lumen 12122 defined by sheath 12120 .
- Distal portion 12152 of sheath 12120 comprises a first region 12156 and a second region 12158 .
- FIG. 29A and FIG. 29B are simplified plan views showing a sheath 12120 in accordance with the present detailed description.
- Sheath 12120 comprises a distal portion 12152 including a first region 12156 , a second region 12158 and a frangible connection between first region 12156 and second region 12158 .
- frangible connection 12160 is intact.
- frangible connection 12160 is broken.
- FIG. 29A and FIG. 29B may be referred to collectively as FIG. 29 .
- Sheath 12120 of FIG. 29 comprises a proximal portion 12150 defining a lumen 12122 .
- an implant 12126 is disposed in lumen 12122 .
- Lumen 12122 fluidly communicates with a distal aperture 12154 defined by distal portion 12152 of sheath 12120 .
- Distal portion 12152 includes a slit 12164 disposed between first region 12156 and second region 12158 .
- a bridge 12162 can be seen spanning slit 12164 .
- distal portion 12152 of sheath 12120 has a first hoop strength and proximal portion 12150 sheath 12120 has a second hoop strength.
- the first hoop strength may be limited by the frangible connection in the embodiment of FIG. 29A . When this is the case, the second hoop strength is greater than the first hoop strength.
- Sheath 12120 of FIG. 29 comprises a proximal portion 12150 defining a lumen 12122 and a distal portion 12152 defining a distal aperture 12154 .
- Lumen 12122 has a lumen width LW.
- Distal aperture has an aperture width AW when frangible connection 12160 is intact. With reference to FIG. 29B , it will be appreciated that the distal aperture 12154 is free to open further when frangible connection 12160 is broken.
- lumen width LW of lumen 12122 is equal to or greater than the width of an implant 12126 disposed in lumen 12122 .
- aperture width AW is smaller than the width of the implant 12126 .
- FIG. 30A , FIG. 30B and FIG. 30C are multiple plan views of an implant 12326 in accordance with the present detailed description.
- FIG. 30A , FIG. 30B and FIG. 30C may be referred to collectively as FIG. 1309 .
- FIG. 30A may be referred to as a top view of implant 12326
- FIG. 30B may be referred to as a side view of implant 12326
- FIG. 30C may be referred to as a bottom view of implant 12326 .
- the terms top view, side view, and bottom view are used herein as a convenient method for differentiating between the views shown in FIG. 30 .
- the implant shown in FIG. 30 may assume various orientations without deviating from the spirit and scope of this detailed description. Accordingly, the terms top view, side view, and bottom view should not be interpreted to limit the scope of the invention recited in the attached claims.
- Ocular implant 12326 of FIG. 30 comprises a body 12328 that extends along a longitudinal central axis 12348 .
- Body 12328 of ocular implant 12326 has a first major surface 12330 and a second major surface 12332 .
- body 12328 is curved about longitudinal central axis 12348 so that first major surface 12330 comprises a concave surface 12336 and second major surface 12332 comprises a convex surface 12334 .
- a distal portion of body 12328 defines a longitudinal channel 12338 including a channel opening 12339 .
- Channel opening 12339 is disposed diametrically opposite a central portion 12335 of concave surface 12336 .
- central portion 12335 of concave surface 12336 defines a plurality of apertures 12337 .
- Each aperture 12337 fluidly communicates with channel 12338 .
- FIG. 31 is a lateral cross-sectional view of ocular implant 12326 taken along section line B-B shown in the previous Figure.
- Ocular implant 12326 comprises a body 12328 having a first major surface 12330 and a second major surface 12332 .
- body 12328 curves around a longitudinal central axis 12348 so that first major surface 12330 comprises a concave surface 12336 and second major surface 12332 comprises a convex surface 12334 .
- the concave surface 12336 of body 12328 defines a longitudinal channel 12338 having a channel opening 12339 .
- body 12328 has a circumferential extent that spans an angle W. In the embodiment of FIG. 31 , angle W has a magnitude that is greater than one hundred eighty degrees.
- FIG. 32 is a cross-sectional view showing an implant 12326 in accordance with the present detailed description.
- Ocular implant 12326 of FIG. 32 comprises a body 12328 that extends along a generally curved longitudinal central axis 348 .
- body 12328 has a distal radius of curvature RD and a proximal radius of curvature RP.
- Each radius of curvature is represented with an arrow in FIG. 32 .
- Distal radius of curvature RD is represented by an arrow extending between a first lateral central axis 12376 and a distal portion of longitudinal central axis 12348 .
- Proximal radius of curvature RP is represented by an arrow extending between a second lateral central axis 12378 and a proximal portion of longitudinal central axis 12348 .
- body 12328 of ocular implant 12326 has an at rest shape that is generally curved. This at rest shape can be established, for example, using a heat-setting process. The rest shape of the implant can be generally aligned with the radius of curvature of Schlemm's canal in a human eye.
- FIG. 33A , FIG. 33B and FIG. 33C are multiple plan views of an implant 12526 in accordance with the present detailed description.
- FIG. 33A , FIG. 33B and FIG. 33C may be referred to collectively as FIG. 33 .
- FIG. 33A may be referred to as a top view of implant 12526
- FIG. 33B may be referred to as a side view of implant 12526
- FIG. 33C may be referred to as a bottom view of implant 12526 .
- the terms top view, side view, and bottom view are used herein as a convenient method for differentiating between the views shown in FIG. 33 . It will be appreciated that the implant shown in FIG. 33 may assume various orientations without deviating from the spirit and scope of this detailed description.
- top view, side view, and bottom view should not be interpreted to limit the scope of the invention recited in the attached claims.
- Ocular implant 12526 of FIG. 33 comprises a body 12528 that extends along a longitudinal central axis 12548 .
- Body 12528 of ocular implant 12526 has a first major surface 12530 and a second major surface 12532 .
- body 12528 is curved about longitudinal central axis 12548 so that first major surface 12530 comprises a concave surface 12536 and second major surface 12532 comprises a convex surface 12534 .
- a distal portion of body 12528 defines a longitudinal channel 12538 including a channel opening 12539 .
- Channel opening 12539 is disposed diametrically opposite a central portion 12535 of concave surface 12536 .
- central portion 12535 of concave surface 12536 defines a plurality of apertures 12537 . Each aperture 12537 fluidly communicates with channel 12538 .
- FIG. 34 is a lateral cross-sectional view of ocular implant 12526 taken along section line C-C shown in the previous Figure.
- Ocular implant 12526 comprises a body having a first major side 12530 and a second major side 12532 .
- body 12528 curves around a longitudinal central axis 1248 so that first major side 12530 comprises a concave surface 12536 and second major side 12532 comprises a convex surface 12534 .
- the concave surface 12536 of body 12528 defines a longitudinal channel 12538 having a channel opening 12539 .
- body 12528 has a circumferential extent that spans an angle C. In the embodiment of FIG.
- angle C has a magnitude that is about one hundred eighty degrees.
- Some useful implants in accordance with the present detailed description comprise a body having a circumferential extend that spans an angle that is about one hundred eighty degrees.
- Some particularly useful implants in accordance with the present detailed description comprise a body having a circumferential extend that spans an angle that is equal to or less than one hundred eighty degrees.
- FIG. 35 is a plan view showing an implant 12526 in accordance with the present detailed description.
- Ocular implant 12526 of FIG. 35 comprises a body 12528 that extends along a generally curved longitudinal central axis 12548 .
- body 12528 has a distal radius of curvature RD and a proximal radius of curvature RP.
- Each radius of curvature is represented with an arrow in FIG. 35 .
- Distal radius of curvature RD is represented by an arrow extending between a first lateral central axis 12576 and a distal portion of longitudinal central axis 12548 .
- Proximal radius of curvature RP is represented by an arrow extending between a second lateral central axis 12578 and a proximal portion of longitudinal central axis 12548 .
- body 12528 of ocular implant 12526 has an at rest shape that is generally curved. This at rest shape can be established, for example, using a heat-setting process.
- FIG. 36A through FIG. 36D are a series of plan views illustrating a method in accordance with the present detailed description.
- FIG. 36A is a plan view showing an implant 12426 .
- Implant 12426 comprises a body 12428 defining a plurality of openings 12440 .
- Openings 12440 include a first opening 12442 and a second opening 12444 .
- FIG. 36B is a plan view showing an assembly 12408 including implant 12426 .
- Assembly 12408 of FIG. 36B may be created by placing a core 12406 in a channel 12438 defined by implant 12426 .
- a sheath 12420 may be placed around implant 12426 and core 12406 .
- core 12406 and implant 12426 may be inserted into a lumen defined by sheath 12420 .
- sheath 12420 may be slipped over implant 12426 and core 12406 .
- FIG. 36C is a plan view showing assembly 12408 disposed in Schlemm's canal SC.
- the wall W of Schlemm's canal SC comprises a plurality of cells 1290 .
- sheath 12420 is disposed between implant 12426 and cells 1290 .
- a method in accordance with the present detailed description may include the step of advancing a distal end of a cannula through a cornea of the eye so that a distal portion of the cannula is disposed in the anterior chamber of the eye.
- the cannula may be used to access Schlemm's canal, for example, by piercing the wall of Schlemm's canal with a distal portion of the cannula.
- a distal portion of sheath 12420 may be advanced out of a distal port of the cannula and into Schlemm's canal SC.
- Ocular implant 12426 may be disposed inside sheath 12420 while the distal portion of sheath 12420 is advance into Schlemm's canal SC.
- ocular implant 12426 comprises a body defining a plurality of openings 12440 .
- openings 12440 are covered by sheath 12420 and that a distal portion of implant 12426 may be advanced into Schlemm's canal while openings 12440 are covered by sheath 12420 .
- Covering openings 12440 as implant 12426 is advanced into Schlemm's canal SC may reduce the trauma inflicted on cells 1290 by the procedure.
- sheath 12420 comprises a coating disposed on an outer surface thereof.
- the properties of the coating may be selected to further reduce the trauma inflicted on cells 1290 by the procedure.
- the coating may comprise, for example, a hydrophilic material.
- the coating may also comprise, for example, a lubricious polymer.
- hydrophilic materials examples include: polyalkylene glycols, alkoxy polyalkylene glycols, copolymers of methylvinyl ether and maleic acid poly(vinylpyrrolidone), poly(N-alkylacrylamide), poly(acrylic acid), poly(vinyl alcohol), poly(ethyleneimine), methyl cellulose, carboxymethyl cellulose, polyvinyl sulfonic acid, heparin, dextran, modified dextran and chondroitin sulphate.
- the distal portion of sheath 12420 is shown extending between a smaller, distal diameter and a larger, proximal diameter.
- the distal portion of sheath 12420 has a generally tapered shape.
- the tapered transition of the distal portion of sheath 12420 may create a nontraumatic transition that dilates Schlemm's canal SC as sheath 12420 is advanced into Schlemm's canal SC. This arrangement may reduce the likelihood that skiving of wall W occurs as sheath 12420 is advanced into Schlemm's canal SC.
- FIG. 36D is a plan view showing implant 12426 disposed in Schlemm's canal SC.
- openings 12440 defined by body 12428 have been uncovered. Openings 12440 may be uncovered, for example, by moving sheath 12420 in a proximal direction relative to implant 12426 . In some applications, this may be accomplished by applying a proximal directed force to sheath 12420 while holding implant 12426 stationary. Implant 12426 may be held stationary, for example, by applying a distally directed reaction force on implant 12426 . In the embodiment of FIG. 36 , a distally directed reaction force may be provided by pushing on a proximal end of implant 12426 with a push tube.
- core 12406 has been removed channel 12438 defined by implant 12426 .
- Core 12406 may be withdrawn from channel 12438 , for example, by moving core 12406 in a proximal direction relative to implant 12426 . In some applications, this may be accomplished by applying a proximal directed force to core 12406 while holding implant 12426 stationary.
- Implant 12426 may be held stationary, for example, by applying a distally directed reaction force on implant 12426 .
- FIG. 37A through FIG. 37D are a series of section views illustrating a method in accordance with the present detailed description.
- the picture plane of FIG. 37A extends laterally across Schlemm's canal SC and the trabecular meshwork 12596 overlaying Schlemm's canal SC.
- the distal end of a cannula 12502 has been positioned proximate Schlemm's canal SC.
- a method in accordance with the present detailed description may include the step of advancing the distal end of cannula 12502 through the cornea of an eye so that a distal portion of cannula 12502 is disposed in the anterior chamber 12594 of the eye.
- FIG. 37B is an additional section view showing Schlemm's canal SC shown in the previous Figure.
- a distal portion of cannula 502 is shown extending through a wall W of Schlemm's canal SC and trabecular meshwork 12596 .
- a distal port 12504 of cannula 12502 fluidly communicates with Schlemm's canal in the embodiment of FIG. 37B .
- FIG. 37C is an additional section view showing Schlemm's canal SC shown in the previous Figure.
- a distal portion of a sheath 12520 is shown extending through distal port 12504 of cannula 12502 and into Schlemm's canal SC.
- Methods in accordance with the present invention can be used to deliver an implant 12526 into Schlemm's canal SC.
- a distal portion of sheath 12520 and a core 12506 may be advanced out of distal port 12504 of cannula 12502 and into Schlemm's canal SC.
- Ocular implant 12526 may be disposed inside sheath 12520 while the distal portion of sheath 12520 is advanced into Schlemm's canal SC.
- FIG. 37D is an additional section view showing implant 12526 shown in the previous Figure.
- sheath 12520 , core 12506 , and cannula 12502 have all been withdrawn from the eye.
- Implant 12526 is shown resting in Schlemm's canal SC in FIG. 37D .
- FIG. 38A and FIG. 38B are simplified plan views showing a sheath 12720 in accordance with the present detailed description.
- FIG. 38A and FIG. 38B may be referred to collectively as FIG. 38 .
- Sheath 12720 of FIG. 38 comprises a proximal portion 12750 defining a lumen 12722 and a distal portion 12752 defining a distal aperture 12754 .
- lumen 12722 is generally larger than distal aperture 12754 .
- distal portion 12752 of sheath 12720 comprises a first region 12756 , a second region 12758 , and a frangible connection 12760 between first region 12756 and second region 12758 .
- a first slit 12764 defined by distal portion 12752 is shown disposed between first region 12756 and second region 12758 .
- frangible connection 12760 comprises a bridge 12762 extending across first slit 12764 .
- distal portion 12752 defines a number of slits in addition to first slit 12764 .
- frangible connection 12760 has been broken.
- Frangible connection 12760 may be selectively broken, for example, by moving sheath 12720 in a proximal direction relative to an implant disposed in lumen 12722 having a diameter larger than the diameters of distal opening 12754 and distal portion 12752 of sheath 12720 .
- distal aperture 12754 becomes larger when frangible connection 12760 is broken.
- distal portion 12752 may comprise various elements that create a localized line of weakness without deviating from the spirit and scope of the present detailed description. Examples of possible elements include: a skive cut extending partially through the wall of distal portion 12720 , a series of holes extending through the wall of distal portion 12720 , a pert cut, a crease, and a score cut.
- distal portion 12752 of sheath 12720 is shown extending between distal opening 12754 and lumen 12722 .
- distal portion 12752 of sheath 12720 has a blunt shape.
- the blunt shape of distal portion 12752 of sheath 12720 may create a nontraumatic transition that dilates Schlemm's canal as sheath 12720 is advanced into Schlemm's canal. This arrangement may reduce the likelihood that skiving of the canal wall occurs as sheath 12720 is advanced into Schlemm's canal.
- the ocular implant can be fabricated by providing a generally flat sheet of material, cutting the sheet of material, and forming the material into a desired shape.
- the ocular implant may be fabricated by providing a tube and laser cutting openings in the tube to form the ocular implant.
- the ocular implant of this invention can be fabricated from various biocompatible materials possessing the necessary structural and mechanical attributes. Both metallic and non-metallic materials may be suitable. Examples of metallic materials include stainless steel, tantalum, gold, titanium, and nickel-titanium alloys known in the art as Nitinol. Nitinol is commercially available from Memry Technologies (Brookfield, Conn.), TiNi Alloy Company (San Leandro, Calif.), and Shape Memory Applications (Sunnyvale, Calif.).
- the ocular implant may include one or more therapeutic agents.
- One or more therapeutic agents may, for example, be incorporated into a polymeric coating that is deposited onto the outer surfaces of the struts and spines of the ocular implant.
- the therapeutic agent may comprise, for example, an anti-glaucoma drug.
- anti-glaucoma drugs include prostaglandin analogs.
- prostaglandin analogs include latanprost.
- the implants of the present disclosure provide a treatment for glaucoma by combining the mechanism of trabecular meshwork (TM) bypass and Schlemm's canal (SC) dilation.
- TM trabecular meshwork
- SC Schlemm's canal
- the trabecular meshwork bypass is achieved through the openings, the longitudinal channel, and channel opening of the implants above, and Schlemm's canal dilation is achieved by supporting Schlemm's canal with the body of the implant itself.
- a comprehensive mathematical model was developed in this disclosure to evaluate changes in fluid dynamics of aqueous humor outflow induced by combinations of trabecular mesh bypass and/or Schlemm's canal dilation, and to predict how the changes would affect outflow facility.
- a control eye was modeled after an ex vivo human anterior segment perfusion model using typical dimensions for the eye and Schlemm's canal. This was done in order to validate the model parameters with experimental data.
- two combinations of bypass and dilation were modeled using the dimensional parameters of implants with 8 mm and 16 mm lengths. The mathematical model was used to predict outflow facilities in control and experimental simulations.
- Schlemm's canal is modeled as a rectangular channel with width (w) and height (h), where h varies with the location (x) along the canal due to trabecular mesh deformation.
- the trabecular mesh is treated as an elastic membrane in the model.
- Collector channels are treated as individual sinks with flow rate, J CC (see the governing equation below).
- Schlemm's canal in the experimental simulations is modeled after either an 8 mm implant or 16 mm implant.
- the region of Schlemm's canal with an implant is also modeled as a rectangular channel but with width (w d ) and height (h d ) corresponding to the implant cross-sectional area.
- the height of Schlemm's canal (h) is intra-ocular pressure (IOP) dependent.
- the dependence is assumed to be linear:
- J TM aqueous humor flux
- R TM trabecular mesh resistance
- P sc is the fluid pressure in the Schlemm's canal
- E is the Young's modulus of the trabecular meshwork
- R TM is the trabecular meshwork's resistance to fluid flow
- Q is the flow rate along the SC
- ⁇ is the viscosity of aqueous humor
- x cc indicates locations of collector channel ostia in the Schlemm's canal
- J CC is the flow rate in the collector channels
- P epi is the pressure in the episcleral veins
- FIGS. 7A-7B show an implant having three “walls” comprising first strut 144 , second strut 146 , and spine 140 which leaves opening or channel 124 open and facing Schlemm's canal when implanted.
- the wall of the implant facing the inner wall of Schlemm's canal (spine 140 ) contains several windows (or openings), which allow the aqueous humor to enter SC through the TM.
- Two scaffold designs are investigated in this disclosure.
- One has a total length of 8 mm with 3 windows and 3 spines (shown in FIGS. 2, 4, 11, 17, 19A -C, 30 A-C, 32 , 33 A-C, 35 ); and another has a total length of 16 mm with 5 windows and 6 spines (shown in FIG. 6, 10, 21A ).
- Individual dimensions of 8 mm and 16 mm implants are shown in Table 2A and 2B, respectively.
- Equations 3 through 5 are unchanged, excepted that w and h are replaced with h d and w d , respectively.
- the width of all implants are assumed to be the same as that of the intact Schlemm's canal; and the height of each implant is calculated from the cross-sectional areas estimated for that device divided by w d .
- the viscosity of aqueous humor ( ⁇ ) at 37° C. is assumed to be the same as that measured at 34° C., because ⁇ is close to the viscosity of water which changes only slightly ( ⁇ 6%) when the temperature is increased from 34° C. to 37° C.
- the pressure in the episcleral vein (P epi ) is close to zero in experiments involving ex vivo perfusion of whole eye or anterior segment, but approximately equal to 8 mmHg in live eyes.
- Implantation of a bypass causes a significant increase in the pressure in this region of Schlemm's canal and can lead to an increase in the diameter of collector channel ostia in the region.
- a parameter, ⁇ can be defined as the ratio of R CC with ostia in control Schlemm's canal versus that in dilated Schlemm's canal.
- ⁇ which is >1
- ⁇ depends on how the three-dimensional shape of the collector channel is changed due to Schlemm's canal dilation and pressure increase, which is unknown at present. If the collector channel is considered as a circular channel, and its diameter is uniformly increased by a factor of two, then ⁇ equals 16 for Newtonian fluid. However, it is likely that only the portion of the collector channel near its ostium is be dilated after device implantation. Thus, a baseline value of ⁇ is assumed to be three.
- the average C of the control eye was 0.198 ⁇ l/min/mmHg (Table 3).
- ⁇ P is increased from 5 to 30 mmHg, C decreased slightly in the control simulation with TM intact, which falls within the range of experimental data of human eyes reported in the literature.
- FIG. 39 illustrates the results of mathematical simulations of the 8 mm and 16 mm implants with frequent and uniform circumferential distribution of collector channels and an IOP of 10 mmHg.
- solid line 390 represents the P sc in Schlemm's canal of the eye with the 8 mm implant
- dashed-line 392 represents the P sc in Schlemm's canal of the eye with the 16 mm implant.
- Circles 394 illustrate the flow in the collector channels of the eye with the 8 mm implant
- triangles 396 show the flow in the collector channels of the eye with the 16 mm implant.
- the pressure in the region of Schlemm's canal (P sc ) with the implants was similar to IOP. Outside this region, P sc decreased exponentially, starting at the distal end of the implants, with the smallest level of P sc slightly greater than controls.
- the outflow rate through the collector channels was highest in the implant regions due to the high P sc and Schlemm's canal dilation-induced reduction in outflow resistance in these collector channels. Outside this region, the profile of Jcc matched the Psc profile and was similar for both implants.
- the collector channels in the scaffold regions contributed to a majority of the overall difference in flow rate through collector channels when compared to controls.
- the average C value for the 8 mm implant was 121% greater than controls with a C value of 0.438 ⁇ l/min/mmHg and the 16 mm implant was 46% greater than the 8 mm implant (222% greater than controls) with a C value of 0.638 ⁇ l/min/mmHg (Table 3 above).
- the 16 mm implant reached twice as many collector channels as the 8 mm implant but only gained 46% greater outflow despite the addition of 6 collector channels. This indicates that as the distance from the collector channels to the inlet increases, the benefit to outflow facility diminishes.
- the circumferential flow region correlates to the regions of increased P sc and J cc for both the 8 mm and 16 mm implant.
- the 16 mm implant maintained a 2.415 ⁇ l/min flow difference versus the 8 mm implant. But when 150 degrees of Schlemm's canal is reached, the difference is reduced to only 0.526 ⁇ l/min, indicating a diminishing advantage with a longer length device.
- the 8 mm implant occupied three clock-hours of Schlemm's canal (20% of Schlemm's canal length), however the collector channels in that region accounted for 54.5% of the total outflow in the eye.
- the 16 mm implant occupied five clock-hours of Schlemm's canal (42% of Schlemm's canal length) which accounted for 74.6% of the total outflow.
- Theoretical in vivo glaucoma scenarios were designed to simulate how different ocular implants could improve outflow in eyes with increased trabecular meshwork resistance (RTM) and reduced collector channel outflow capacity in the hemisphere of the implant.
- Three scenarios were simulated in Table 5, with fixed conventional outflow rate of 1.5 ⁇ L/min 27, 28 and Pepi of 10 mmHg.
- the first scenario was a normal eye, which assumed R TM to be 2.12 mmHg/4/min and no blocked collector channels.
- the second scenario assumed R TM to be 6.34 mmHg/4/min and 50% of the collector channels in the implanted hemisphere to be uniformly blocked including the collector channels at the trabecular mesh bypass.
- the third scenario assumed R TM to be 8.78 mmHg/4/min and 75% of the collector channels in the implanted hemisphere to be uniformly blocked including the collector channel at the trabecular meshwork bypass.
- the model shows the effects of trabecular meshwork bypass and Schlemm's canal dilation on outflow facility and subsequent IOP reduction.
- increasing the dilated portion of Schlemm's canal from the bypass improved outflow facility. But, at a certain distance from the bypass there was diminished improvement. This indicates that dilation near the bypass creates circumferential flow from the bypass which allows more collector channels to be utilized.
- Fluid dynamic mathematical modeling of scaffolding ocular implants as described herein shows that bypassing the trabecular meshwork increases the pressure within Schlemm's canal, and increases circumferential flow rate, and the flow rate into collector channels adjacent to the trabecular meshwork bypass.
- the larger bypass size creates a larger increase in the circumferential flow when compared with controls.
- Dilation of Schlemm's canal adjacent to the trabecular meshwork bypass increases the pressure in Schlemm's canal in the area of dilation which further increases the circumferential flow.
- Increasing the length of dilation increases the number of collector channels accessed by the implant, however, there was diminishing improvement in circumferential flow and flow rate into collector channels over a distance of approximately one quadrant in the eye beyond the region with the implant.
Landscapes
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Prostheses (AREA)
Abstract
Description
- This application claims the benefit under 35 U.S.C. §119 of U.S. Application No. 62/110,293, titled “Methods and Devices for Increasing Aqueous Humor Outflow”, filed Jan. 30, 2015. This application is a continuation-in-part of U.S. application Ser. No. 14/691,267, filed Apr. 20, 2015, and is a continuation-in-part of U.S. application Ser. No. 14/932,658, filed Nov. 4, 2015, the disclosures of which are incorporated by reference as if fully set forth herein.
- All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
- The present invention relates generally to devices that are implanted within the eye. More particularly, the present invention relates to devices that facilitate the transfer of fluid from within one area of the eye to another area of the eye.
- According to a draft report by The National Eye Institute (NEI) at The United States National Institutes of Health (NIH), glaucoma is now the leading cause of irreversible blindness worldwide and the second leading cause of blindness, behind cataract, in the world. Thus, the NEI draft report concludes, “it is critical that significant emphasis and resources continue to be devoted to determining the pathophysiology and management of this disease.” Glaucoma researchers have found a strong correlation between high intraocular pressure and glaucoma. For this reason, eye care professionals routinely screen patients for glaucoma by measuring intraocular pressure using a device known as a tonometer. Many modern tonometers make this measurement by blowing a sudden puff of air against the outer surface of the eye.
- The eye can be conceptualized as a ball filled with fluid. There are two types of fluid inside the eye. The cavity behind the lens is filled with a viscous fluid known as vitreous humor. The cavities in front of the lens are filled with a fluid know as aqueous humor. Whenever a person views an object, he or she is viewing that object through both the vitreous humor and the aqueous humor.
- Whenever a person views an object, he or she is also viewing that object through the cornea and the lens of the eye. In order to be transparent, the cornea and the lens can include no blood vessels. Accordingly, no blood flows through the cornea and the lens to provide nutrition to these tissues and to remove wastes from these tissues. Instead, these functions are performed by the aqueous humor. A continuous flow of aqueous humor through the eye provides nutrition to portions of the eye (e.g., the cornea and the lens) that have no blood vessels. This flow of aqueous humor also removes waste from these tissues.
- Aqueous humor is produced by an organ known as the ciliary body. The ciliary body includes epithelial cells that continuously secrete aqueous humor. In a healthy eye, a stream of aqueous humor flows out of the anterior chamber of the eye through the trabecular meshwork and into Schlemm's canal as new aqueous humor is secreted by the epithelial cells of the ciliary body. This excess aqueous humor enters the venous blood stream from Schlemm's canal and is carried along with the venous blood leaving the eye.
- When the natural drainage mechanisms of the eye stop functioning properly, the pressure inside the eye begins to rise. Researchers have theorized prolonged exposure to high intraocular pressure causes damage to the optic nerve that transmits sensory information from the eye to the brain. This damage to the optic nerve results in loss of peripheral vision. As glaucoma progresses, more and more of the visual field is lost until the patient is completely blind.
- In addition to drug treatments, a variety of surgical treatments for glaucoma have been performed. For example, shunts were implanted to direct aqueous humor from the anterior chamber to the extraocular vein (Lee and Scheppens, “Aqueous-venous shunt and intraocular pressure,” Investigative Ophthalmology (February 1966)). Other early glaucoma treatment implants led from the anterior chamber to a sub-conjunctival bleb (e.g., U.S. Pat. No. 4,968,296 and U.S. Pat. No. 5,180,362). Still others were shunts leading from the anterior chamber to a point just inside Schlemm's canal (Spiegel et al., “Schlemm's canal implant: a new method to lower intraocular pressure in patients with POAG?” Ophthalmic Surgery and Lasers (June 1999); U.S. Pat. No. 6,450,984; U.S. Pat. No. 6,450,984). In addition to drug treatments, a variety of surgical treatments for glaucoma have been performed. For example, shunts were implanted to direct aqueous humor from the anterior chamber to the extraocular vein (Lee and Scheppens, “Aqueous-venous shunt and intraocular pressure,” Investigative Ophthalmology (February 1966)). Other early glaucoma treatment implants led from the anterior chamber to a sub-conjunctival bleb (e.g., U.S. Pat. No. 4,968,296 and U.S. Pat. No. 5,180,362). Still others were shunts leading from the anterior chamber to a point just inside Schlemm's canal (Spiegel et al., “Schlemm's canal implant: a new method to lower intraocular pressure in patients with POAG?” Ophthalmic Surgery and Lasers (June 1999); U.S. Pat. No. 6,450,984; U.S. Pat. No. 6,450,984).
- This disclosure pertains to an ocular implant comprising a longitudinally extending body having an inlet portion and a Schlemm's canal portion distal to the inlet portion, the inlet portion being configured to extend into and be in fluid communication with an anterior chamber of a human eye and the Schlemm's canal portion being configured to be inserted into Schlemm's canal adjacent to collector channels of the eye, a plurality of alternating spines and frames positioned longitudinally along at least a portion of the Schlemm's canal portion wherein the plurality of alternating spines and frames define a central channel extending therethrough, with the central channel being in fluid communication with the inlet portion, each of the spines having edges partially defining an opening across from the central channel and in fluid communication with the central channel, and each of the frames including first and second struts, the first and second struts each having an edge contiguous with an edge of an adjacent spine, the edges defining the opening in fluid communication with the central channel, wherein the ocular implant is configured to provide at least a 121% increase in average outflow facility of aqueous humor from the anterior chamber through the collector channels of the eye.
- In some embodiments, the implant comprises at least three openings across from the central channel.
- In other embodiments, the average outflow facility comprises 0.438 μl/min/mmHg.
- In one embodiment, a peak circumferential flow rate through the ocular implant comprises 3.2 μl/min.
- In some embodiments, the implant comprises at least six openings across from the central channel.
- In one embodiment, the average outflow facility comprises 0.638 μl/min/mmHg.
- In some embodiments, a peak circumferential flow rate through the ocular implant comprises 5.7 μl/min.
- In one embodiment, the average outflow facility of the eye prior to implantation of the ocular implant comprises 0.138 μl/min/mmHg.
- An ocular implant adapted to reside at least partially in a portion of Schlemm's canal of an eye adjacent to collector channels of the eye is provided, the implant comprising a longitudinally extending curved body including a proximal portion and a distal portion, the distal portion of the curved body defining a longitudinal channel including a channel opening, and the curved body being adapted and configured such that the distal portion of the curved body resides in Schlemm's canal and the proximal portion extends into the anterior space of the eye while the ocular implant assumes an orientation in which the channel opening is adjacent a major side of Schlemm's canal when the ocular implant is implanted, wherein the ocular implant is configured to provide a 121%-222% increase in average outflow facility of aqueous humor from the anterior chamber through the collector channels of the eye.
- In some embodiments, the implant comprises at least three openings across from the central channel.
- In other embodiments, the average outflow facility comprises 0.438 μl/min/mmHg.
- In one embodiment, a peak circumferential flow rate through the ocular implant comprises 3.2 μl/min.
- In some embodiments, the implant comprises at least six openings across from the central channel.
- In one embodiment, the average outflow facility comprises 0.638 μl/min/mmHg.
- In some embodiments, a peak circumferential flow rate through the ocular implant comprises 5.7 μl/min.
- In one embodiment, the average outflow facility of the eye prior to implantation of the ocular implant comprises 0.138 μl/min/mmHg.
- In one embodiment, the distal portion of the curved body occupies up to 20% of Schlemm's canal but accounts for up to 54.5% of total outflow in the eye.
- In another embodiment, the distal portion of the curved body occupies up to 40% of Schlemm's canal but accounts for up to 74.6% of total outflow in the eye.
- An ocular implant is provided comprising an inlet portion and a Schlemm's canal portion distal to the inlet portion, the inlet portion being disposed at a proximal end of the implant and sized and configured to be placed within an anterior chamber of a human eye, the inlet portion having an inlet adapted to be in fluid communication with the anterior chamber, the Schlemm's canal portion comprising a central channel in fluid communication with the inlet, the central channel extending longitudinally in the Schlemm's canal portion, a first element disposed along the central channel, a second element disposed along the central channel distal to the first element, a third element disposed along the central channel distal to the first element and proximal to the second, a fourth element disposed along the central channel distal to the second element, the first, second, third and fourth elements each comprising two edges partially defining an elongate opening in fluid communication with the central channel, each of the first, second, third and fourth elements having circumferential extents less than 360 degrees so that the elongate opening extends continuously along the first, second, third and fourth elements, the circumferential extents of the first and second elements being less than the circumferential extents of the third and fourth elements, the Schlemm's canal portion being arranged and configured to be disposed within Schlemm's canal of the eye when the inlet portion is disposed in the anterior chamber, wherein the ocular implant is configured to provide a 121%-222% increase in average outflow facility of aqueous humor from the anterior chamber through the collector channels of the eye.
- In some embodiments, the implant comprises at least three openings across from the central channel.
- In other embodiments, the average outflow facility comprises 0.438 μl/min/mmHg.
- In one embodiment, a peak circumferential flow rate through the ocular implant comprises 3.2 μl/min.
- In some embodiments, the implant comprises at least six openings across from the central channel.
- In one embodiment, the average outflow facility comprises 0.638 μl/min/mmHg.
- In some embodiments, a peak circumferential flow rate through the ocular implant comprises 5.7 μl/min.
- In one embodiment, the average outflow facility of the eye prior to implantation of the ocular implant comprises 0.138 μl/min/mmHg.
- In one embodiment, the distal portion of the curved body occupies up to 20% of Schlemm's canal but accounts for up to 54.5% of total outflow in the eye.
- In another embodiment, the distal portion of the curved body occupies up to 40% of Schlemm's canal but accounts for up to 74.6% of total outflow in the eye.
- A method of treating glaucoma is provided, comprising supporting tissue forming Schlemm's canal in an eye with an implant extending at least partially in the canal along an axial length within the canal, contacting with the implant less than 50% of the tissue forming the canal along the axial length, disposing an inlet portion of the implant in an anterior chamber of the eye, and providing fluid communication between the anterior chamber and the canal axially through the inlet into a channel of the implant such that an average outflow facility between the anterior chamber and the canal is increased by 121%-222%, and wherein the implant comprises open areas separated by spine areas along a first longitudinal section, the spine areas partially defining the channel, the supporting step comprising orienting the first longitudinal section openings towards a trabecular mesh portion of the canal.
- An ocular implant adapted to reside at least partially in a portion of Schlemm's canal of a human eye is provided, the implant comprising a body configured to extend within Schlemm's canal in a curved volume having a large radius side and a short radius side, the body having a circumferential extent within the curved volume that varies along the length of the body between sections having a lesser circumferential extent and sections having a greater circumferential extent, wherein the body defines a channel extending longitudinally through the body, the channel having a substantially open side disposed on the large radius side at one of the sections of lesser circumferential extent and an adjacent section of greater circumferential extent and a plurality of openings along the length of the body on the short radius side, the openings being in fluid communication with the channel, and an inlet portion configured to be disposed in an anterior chamber of the eye when the body is in Schlemm's canal, the inlet portion disposed on a proximal end of the body in fluid communication with the channel, the inlet portion defining one or more openings in fluid communication with the anterior chamber of the eye, wherein the ocular implant is configured to provide a 121%-222% increase in average outflow facility of aqueous humor from the anterior chamber through the collector channels of the eye.
- An ocular implant adapted to reside at least partially in a portion of Schlemm's canal of an eye, the eye having an iris defining a pupil is provided, the implant comprising a longitudinally extending curved body including a proximal portion and a distal portion, the distal portion of the curved body having a central longitudinal axis defined by a radius of curvature and a lateral cross section having a first lateral extent and a second lateral extent, an aspect ratio of the first lateral extent to the second lateral extent being greater than or equal to about two, the distal portion of the curved body defining a longitudinal channel including a channel opening, the channel opening included in defining the first lateral extent, the curved body being adapted and configured such that the distal portion of the curved body resides in Schlemm's canal and the proximal portion extends into the anterior space of the eye while the ocular implant assumes an orientation in which the channel opening is adjacent a major side of Schlemm's canal when the ocular implant is implanted, and wherein the ocular implant is configured to provide a 121%-222% increase in average outflow facility of aqueous humor from the anterior chamber through the collector channels of the eye.
- The novel features of the invention are set forth with particularity in the claims that follow. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
-
FIG. 1 is a stylized perspective view depicting a portion of a human eye and a portion of an ocular implant disposed in Schlemm's canal. -
FIG. 2 is an enlarged perspective view showing a portion of the implant ofFIG. 1 . -
FIG. 3 is a perspective view showing a volume defined by the body of the ocular implant ofFIGS. 1 and 2 . -
FIG. 4 is a perspective view showing a first plane intersecting the body of an ocular implant. -
FIG. 5 is a perspective view showing a bending moment being applied to an ocular implant. -
FIG. 6 is a plan view of the implant shown inFIG. 5 but in the absence of any bending moment. -
FIG. 7A is a lateral cross-sectional view of the ocular implant ofFIG. 6 taken along section line A-A ofFIG. 6 . -
FIG. 7B is a lateral cross-sectional view of the ocular implant ofFIG. 6 taken along section line B-B ofFIG. 6 . -
FIG. 8 is an enlarged cross-sectional view of the ocular implant ofFIG. 6 taken along section line B-B ofFIG. 6 . -
FIG. 9 is an enlarged cross-sectional view of the ocular implant ofFIG. 6 taken along section line A-A ofFIG. 6 . -
FIG. 10 is a plan view showing an ocular implant according to another embodiment of the invention having a longitudinal radius of curvature that varies along its length. -
FIG. 11 is a perspective view showing an ocular implant according to yet another embodiment of the invention that has substantially no radius of curvature. -
FIG. 12 is a stylized representation of a medical procedure in accordance with this detailed description. -
FIG. 13A is a perspective view further illustrating adelivery system 100 used in the medical procedure shown in the previous Figure.FIG. 13B is an enlarged detail view further illustrating a cannula of the delivery system shown in the previous Figure. -
FIG. 14 is a stylized perspective view illustrating the anatomy of an eye. -
FIG. 15 is a stylized perspective view showing Schlemm's canal and an iris of the eye shown in the previous Figure. -
FIG. 16 is an enlarged cross-sectional view further illustrating Schlemm's canal SC shown in the previous Figure. -
FIG. 17 is a perspective view showing an ocular implant in accordance with this detailed description. -
FIG. 18A andFIG. 18B are section views showing an ocular implant disposed in Schlemm's canal of an eye. -
FIG. 19A ,FIG. 19B andFIG. 19C are multiple plan views illustrating an implant in accordance with the present detailed description. -
FIG. 20 is a lateral cross-sectional view of an ocular implant taken along section line A-A shown in the previous Figure. -
FIG. 21A is a perspective view of an ocular implant andFIG. 21B is a stylized perspective view showing Schlemm's canal SC encircling an iris. -
FIG. 22A is a perspective view showing adelivery system 12100 that may be used to advance an ocular implant into Schlemm's canal of an eye.FIG. 22B is an enlarged detail view illustrating a cannula portion of the delivery system. -
FIG. 23 is an enlarged perspective view of an assembly including a cannula, an ocular implant, and a sheath. -
FIG. 24 is an additional perspective view of the assembly shown in the previous Figure. -
FIG. 25 is another perspective view of an assembly including a cannula, an ocular implant, and a sheath. -
FIG. 26 is an additional perspective view of the assembly shown in the previous Figure. -
FIG. 27A andFIG. 27B are perspective views showing a sheath in accordance with the present detailed description. -
FIG. 28 is a perspective view of an assembly including the sheath shown in the previous Figure. -
FIG. 29A andFIG. 29B are simplified plan views showing a sheath in accordance with the present detailed description. -
FIG. 30A ,FIG. 30B andFIG. 30C are plan views showing an implant in accordance with the present detailed description. -
FIG. 31 is a lateral cross-sectional view of an ocular implant taken along section line A-A shown in the previous Figure. -
FIG. 32 is a plan view showing an implant in accordance with the present detailed description. -
FIG. 33A ,FIG. 33B andFIG. 33C are plan views showing an additional implant in accordance with the present detailed description. -
FIG. 34 is a lateral cross-sectional view of an ocular implant taken along section line B-B shown in the previous Figure. -
FIG. 35 is a plan view showing an implant in accordance with the present detailed description. -
FIG. 36A throughFIG. 36D are a series of plan views illustrating a method in accordance with the present detailed description. -
FIG. 37A throughFIG. 37D are a series of section views illustrating a method in accordance with the present detailed description. -
FIG. 38A andFIG. 38B are simplified plan views showing a sheath in accordance with the present detailed description. -
FIG. 39 is a diagram showing the results of mathematical simulations of 8 mm and 16 mm ocular implants. -
FIG. 40 is a diagram showing circumferential flow rates for 8 mm and 16 mm ocular implants. -
FIG. 1 is a stylized perspective view depicting a portion of ahuman eye 20.Eye 20 can be conceptualized as a fluid filled ball having two chambers.Sclera 22 ofeye 20 surrounds aposterior chamber 24 filled with a viscous fluid known as vitreous humor.Cornea 26 ofeye 20 encloses an anterior chamber 30 that is filled with a fluid know as aqueous humor. Thecornea 26 meets the sclera 22 at a limbus 28 ofeye 20. Alens 32 ofeye 20 is located between anterior chamber 30 andposterior chamber 24.Lens 32 is held in place by a number ofciliary zonules 34. - Whenever a person views an object, he or she is viewing that object through the cornea, the aqueous humor, and the lens of the eye. In order to be transparent, the cornea and the lens can include no blood vessels. Accordingly, no blood flows through the cornea and the lens to provide nutrition to these tissues and to remove wastes from these tissues. Instead, these functions are performed by the aqueous humor. A continuous flow of aqueous humor through the eye provides nutrition to portions of the eye (e.g., the cornea and the lens) that have no blood vessels. This flow of aqueous humor also removes waste from these tissues.
- Aqueous humor is produced by an organ known as the ciliary body. The ciliary body includes epithelial cells that continuously secrete aqueous humor. In a healthy eye, a stream of aqueous humor flows out of the eye as new aqueous humor is secreted by the epithelial cells of the ciliary body. This excess aqueous humor enters the blood stream and is carried away by venous blood leaving the eye.
- In a healthy eye, aqueous humor flows out of the anterior chamber 30 through the
trabecular meshwork 36 and into Schlemm'scanal 38, located at the outer edge of theiris 42. Aqueous humor exits Schlemm'scanal 38 by flowing through a number ofoutlets 40. After leaving Schlemm'scanal 38, aqueous humor is absorbed into the venous blood stream. - In
FIG. 1 , anocular implant 100 is disposed in Schlemm'scanal 38 ofeye 20.Ocular implant 100 has abody 102 including a plurality oftissue supporting frames 104 and a plurality ofspines 106.Body 102 also includes afirst edge 120 and asecond edge 122 that define afirst opening 124.First opening 124 is formed as a slot and fluidly communicates with anelongate channel 126 defined by aninner surface 128 ofbody 102. With reference toFIG. 1 , it will be appreciated thatfirst opening 124 is disposed on anouter side 130 ofbody 102. Accordingly,channel 126 opens in a radiallyoutward direction 132 viafirst opening 124. -
Ocular implant 100 may be inserted into Schlemm's canal of a human eye to facilitate the flow of aqueous humor out of the anterior chamber. This flow may include axial flow along Schlemm's canal, flow from the anterior chamber into Schlemm's canal, and flow leaving Schlemm's canal via outlets communicating with Schlemm's canal. When in place within the eye,ocular implant 100 will support trabecular mesh tissue and Schlemm's canal tissue and will provide for improved communication between the anterior chamber and Schlemm's canal (via the trabecular meshwork) and between pockets or compartments along Schlemm's canal. As shown inFIG. 1 , the implant is preferably oriented so that thefirst opening 124 is disposed radially outwardly within Schlemm's canal. -
FIG. 2 is an enlarged perspective view showing a portion ofocular implant 100 shown in the previous figure.Ocular implant 100 has abody 102 that extends along a generally curvedlongitudinal axis 134.Body 102 has a plurality oftissue supporting frames 104 and a plurality ofspines 106. As shown inFIG. 2 , thesespines 106 and frames 104 are arranged in a repeating AB pattern in which each A is a tissue supporting frame and each B is a spine. In the embodiment ofFIG. 2 , one spine extends between each adjacent pair offrames 104 - The
frames 104 ofbody 102 include afirst frame 136 ofocular implant 100 that is disposed between afirst spine 140 and asecond spine 142. In the embodiment ofFIG. 2 ,first frame 136 is formed as afirst strut 144 that extends betweenfirst spine 140 andsecond spine 142.First frame 136 also includes asecond strut 146 extending betweenfirst spine 140 andsecond spine 142. In the exemplary embodiment ofFIG. 2 , each strut undulates in a circumferential direction as it extends longitudinally betweenfirst spine 140 andsecond spine 142. - In the embodiment of
FIG. 2 ,body 102 has alongitudinal radius 150 and alateral radius 148.Body 102 ofocular implant 100 includes afirst edge 120 and asecond edge 122 that define afirst opening 124. First opening 124 fluidly communicates with anelongate channel 126 defined by aninner surface 128 ofbody 102. Asecond opening 138 is defined by asecond edge 122A of afirst strut 144 and a second edge 122B of asecond strut 146.First opening 124,second opening 138 and additional openings defined byocular implant 100 allow aqueous humor to flow laterally across and/or laterally throughocular implant 100. The outer surfaces ofbody 102 define avolume 152. -
FIG. 3 is an additional perspectiveview showing volume 152 defined by the body of the ocular implant shown in the previous figure. With reference toFIG. 3 , it will be appreciated thatvolume 152 extends along a generally curvedlongitudinal axis 134.Volume 152 has alongitudinal radius 150, alateral radius 148, and a generally circularlateral cross section 153. -
FIG. 4 is a perspective view showing afirst plane 154 and a second plane 155 that both intersectocular implant 100. InFIG. 4 ,first plane 154 is delineated with hatch marks. With reference toFIG. 4 , it will be appreciated thatspines 106 ofbody 102 are generally aligned with one another and thatfirst plane 154 intersects allspines 106 shown inFIG. 4 . In the embodiment ofFIG. 4 ,body 102 ofocular implant 100 is generally symmetric aboutfirst plane 154. - In the embodiment of
FIG. 4 , the flexibility ofbody 102 is at a maximum whenbody 102 is bending alongfirst plane 154, andbody 102 has less flexibility when bending along a plane other than first plane 154 (e.g., a plane that intersects first plane 154). For example, in the embodiment shown inFIG. 4 ,body 102 has a second flexibility when bending along second plane 155 that is less than the first flexibility thatbody 102 has when bending alongfirst plane 154. - Stated another way, in the embodiment of
FIG. 4 , the bending modulus ofbody 102 is at a minimum whenbody 102 is bent alongfirst plane 154.Body 102 has a first bending modulus when bent alongfirst plane 154 and a greater bending modulus when bent along a plane other than first plane 154 (e.g., a plane that intersects first plane 154). For example, in the embodiment shown inFIG. 4 ,body 102 has a second bending modulus when bent along second plane 155 that is greater than the first bending modulus thatbody 102 has when bent alongfirst plane 154. -
FIG. 5 is an enlarged perspective view showing a portion ofocular implant 100 shown in the previous figure. In the exemplary embodiment ofFIG. 5 , a bending moment M is being applied tobody 102 ofocular implant 100. Bending moment M acts about afirst axis 156 that is generally orthogonal tofirst plane 154. Asecond axis 158 and athird axis 160 are also shown inFIG. 5 .Second axis 158 is generally perpendicular tofirst axis 156.Third axis 160 is skewed relative tofirst axis 156. - An
inner surface 128 ofbody 102 defines achannel 126.Body 102 ofocular implant 100 includes afirst edge 120 and asecond edge 123 that define afirst opening 124.Channel 126 ofocular implant 100 fluidly communicates withfirst opening 124. Asecond opening 138 is defined by asecond edge 122A of afirst strut 144 and a second edge 122B of asecond strut 146.First opening 124,second opening 138 and additional openings defined byocular implant 100 allow aqueous humor to flow laterally across and/or laterally throughocular implant 100. - As shown in
FIG. 5 ,ocular implant 100 has afirst spine 140 and asecond spine 142.First strut 144 and asecond strut 146 form afirst frame 136 ofocular implant 100 that extends betweenfirst spine 140 andsecond spine 142. In the exemplary embodiment ofFIG. 5 , each strut undulates in a circumferential direction as it extends longitudinally betweenfirst spine 140 andsecond spine 142. - In the embodiment of
FIG. 5 , the flexibility ofbody 102 is at a maximum whenbody 102 is bent by a moment acting aboutfirst axis 156, andbody 102 has less flexibility when bent by a moment acting about an axis other than first axis 156 (e.g.,second axis 158 and third axis 160). Stated another way, the bending modulus ofbody 102 is at a minimum whenbody 102 is bent by a moment acting aboutfirst axis 156, andbody 102 has a greater bending modulus when bent by a moment acting about an axis other than first axis 156 (e.g.,second axis 158 and third axis 160). -
FIG. 6 is a plan view showingocular implant 100 shown in the previous figure. In the embodiment ofFIG. 6 , no external forces are acting onbody 102 ofocular implant 100, andbody 102 is free to assume the generally curved resting shape depicted inFIG. 6 .Body 102 defines afirst opening 124 that is disposed on anouter side 130 ofbody 102. Achannel 126 is defined by the inner surface ofbody 102 and opens in a radiallyoutward direction 132 viafirst opening 124. - Section lines A-A and B-B are visible in
FIG. 6 . Section line A-A intersects afirst frame 136 ofocular implant 100. Section line B-B intersects afirst spine 140 ofocular implant 100. -
FIG. 7A is a lateral cross-sectional view ofocular implant 100 taken along section line A-A shown in the previous figure. Section line A-A intersects afirst strut 144 and asecond strut 146 offirst frame 136 at the point where the circumferential undulation of these struts is at its maximum.Body 102 ofocular implant 100 has alongitudinal radius 150 and alateral radius 148. Aninner surface 128 ofbody 102 defines achannel 126. Afirst opening 124 fluidly communicates withchannel 126. - In
FIG. 7A ,first opening 124 inbody 102 can be seen extending betweenfirst edge 120A offirst strut 144 and afirst edge 120B ofsecond strut 146. With reference toFIG. 7A , it will be appreciated thatsecond strut 146 has a shape that is a mirror image of the shape offirst strut 144. -
FIG. 7B is a lateral cross-sectional view ofocular implant 100 taken along section line B-B shown in the previous figure. Section line B-B intersectsfirst spine 140 ofocular implant 100.Body 102 has alongitudinal radius 150 and alateral radius 148. In the embodiment ofFIG. 7B , thecenter 159 oflateral radius 148 and thecenter 163 oflongitudinal radius 150 are disposed on opposite sides offirst spine 140. Thecenter 159 oflateral radius 148 is disposed on a first side offirst spine 140. Thecenter 163 oflongitudinal radius 150 is disposed on a second side ofsecond spine 142. -
FIG. 8 is an enlarged cross-sectional view ofocular implant 100 taken along section line B-B ofFIG. 6 .First spine 140 includes a firstmajor side 160, a secondmajor side 162, a firstminor side 164, and secondminor side 166. With reference toFIG. 8 , it will be appreciated that firstmajor side 160 comprises aconcave surface 168. Secondmajor side 162 is opposite firstmajor side 160. In the embodiment ofFIG. 8 , secondmajor side 162 comprises aconvex surface 170. - The geometry of the spine provides the ocular implant with flexibility characteristics that may aid in advancing the ocular implant into Schlemm's canal. In the embodiment of
FIG. 8 ,first spine 140 has a thickness T1 extending between firstmajor side 160 and secondmajor side 162. Also in the embodiment ofFIG. 8 ,first spine 140 has a width W1 extending between firstminor side 164 and secondminor side 166. - In some useful embodiments, the spine of an ocular implant in accordance with this detailed description has an aspect ratio of width W1 to thickness T1 greater than about 2. In some particularly useful embodiments, the spine of an ocular implant in accordance with this detailed description has an aspect ratio of width W1 to thickness T1 greater than about 4. In one useful embodiment, the ocular implant has a spine with an aspect ratio of width W1 to thickness T1 of about 5.2.
- A
first axis 156, asecond axis 158 and athird axis 160 are shown inFIG. 8 .Second axis 158 is generally perpendicular tofirst axis 156.Third axis 160 is skewed relative tofirst axis 156. - In the embodiment of
FIG. 8 , the flexibility offirst spine 140 is at a maximum whenfirst spine 140 is bent by a moment acting aboutfirst axis 156.First spine 140 has a first flexibility when bent by a moment acting aboutfirst axis 156 and less flexibility when bent by a moment acting about an axis other than first axis 156 (e.g.,second axis 158 and third axis 160). For example,first spine 140 has a second flexibility when bent by a moment acting aboutsecond axis 158 shown inFIG. 8 . This second flexibility is less than the first flexibility thatfirst spine 140 has when bent by a moment acting aboutfirst axis 156. - In the embodiment of
FIG. 8 , the bending modulus offirst spine 140 is at a minimum whenfirst spine 140 is bent by a moment acting aboutfirst axis 156.First spine 140 has a first bending modulus when bent by a moment acting aboutfirst axis 156 and a greater bending modulus when bent by a moment acting about an axis other than first axis 156 (e.g.,second axis 158 and third axis 160). For example,first spine 140 has a second bending modulus when bent by a moment acting aboutsecond axis 158 shown inFIG. 8 . This second bending modulus is greater than the first bending modulus thatfirst spine 140 has when bent by a moment acting aboutfirst axis 156. -
FIG. 9 is an enlarged cross-sectional view ofocular implant 100 taken along section line A-A ofFIG. 6 . Section line A-A intersectsfirst strut 144 andsecond strut 146 at the point where the circumferential undulation of these struts is at its maximum. - Each strut shown in
FIG. 9 includes a firstmajor side 160, a secondmajor side 162, a firstminor side 164, and secondminor side 166. With reference toFIG. 9 , it will be appreciated that each firstmajor side 160 comprises aconcave surface 168 and each secondmajor side 162 comprises aconvex surface 170. - In the embodiment of
FIG. 9 , each strut has a thickness T2 extending between firstmajor side 160 and secondmajor side 162. Also in the embodiment ofFIG. 9 , each strut has a width W2 extending between firstminor side 164 and secondminor side 166. In some useful embodiments, an ocular implant in accordance with this detailed description includes spines having a width W1 that is greater than the width W2 of the struts of the ocular implant. - In some useful embodiments, the struts of an ocular implant in accordance with this detailed description have an aspect ratio of width W2 to thickness T2 greater than about 2. In some particularly useful embodiments, the struts of an ocular implant in accordance with this detailed description have an aspect ratio of width W2 to thickness T2 greater than about 4. One exemplary ocular implant has struts with an aspect ratio of width W2 to thickness T2 of about 4.4.
-
Body 102 ofocular implant 100 has alongitudinal radius 150 and alateral radius 148. In some useful embodiments, an ocular implant in accordance with this detailed description is sufficiently flexible to assume a shape matching the longitudinal curvature of Schlemm's canal when the ocular implant advanced into the eye. Also in some useful embodiments, a length of the ocular implant is selected so that the implant will extend across a pre-selected angular span when the implant is positioned in Schlemm's canal. Examples of pre-selected angular spans that may be suitable in some applications include 60°, 90°, 150° and 180°. The diameter of an ocular implant in accordance with this detailed description may be selected so that the ocular implant is dimensioned to lie within and support Schlemm's canal. In some useful embodiments, the diameter of the ocular implant ranges between about 0.005 inches and about 0.04 inches. In some particularly useful embodiments, the diameter of the ocular implant ranges between about 0.005 inches and about 0.02 inches. - It is to be appreciated that an ocular implant in accordance with the present detailed description may be straight or curved. If the ocular implant is curved, it may have a substantially uniform longitudinal radius throughout its length, or the longitudinal radius of the ocular implant may vary along its length.
FIG. 6 shows one example of an ocular implant having a substantially uniform radius of curvature.FIG. 10 shows one example of an ocular implant having a longitudinal radius of curvature that varies along the length of the ocular implant. An example of a substantially straight ocular implant is shown inFIG. 11 . -
FIG. 10 is a plan view showing anocular implant 200 having a radius of curvature that varies along its length. In the embodiment ofFIG. 10 ,ocular implant 200 has an at rest shape that is generally curved. This at rest shape can be established, for example, using a heat-setting process. The ocular implant shape shown inFIG. 10 includes a distal radius RA, a proximal radius RC, and an intermediate radius RB. In the embodiment ofFIG. 10 , distal radius RA is larger than both intermediate radius RB and proximal radius RC. Also in the embodiment ofFIG. 10 , intermediate radius RB is larger than proximal radius RC and smaller than distal radius RA. In one useful embodiment, distal radius RA is about 0.320 inches, intermediate radius RB is about 0.225 inches and proximal radius RC is about 0.205 inches. - In the embodiment of
FIG. 10 , a distal portion of the ocular implant follows an arc extending across an angle AA. A proximal portion of the ocular implant follows an arc extending across an angle AC. An intermediate portion of the ocular implant is disposed between the proximal portion and the distal portion. The intermediate portion extends across an angle AB. In one useful embodiment, angle AA is about 55 degrees, angle AB is about 79 degrees and angle AC is about 60 degrees. -
Ocular implant 200 may be used in conjunction with a method of treating the eye of a human patient for a disease and/or disorder (e.g., glaucoma). Some such methods may include the step of inserting a core member into a lumen defined byocular implant 200. The core member may comprise, for example, a wire or tube. The distal end of the ocular implant may be inserted into Schlemm's canal. The ocular implant and the core member may then be advanced into Schlemm's canal until the ocular implant has reached a desired position. In some embodiments, an inlet portion of the implant may be disposed in the anterior chamber of eye while the remainder of the implant extends through the trabecular mesh into Schlemm's canal. The core member may then be withdrawn from the ocular implant, leaving the implant in place to support tissue forming Schlemm's canal. Further details of ocular implant delivery systems may be found in U.S. application Ser. No. 11/943,289, filed Nov. 20, 2007, now U.S. Pat. No. 8,512,404, the disclosure of which is incorporated herein by reference. - The flexibility and bending modulus features of the ocular implant of this invention help ensure proper orientation of the implant within Schlemm's canal.
FIG. 1 shows the desired orientation ofopening 124 when theimplant 100 is disposed in Schlemm's canal. As shown, opening 124 faces radially outward. Theimplant 100 is therefore designed so that it is maximally flexible when bent along a plane defined by the longitudinal axis ofimplant 100 as shown inFIG. 1 , and less flexible when bent in other planes, thereby enabling the curved shape of Schlemm's canal to help place the implant in this orientation automatically if the implant is initially placed in Schlemm's canal in a different orientation. -
FIG. 11 is a perspective view showing anocular implant 300 in accordance with an additional embodiment in accordance with the present detailed description. With reference toFIG. 11 , it will be appreciated thatocular implant 300 has a resting (i.e., unstressed) shape that is generally straight.Ocular implant 300 extends along alongitudinal axis 334 that is generally straight. In some useful embodiments,ocular implant 300 is sufficiently flexible to assume a curved shape when advanced into Schlemm's canal of an eye. -
Ocular implant 300 comprises abody 302. With reference toFIG. 11 , it will be appreciated thatbody 302 comprises a plurality of tissue supporting frames 304 and a plurality of spines 306. As shown inFIG. 11 , these spines 306 and frames 304 are arranged in an alternating pattern in which one spine extends between each adjacent pair of frames 304. The frames 304 ofbody 302 include afirst frame 336 ofocular implant 300 is disposed between afirst spine 340 and asecond spine 342. In the embodiment ofFIG. 11 ,first frame 336 comprises afirst strut 344 that extends betweenfirst spine 340 andsecond spine 342. Asecond strut 346 of first frame also extends betweenfirst spine 340 andsecond spine 342. Each strut undulates in a circumferential direction as it extends longitudinally betweenfirst spine 340 andsecond spine 342. - An
inner surface 328 ofbody 302 defines achannel 326.Body 302 ofocular implant 300 includes afirst edge 320 and asecond edge 322 that define afirst opening 324.Channel 326 ofocular implant 300 fluidly communicates withfirst opening 324.First strut 344 offirst frame 336 comprises afirst edge 325A.Second strut 346 has afirst edge 325B. InFIG. 11 ,first opening 324 inbody 302 can be seen extending betweenfirst edge 325A offirst strut 344 and afirst edge 325B ofsecond strut 346. - A
first axis 356, asecond axis 358 and athird axis 360 are shown inFIG. 11 .Second axis 358 is generally perpendicular tofirst axis 356.Third axis 360 is generally skewed relative tofirst axis 356. The flexibility ofbody 302 is at a maximum whenbody 302 is bent by a moment acting aboutfirst axis 356, andbody 302 has less flexibility when bent by a moment acting about an axis other than first axis 356 (e.g.,second axis 358 and third axis 360). Stated another way, in the embodiment ofFIG. 11 , the bending modulus ofbody 302 is at a minimum whenbody 302 is bent by a moment acting aboutfirst axis 356, andbody 302 has a greater bending modulus when bent by a moment acting about an axis other than first axis 356 (e.g.,second axis 358 and third axis 360). - Many of the figures illustrating embodiments of the invention show only portions of the ocular implant. It should be understood that many embodiments of the invention include an inlet portion (such as
inlet 101 inFIG. 6 andinlet 201 inFIG. 10 ) that can be placed within the anterior chamber to provide communication of aqueous humor from the anterior chamber through the trabecular mesh into Schlemm's canal via the ocular implant. Further details of the inlet feature may be found in U.S. application Ser. No. 11/860,318. -
FIG. 12 is a stylized representation of a medical procedure in accordance with this detailed description. In the procedure ofFIG. 12 , a physician is treating aneye 1220 of a patient P. In the procedure ofFIG. 12 , the physician is holding adelivery system 12100 in his or her right hand RH. The physician's left hand (not shown) may be used to hold the handle H of agonio lens 1223. It will be appreciated that some physician's may prefer holding the delivery system handle in the left hand and the gonio lens handle H in the right hand RH. - During the procedure illustrated in
FIG. 12 , the physician may view the interior of the anterior chamber usinggonio lens 1223 and amicroscope 1225. Detail A ofFIG. 12 is a stylized simulation of the image viewed by the physician. A distal portion of acannula 12102 is visible in Detail A. A shadow-like line indicates the location of Schlemm's canal SC which is lying under various tissue (e.g., the trabecular meshwork) that surround the anterior chamber. Adistal opening 12104 ofcannula 12102 is positioned near Schlemm's canal SC ofeye 1220. In some methods in accordance with this detailed description,distal opening 12104 ofcannula 12102 is placed in fluid communication with Schlemm's canal SC. When this is the case, an ocular implant may be advanced throughdistal opening 12104 and into Schlemm's canal SC. -
FIG. 13A is a perspective view further illustratingdelivery system 12100 andeye 1220 shown in the previous Figure. InFIG. 13A ,cannula 12102 ofdelivery system 12100 is shown extending through acornea 1240 ofeye 1220. A distal portion ofcannula 12102 is disposed inside the anterior chamber defined bycornea 1240 ofeye 1220. In the embodiment ofFIG. 13A ,cannula 12102 is configured so that adistal opening 12104 ofcannula 12102 can be placed in fluid communication with Schlemm's canal. - In the embodiment of
FIG. 13A , an ocular implant is disposed in a lumen defined bycannula 12102.Delivery system 12100 includes a mechanism that is capable of advancing and retracting the ocular implant along the length ofcannula 12102. The ocular implant may be placed in Schlemm's canal ofeye 1220 by advancing the ocular implant throughdistal opening 12104 ofcannula 12102 whiledistal opening 12104 is in fluid communication with Schlemm's canal. -
FIG. 13B is an enlarged detail view further illustratingcannula 12102 ofdelivery system 12100. In the illustrative embodiment ofFIG. 13B , anocular implant 12126 has been advanced throughdistal opening 12104 ofcannula 12102.Cannula 12102 ofFIG. 13B defines apassageway 12124 that fluidly communicates withdistal opening 12104.Ocular implant 12126 may be moved alongpassageway 12124 and through distal opening bydelivery system 12100.Delivery system 12100 includes a mechanism capable of performing this function. -
FIG. 14 is a stylized perspective view illustrating a portion ofeye 1220 discussed above.Eye 1220 includes aniris 1230 defining apupil 1232. InFIG. 14 ,eye 1220 is shown as a cross-sectional view created by a cutting plane passing through the center ofpupil 1232.Eye 1220 can be conceptualized as a fluid filled ball having two chambers.Sclera 1234 ofeye 1220 surrounds a posterior chamber PC filled with a viscous fluid known as vitreous humor.Cornea 1236 ofeye 1220 encloses an anterior chamber AC that is filled with a fluid known as aqueous humor. Thecornea 1236 meets thesclera 1234 at alimbus 1238 ofeye 1220. Alens 1240 ofeye 1220 is located between anterior chamber AC and posterior chamber PC.Lens 1240 is held in place by a number ofciliary zonules 1242. - Whenever a person views an object, he or she is viewing that object through the cornea, the aqueous humor, and the lens of the eye. In order to be transparent, the cornea and the lens can include no blood vessels. Accordingly, no blood flows through the cornea and the lens to provide nutrition to these tissues and to remove wastes from these tissues. Instead, these functions are performed by the aqueous humor. A continuous flow of aqueous humor through the eye provides nutrition to portions of the eye (e.g., the cornea and the lens) that have no blood vessels. This flow of aqueous humor also removes waste from these tissues.
- Aqueous humor is produced by an organ known as the ciliary body. The ciliary body includes epithelial cells that continuously secrete aqueous humor. In a healthy eye, a stream of aqueous humor flows out of the eye as new aqueous humor is secreted by the epithelial cells of the ciliary body. This excess aqueous humor enters the blood stream and is carried away by venous blood leaving the eye.
- Schlemm's canal SC is a tube-like structure that encircles
iris 1230. Two laterally cut ends of Schlemm's canal SC are visible in the cross-sectional view ofFIG. 14 . In a healthy eye, aqueous humor flows out of anterior chamber AC and into Schlemm's canal SC. Aqueous humor exits Schlemm's canal SC and flows into a number of collector channels. After leaving Schlemm's canal SC, aqueous humor is absorbed into the venous blood stream and carried out of the eye. -
FIG. 15 is a stylized perspective view showing Schlemm's canal SC andiris 1230 ofeye 1220 shown in the previous Figure. InFIG. 15 , Schlemm's canal SC is shown encirclingiris 1230. With reference toFIG. 15 , it will be appreciated that Schlemm's canal SC mayoverhang iris 1230 slightly.Iris 1230 defines apupil 1232. In the embodiment ofFIG. 15 , Schlemm's canal SC andiris 1230 are shown in cross-section, with a cutting plane passing through the center ofpupil 1232. - The shape of Schlemm's canal SC is somewhat irregular, and can vary from patient to patient. The shape of Schlemm's canal SC may be conceptualized as a cylindrical-tube that has been partially flattened. With reference to
FIG. 15 , it will be appreciated that Schlemm's canal SC has a firstmajor side 1250, a secondmajor side 1252, a firstminor side 1254, and a secondminor side 1256. - Schlemm's canal SC forms a ring around
iris 1230 withpupil 1232 disposed in the center of that ring. With reference toFIG. 15 , it will be appreciated that firstmajor side 1250 is on the outside of the ring formed by Schlemm's canal SC and secondmajor side 1252 is on the inside of the ring formed by Schlemm's canal SC. Accordingly, firstmajor side 1250 may be referred to as an outer major side of Schlemm's canal SC and secondmajor side 1252 may be referred to as an inner major side of Schlemm's canal SC. With reference toFIG. 15 , it will be appreciated that firstmajor side 1250 is further frompupil 1232 than secondmajor side 1252. -
FIG. 16 is an enlarged cross-sectional view further illustrating Schlemm's canal SC shown in the previous Figure. With reference toFIG. 16 , it will be appreciated that Schlemm's canal SC comprises a wall W defining alumen 1258. The shape of Schlemm's canal SC is somewhat irregular, and can vary from patient to patient. The shape of Schlemm's canal SC may be conceptualized as a cylindrical-tube that has been partially flattened. The cross-sectional shape oflumen 1258 may be compared to the shape of an ellipse. Amajor axis 1260 and aminor axis 1262 oflumen 1258 are illustrated with dashed lines inFIG. 16 . - The length of
major axis 1260 andminor axis 1262 can vary from patient to patient. The length ofminor axis 1262 is between one and thirty micrometers in most patients. The length ofmajor axis 1260 is between one hundred and fifty micrometers and three hundred and fifty micrometers in most patients. - With reference to
FIG. 16 , it will be appreciated that Schlemm's canal SC comprises a firstmajor side 1250, a secondmajor side 1252, a firstminor side 1254, and a secondminor side 1256. In the embodiment ofFIG. 16 , firstmajor side 1250 is longer than both firstminor side 1254 and secondminor side 1256. Also in the embodiment ofFIG. 16 , secondmajor side 1252 is longer than both firstminor side 1254 and secondminor side 1256. -
FIG. 17 is a perspective view showing an ocular implant in accordance with this detailed description.Ocular implant 12126 ofFIG. 17 comprises abody 12128 that extends along a generally curved longitudinalcentral axis 12148. In the embodiment ofFIG. 17 ,body 12128 has a radius of curvature R that is represented with an arrow extending between a lateralcentral axis 12176 andbody 12128. -
Body 12128 ofocular implant 12126 has a firstmajor surface 12130 and a secondmajor surface 12132. With reference toFIG. 17 , it will be appreciated thatbody 12128 is curved about longitudinalcentral axis 12148 so that firstmajor surface 12130 comprises aconcave surface 12136 and secondmajor surface 12132 comprises aconvex surface 12134. The curvature ofbody 12128 can be pre-sized and configured to align with the curvature of Schlemm's canal in a patient's eye. - A distal portion of
body 12128 defines alongitudinal channel 12138 including achannel opening 12139.Channel opening 12139 is disposed diametrically opposite acentral portion 12135 ofconcave surface 12136. Because of the curvature of thebody 12128, an outer diameter of the implant defined by thechannel opening 12139 will be greater than an inner diameter of the implant defined bysurface 12132. In some embodiments, the body is pre-biased to assume a configuration in which thechannel opening 12139 is disposed along an outer diameter of the body, ensuring that the channel opening can be positioned adjacent to the firstmajor side 1250 of Schlemm's canal. - In the embodiment of
FIG. 17 ,central portion 12135 ofconcave surface 12136 defines a plurality ofapertures 12137. Eachaperture 12137 fluidly communicates withchannel 12138. In some useful embodiments,body 12128 is adapted and configured such thatocular implant 12126 assumes an orientation in whichchannel opening 12139 is adjacent a major side of Schlemm's canal whenocular implant 12126 is disposed in Schlemm's canal.Ocular implant 12126 can be made, for example, bylaser cutting body 12128 from a length of metal or a shape memory material (e.g., nitinol or stainless steel) tubing. -
FIG. 18A andFIG. 18B are section views showing anocular implant 12126 disposed in Schlemm's canal SC of an eye.FIG. 18A andFIG. 18B may be collectively referred to asFIG. 18 . The eye ofFIG. 18 includes aniris 1230. A central portion ofiris 1230 defines apupil 1232. Schlemm's canal SC is disposed near an outer edge ofiris 1230. The trabecular meshwork TM extends up from the iris of overlays Schlemm's canal SC. The picture plane ofFIG. 18 extends laterally across Schlemm's canal SC and the trabecular meshwork TM. - Schlemm's canal SC forms a ring around
iris 1230 withpupil 1232 disposed in the center of that ring. Schlemm's canal SC has a firstmajor side 1250, a secondmajor side 1252, a firstminor side 1254, and a secondminor side 1256. With reference toFIG. 18 , it will be appreciated that firstmajor side 1250 is further frompupil 1232 than secondmajor side 1252. In the embodiment ofFIG. 18 , firstmajor side 1250 is an outer major side of Schlemm's canal SC and secondmajor side 1252 is an inner major side of Schlemm's canal SC. - In the embodiment of
FIG. 18A , a distal portion ofocular implant 12126 is shown resting in Schlemm's canal SC. A proximal portion ofocular implant 12126 is shown extending out of Schlemm's canal SC, through trebecular meshwork TM and into anterior chamber AC.Ocular implant 12126 ofFIG. 18 comprises a body having a firstmajor surface 12130 and a secondmajor surface 12132. With reference toFIG. 17 , it will be appreciated that the body ofocular implant 126 is curved about a longitudinal central axis so that firstmajor surface 12130 comprises a concave surface and secondmajor surface 12132 comprises a convex surface. - A distal portion of
ocular implant 12126 defines alongitudinal channel 12138 including achannel opening 12139.Channel opening 12139 is disposed diametrically opposite acentral portion 12135 of firstmajor surface 12130. In the embodiment ofFIG. 18A ,ocular implant 12126 is assuming an orientation in whichchannel opening 12139 is adjacent and open to first major side 50 of Schlemm's canal. In the embodiment ofFIG. 18B ,ocular implant 12126 is assuming an orientation in whichchannel opening 12139 is adjacent and open to secondmajor side 1252 of Schlemm's canal. -
FIG. 19A ,FIG. 19B andFIG. 19C illustrate multiple plan views of animplant 12126 in accordance with the present detailed description.FIG. 19A ,FIG. 19B andFIG. 19C may be referred to collectively asFIG. 19 . It is customary to refer to multi-view projections using terms such as front view, top view, and side view. In accordance with this convention,FIG. 19A may be referred to as a top view ofimplant 12126,FIG. 19B may be referred to as a side view ofimplant 12126, andFIG. 19C may be referred to as a bottom view ofimplant 12126. The terms top view, side view, and bottom view are used herein as a convenient method for differentiating between the views shown inFIG. 19 . It will be appreciated that the implant shown inFIG. 8 may assume various orientations without deviating from the spirit and scope of this detailed description. Accordingly, the terms top view, side view, and bottom view should not be interpreted to limit the scope of the invention recited in the attached claims. -
Ocular implant 12126 ofFIG. 19 comprises abody 12128 that extends along a longitudinalcentral axis 12148.Body 12128 ofocular implant 12126 has a firstmajor surface 12130 and a secondmajor surface 12132. In the embodiment ofFIG. 19 ,body 12128 is curved about longitudinalcentral axis 12148 so that firstmajor surface 12130 comprises aconcave surface 12136 and secondmajor surface 12132 comprises aconvex surface 12134. - A distal portion of
body 12128 defines alongitudinal channel 12138 including achannel opening 12139.Channel opening 12139 is disposed diametrically opposite acentral portion 12135 ofconcave surface 12136. In the embodiment ofFIG. 19 ,central portion 12135 ofconcave surface 12136 defines a plurality ofapertures 12137. Eachaperture 12137 fluidly communicates withchannel 12138. In some useful embodiments,body 12128 is adapted and configured such thatocular implant 12126 assumes an orientation in whichchannel opening 12139 is adjacent a major side of Schlemm's canal whenocular implant 12126 is disposed in Schlemm's canal. -
FIG. 20 is a lateral cross-sectional view ofocular implant 12126 taken along section line A-A shown in the previous Figure.Ocular implant 12126 comprises abody 12128 having a firstmajor surface 12130 and a secondmajor surface 12132. With reference toFIG. 20 , it will be appreciated thatbody 12128 curves around a longitudinalcentral axis 12148 so that firstmajor surface 12130 comprises aconcave surface 12136 and secondmajor surface 12132 comprises aconvex surface 12134. Theconcave surface 12136 ofbody 12128 defines alongitudinal channel 12138 having achannel opening 12139. - As shown in
FIG. 20 ,channel 12138 has a width WD and a depth DP.Body 12128 ofocular implant 12126 has a first lateral extent EF and a second lateral extent ES. In some cases,body 12128 is adapted and configured such thatocular implant 12126 automatically assumes an orientation in which the channel opening is adjacent a major side of Schlemm's canal whenocular implant 12126 is disposed in Schlemm's canal. In some useful embodiments, an aspect ratio of first lateral extent EF to second lateral extent ES is greater than about one. In some particularly useful embodiments, the aspect ratio of first lateral extent EF to second lateral extent ES is about two. In some useful embodiments, the aspect ratio of first lateral extent EF to second lateral extent ES is greater than about two. In some useful embodiments, an aspect ratio of channel width WD to channel depth DP is greater than about one. In some particularly useful embodiments, the aspect ratio of channel width WD to channel depth DP is about two. In some useful embodiments, the aspect ratio of channel width WD to channel depth DP is greater than about two. -
FIG. 21A is a perspective view of anocular implant 12126 andFIG. 21B is a stylized perspective view showing Schlemm's canal SC encircling aniris 1230.FIG. 21A andFIG. 21B may be collectively referred to asFIG. 21 . With reference toFIG. 21B , it will be appreciated that Schlemm's canal SC mayoverhang iris 1230 slightly.Iris 1230 defines apupil 1232. Schlemm's canal SC forms a ring aroundiris 1230 withpupil 1232 disposed in the center of that ring. With reference toFIG. 21B , it will be appreciated that Schlemm's canal SC has a firstmajor side 1250, a secondmajor side 1252, a firstminor side 1254, and a secondminor side 1256. With reference toFIG. 21B , it will be appreciated that firstmajor side 1250 is further frompupil 1232 than secondmajor side 1252. In the embodiment ofFIG. 21B , firstmajor side 1250 is an outer major side of Schlemm's canal SC and secondmajor side 1252 is an inner major side of Schlemm's canal SC. - For purposes of illustration, a
window 1270 is cut through firstmajor side 1250 of Schlemm's canal SC inFIG. 21B . Throughwindow 1270, anocular implant 12126 can be seen residing in a lumen defined by Schlemm's canal.Ocular implant 12126 ofFIG. 21 comprises abody 12128 having a firstmajor surface 12130. Firstmajor surface 12130 ofbody 12128 comprises aconcave surface 12136.Body 12128 defines alongitudinal channel 12138 including achannel opening 12139.Channel opening 12139 is disposed diametrically opposite acentral portion 12135 ofconcave surface 12136. In the embodiment ofFIG. 21B ,ocular implant 12126 is assuming an orientation in whichchannel opening 12139 is adjacent firstmajor side 1250 of Schlemm's canal. -
FIG. 22A is a perspective view showing adelivery system 12100 that may be used to advance anocular implant 12126 into Schlemm's canal of an eye.Delivery system 12100 includes acannula 12102 that is coupled to ahandle H. Cannula 12102 defines a distal opening 21104. The distal portion of cannula 21102 ofdelivery system 12100 is configured and adapted to be inserted into the anterior chamber of a human subject's eye so thatdistal opening 12104 is positioned near Schlemm's canal of the eye.Cannula 12102 is sized and configured so that the distal end of cannula 21102 can be advanced through the trabecular meshwork of the eye and into Schlemm's canal. Positioningcannula 12102 in this way placesdistal opening 12104 in fluid communication with Schlemm's canal. - In the embodiment of
FIG. 22A , an ocular implant is disposed in a passageway defined bycannula 12102.Delivery system 12100 includes a mechanism that is capable of advancing and retracting the ocular implant along the length ofcannula 12102. The ocular implant may be placed in Schlemm's canal ofeye 1220 by advancing the ocular implant throughdistal opening 12104 ofcannula 12102 whiledistal opening 12104 is in fluid communication with Schlemm's canal. -
FIG. 22B is an enlarged detail view further illustratingcannula 12102 ofdelivery system 12100. With reference toFIG. 22B , it will be appreciated thatcannula 12102 comprises a tubular member defining adistal opening 12104, aproximal opening 12105, and apassageway 12124 extending betweenproximal opening 12105 anddistal opening 12104. With reference toFIG. 22B , it will be appreciated thatcannula 12102 includes acurved portion 12107 disposed betweendistal opening 12104 andproximal opening 12105. - In the embodiment of
FIG. 22B , anocular implant 12126 is disposed inpassageway 12124 defined bycannula 12102.Ocular implant 12126 ofFIG. 22B comprises abody 12128 that extends along a generally curved longitudinalcentral axis 12148.Body 12128 ofocular implant 12126 has a firstmajor surface 12130 and a secondmajor surface 12132. With reference toFIG. 22B , it will be appreciated thatbody 12128 is curved about longitudinalcentral axis 12148 so that firstmajor surface 12130 defines alongitudinal channel 12138 and secondmajor surface 12132 comprises aconvex surface 12134.Longitudinal channel 12138 includes achannel opening 12139.Ocular implant 12126 is orient relative todelivery cannula 12102 such thatlongitudinal channel 12138 ofocular implant 12126 opens in a radially outward direction RD whenocular implant 12126 is disposed incurved portion 12107. Radially outward direction RD is illustrated using an arrow inFIG. 22B .Distal opening 12104 ofcannula 12102 may be placed in fluid communication with Schlemm's canal of an eye.Implant 12126 may be advanced throughdistal opening 12104 and into Schlemm's canal while assuming the orientation shown inFIG. 22B . When this is the case,ocular implant 12126 may be oriented such thatchannel opening 12139 is adjacent an outer major side of Schlemm's canal whenocular implant 12126 is disposed in Schlemm's canal. -
FIG. 23 is an enlarged perspective view of anassembly 12106 including anocular implant 12126, asheath 12120, and acannula 12102. For purposes of illustration,cannula 12102 is cross-sectionally illustrated inFIG. 23 . In the embodiment ofFIG. 23 , asheath 12120 is shown extending into apassageway 12124 defined bycannula 12102. InFIG. 23 ,sheath 12120 is illustrated in a transparent manner with a pattern of dots indicating the presence ofsheath 12120. - With reference to
FIG. 23 , it will be appreciated that animplant 12126 is disposed in alumen 12122 defined bysheath 12120.Implant 12126 comprises abody 12128 having a firstmajor surface 12130 and a secondmajor surface 12132. In the embodiment ofFIG. 23 ,body 12128 curves around a longitudinal central axis so that firstmajor surface 12130 comprises a concave surface and secondmajor surface 12132 comprises aconvex surface 12134. The concave surface ofbody 12128 defines alongitudinal channel 12138. InFIG. 23 , acore 12166 is shown extending throughlongitudinal channel 12138. -
Body 12128 ofocular implant 12126 defines a plurality ofopenings 12140. In the embodiment ofFIG. 23 ,sheath 12120 is coveringopenings 12140. With reference toFIG. 23 , it will be appreciated thatsheath 12120 comprises aproximal portion 12150 defining alumen 12122 and adistal portion 12152 defining adistal aperture 12154.Core 12166 is shown extending throughdistal aperture 12154 inFIG. 23 . In the embodiment ofFIG. 23 ,distal portion 12152 ofsheath 12120 has a generally tapered shape. -
FIG. 24 is an additional perspective view ofassembly 12106 shown in the previous Figure. InFIG. 24 ,core 12166,sheath 12120, andimplant 12126 are shown extending through adistal port 12104 ofcannula 12102.Core 12166,sheath 12120, andimplant 12126 have been moved in a distal direction relative to the position of those elements shown in the previous Figure. - A
push tube 12180 is visible inFIG. 24 . InFIG. 24 , a distal end ofpush tube 12180 is shown contacting a proximal end ofimplant 12126. In the embodiment ofFIG. 24 ,push tube 12180 is disposed in alumen 12122 defined bysheath 12120.Sheath 12120 comprises aproximal portion 12150 defining apassageway 12124 and adistal portion 12152 defining adistal aperture 12154.Implant 12126 is disposed inlumen 12122 defined bysheath 12120. InFIG. 24 ,core 12166 is shown extending through achannel 12138 defined byimplant 12126 and adistal aperture 12154 defined bydistal portion 12152 ofsheath 12120. -
FIG. 25 is an additional perspectiveview showing assembly 12106 shown in the previous Figure. With reference toFIG. 25 , it will be appreciated thatimplant 12126 is disposed outside ofcannula 12102. In the embodiment ofFIG. 25 ,core 12166,sheath 12120, and pushtube 12180 have been advanced further so thatimplant 12126 is in a position outside ofcannula 12102. - Methods in accordance with the present invention can be used to deliver an implant into Schlemm's canal of an eye. In these methods, a distal portion of
core 12166 andsheath 12120 may be advanced out of the distal port ofcannula 12102 and into Schlemm's canal.Ocular implant 12126 may be disposed insidesheath 12120 while the distal portion of thesheath 12120 is advanced into Schlemm's canal.Sheath 12120 andcore 12166 may then be retracted whilepush tube 12180 preventsimplant 12126 from being pulled proximally. -
FIG. 26 is an additional perspective view showing theassembly 12106 shown in the previous Figure. In the embodiment ofFIG. 26 ,core 12166 andsheath 12120 have been moved in a proximal direction relative toimplant 12126. With reference toFIG. 26 , it will be appreciated thatimplant 12126 is now disposed outside ofsheath 12120. Some methods in accordance with the present detailed description include the step of applying a proximally directed force tosheath 12120 andcore 12166 while providing a distally directed reactionary force onimplant 12126 to preventimplant 12126 from moving proximally. When this is the case,implant 12126 may pass throughdistal aperture 12154 ofsheath 12120 assheath 12120 is retracted overimplant 12126. - In the embodiment of
FIG. 26 ,distal portion 12152 ofsheath 12120 comprises afirst region 12156 and asecond region 12158. The frangible connection betweenfirst region 12156 andsecond region 12158 has been broken in the embodiment ofFIG. 26 . This frangible connection may be selectively broken, for example, whensheath 12120 is moved in a proximal direction relative to implant 12126 due to the larger diameter ofimplant 12126 with respect to the diameters ofdistal portion 12152 andopening 12154 ofsheath 12120. With reference toFIG. 26 , it will be appreciated that the width ofdistal aperture 12154 becomes larger when the frangible connection is broken. - With reference to the Figures described above, it will be appreciated that methods in accordance with the present detailed description may be used to position a distal portion of an implant in Schlemm's canal of an eye. A method in accordance with the present detailed description may include the step of advancing a distal end of a cannula through a cornea of the eye so that a distal portion of the cannula is disposed in the anterior chamber of the eye. The cannula may be used to access Schlemm's canal, for example, by piercing the wall of Schlemm's canal with a distal portion of the cannula. A distal portion of a sheath may be advanced out of a distal port of the cannula and into Schlemm's canal. An ocular implant may be disposed inside the sheath while the distal portion of the sheath is advanced into Schlemm's canal.
- In some useful methods, the ocular implant comprises a body defining a plurality of apertures and the method includes the step of covering the apertures with a sheath. When this is the case, the distal portion of the implant may be advanced into Schlemm's canal while the apertures are covered by the sheath. Covering the apertures as the implant is advanced into Schlemm's canal may reduce the trauma inflicted on Schlemm's canal by the procedure. The apertures may be uncovered, for example, after the implant has reached a desired location (e.g., inside Schlemm's canal).
- The apertures of the implant may be uncovered, for example, by moving the sheath in a proximal direction relative to the implant. In some applications, this may be accomplished by applying a proximal directed force to the sheath while holding the implant stationary. The implant may be held stationary, for example, by applying a distally directed reaction force on the implant. In one embodiment, a distally directed reaction force is provided by pushing on a proximal end of the implant with a push tube.
- Some methods include the step of ceasing advancement of the sheath into Schlemm's canal when a proximal portion of the implant remains in an anterior chamber of the eye and a distal portion of the implant lies in Schlemm's canal. When this is the case, only a distal portion of the implant is advanced into Schlemm's canal. The portion of the implant extending out of Schlemm's canal and into the anterior chamber may provide a path for fluid flow between the anterior chamber and Schlemm's canal.
- An assembly may be created by placing a core in a channel defined by the ocular implant. A sheath may be placed around the implant and the core. For example, the core and the implant may then be inserted into the lumen of a sheath. By way of another example, the sheath may be slipped over the implant and the core. The core may be withdrawn from the channel defined by the ocular implant, for example, after the implant has been delivered to a desired location.
- The core may be withdrawn from the channel, for example, by moving the core in a proximal direction relative to the implant. In some applications, this may be accomplished by applying a proximal directed force to the core while holding the implant stationary. The implant may be held stationary, for example, by applying a distally directed reaction force on the implant. In one embodiment, a distally directed reaction force is provided by pushing on a proximal end of the implant with a push tube.
- The core, the implant, and the sheath may be advanced into Schlemm's canal together. Once the implant is in a desired location, the core and the sheath may be withdrawn from the Schlemm's canal leaving the implant in the desired location. In some methods, the core and the sheath are withdrawn from Schlemm's canal simultaneously.
-
FIG. 27A andFIG. 27B are perspective views showing asheath 12120 in accordance with the present detailed description.FIG. 27A andFIG. 27B may be referred to collectively asFIG. 27 .Sheath 12120 ofFIG. 27 comprises aproximal portion 12150 defining alumen 12122 and adistal portion 12152 defining adistal aperture 12154. With reference toFIG. 27 , it will be appreciated thatlumen 12122 is generally larger thandistal aperture 12154. - In the embodiment of
FIG. 27A ,distal portion 12152 ofsheath 12120 comprises afirst region 12156, asecond region 12158, and afrangible connection 12160 betweenfirst region 12156 andsecond region 12158. InFIG. 27A , aslit 12164 defined bydistal portion 12152 is shown disposed betweenfirst region 12156 andsecond region 12158. In the embodiment ofFIG. 27A ,frangible connection 12160 comprises abridge 12162 extending acrossslit 12164. - In the embodiment of
FIG. 27B ,frangible connection 12160 has been broken.Frangible connection 12160 may be selectively broken, for example, by movingsheath 12120 in a proximal direction relative to an implant disposed inlumen 12122 having a diameter larger than the diameters ofdistal opening 12154 anddistal portion 12152 ofsheath 12120. With reference toFIG. 27 , it will be appreciated thatdistal aperture 12154 becomes larger whenfrangible connection 12160 is broken. - In the embodiment of
FIG. 27 , the presence ofslit 12164 creates a localized line of weakness indistal portion 12152 ofsheath 12120. This localized line of weakness causesdistal portion 12152 to selectively tear in the manner shown inFIG. 27 . It is to be appreciated thatdistal portion 12152 may comprise various elements that create a localized line of weakness without deviating from the spirit and scope of the present detailed description. Examples of possible elements include: a skive cut extending partially through the wall ofdistal portion 12120, a series of holes extending through the wall ofdistal portion 12120, a perf cut, a crease, and a score cut. -
FIG. 28 is a perspective view of anassembly including sheath 12120 shown in the previous Figure. In the embodiment ofFIG. 28 , animplant 12126 is shown extending throughdistal aperture 12154 defined bydistal portion 12152 ofsheath 12120.Implant 12126 defines achannel 12138. InFIG. 28 , acore 12166 can be seen resting inchannel 12138.Implant 12126 andcore 12166 extend proximally intolumen 12122 defined bysheath 12120.Distal portion 12152 ofsheath 12120 comprises afirst region 12156 and asecond region 12158. -
FIG. 29A andFIG. 29B are simplified plan views showing asheath 12120 in accordance with the present detailed description.Sheath 12120 comprises adistal portion 12152 including afirst region 12156, asecond region 12158 and a frangible connection betweenfirst region 12156 andsecond region 12158. In the embodiment ofFIG. 19A ,frangible connection 12160 is intact. In the embodiment ofFIG. 19B ,frangible connection 12160 is broken.FIG. 29A andFIG. 29B may be referred to collectively asFIG. 29 . -
Sheath 12120 ofFIG. 29 comprises aproximal portion 12150 defining alumen 12122. In the embodiment ofFIG. 29 , animplant 12126 is disposed inlumen 12122.Lumen 12122 fluidly communicates with adistal aperture 12154 defined bydistal portion 12152 ofsheath 12120.Distal portion 12152 includes aslit 12164 disposed betweenfirst region 12156 andsecond region 12158. InFIG. 29A , abridge 12162 can be seen spanningslit 12164. In some useful embodiments,distal portion 12152 ofsheath 12120 has a first hoop strength andproximal portion 12150sheath 12120 has a second hoop strength. The first hoop strength may be limited by the frangible connection in the embodiment ofFIG. 29A . When this is the case, the second hoop strength is greater than the first hoop strength. -
Sheath 12120 ofFIG. 29 comprises aproximal portion 12150 defining alumen 12122 and adistal portion 12152 defining adistal aperture 12154.Lumen 12122 has a lumen width LW. Distal aperture has an aperture width AW whenfrangible connection 12160 is intact. With reference toFIG. 29B , it will be appreciated that thedistal aperture 12154 is free to open further whenfrangible connection 12160 is broken. - In some useful embodiments, lumen width LW of
lumen 12122 is equal to or greater than the width of animplant 12126 disposed inlumen 12122. In some of these useful embodiments, aperture width AW is smaller than the width of theimplant 12126. When this is the case,frangible connection 12160 can be selectively broken by movingsheath 12120 in a proximal direction relative to theimplant 12126. -
FIG. 30A ,FIG. 30B andFIG. 30C are multiple plan views of animplant 12326 in accordance with the present detailed description.FIG. 30A ,FIG. 30B andFIG. 30C may be referred to collectively asFIG. 1309 .FIG. 30A may be referred to as a top view ofimplant 12326,FIG. 30B may be referred to as a side view ofimplant 12326, andFIG. 30C may be referred to as a bottom view ofimplant 12326. The terms top view, side view, and bottom view are used herein as a convenient method for differentiating between the views shown inFIG. 30 . It will be appreciated that the implant shown inFIG. 30 may assume various orientations without deviating from the spirit and scope of this detailed description. Accordingly, the terms top view, side view, and bottom view should not be interpreted to limit the scope of the invention recited in the attached claims. -
Ocular implant 12326 ofFIG. 30 comprises abody 12328 that extends along a longitudinalcentral axis 12348.Body 12328 ofocular implant 12326 has a firstmajor surface 12330 and a secondmajor surface 12332. In the embodiment ofFIG. 30 ,body 12328 is curved about longitudinalcentral axis 12348 so that firstmajor surface 12330 comprises aconcave surface 12336 and secondmajor surface 12332 comprises aconvex surface 12334. - A distal portion of
body 12328 defines alongitudinal channel 12338 including achannel opening 12339.Channel opening 12339 is disposed diametrically opposite acentral portion 12335 ofconcave surface 12336. In the embodiment ofFIG. 30 ,central portion 12335 ofconcave surface 12336 defines a plurality ofapertures 12337. Eachaperture 12337 fluidly communicates withchannel 12338. -
FIG. 31 is a lateral cross-sectional view ofocular implant 12326 taken along section line B-B shown in the previous Figure.Ocular implant 12326 comprises abody 12328 having a firstmajor surface 12330 and a secondmajor surface 12332. With reference toFIG. 31 , it will be appreciated thatbody 12328 curves around a longitudinalcentral axis 12348 so that firstmajor surface 12330 comprises aconcave surface 12336 and secondmajor surface 12332 comprises aconvex surface 12334. Theconcave surface 12336 ofbody 12328 defines alongitudinal channel 12338 having achannel opening 12339. As shown inFIG. 31 ,body 12328 has a circumferential extent that spans an angle W. In the embodiment ofFIG. 31 , angle W has a magnitude that is greater than one hundred eighty degrees. -
FIG. 32 is a cross-sectional view showing animplant 12326 in accordance with the present detailed description.Ocular implant 12326 ofFIG. 32 comprises abody 12328 that extends along a generally curved longitudinal central axis 348. In the embodiment ofFIG. 32 ,body 12328 has a distal radius of curvature RD and a proximal radius of curvature RP. Each radius of curvature is represented with an arrow inFIG. 32 . Distal radius of curvature RD is represented by an arrow extending between a first lateralcentral axis 12376 and a distal portion of longitudinalcentral axis 12348. Proximal radius of curvature RP is represented by an arrow extending between a second lateralcentral axis 12378 and a proximal portion of longitudinalcentral axis 12348. In the embodiment ofFIG. 32 ,body 12328 ofocular implant 12326 has an at rest shape that is generally curved. This at rest shape can be established, for example, using a heat-setting process. The rest shape of the implant can be generally aligned with the radius of curvature of Schlemm's canal in a human eye. -
FIG. 33A ,FIG. 33B andFIG. 33C are multiple plan views of animplant 12526 in accordance with the present detailed description.FIG. 33A ,FIG. 33B andFIG. 33C may be referred to collectively asFIG. 33 .FIG. 33A may be referred to as a top view ofimplant 12526,FIG. 33B may be referred to as a side view ofimplant 12526, andFIG. 33C may be referred to as a bottom view ofimplant 12526. The terms top view, side view, and bottom view are used herein as a convenient method for differentiating between the views shown inFIG. 33 . It will be appreciated that the implant shown inFIG. 33 may assume various orientations without deviating from the spirit and scope of this detailed description. - Accordingly, the terms top view, side view, and bottom view should not be interpreted to limit the scope of the invention recited in the attached claims.
-
Ocular implant 12526 ofFIG. 33 comprises abody 12528 that extends along a longitudinalcentral axis 12548.Body 12528 ofocular implant 12526 has a firstmajor surface 12530 and a secondmajor surface 12532. In the embodiment ofFIG. 33 ,body 12528 is curved about longitudinalcentral axis 12548 so that firstmajor surface 12530 comprises aconcave surface 12536 and secondmajor surface 12532 comprises aconvex surface 12534. - A distal portion of
body 12528 defines alongitudinal channel 12538 including achannel opening 12539.Channel opening 12539 is disposed diametrically opposite acentral portion 12535 ofconcave surface 12536. In the embodiment ofFIG. 33 ,central portion 12535 ofconcave surface 12536 defines a plurality ofapertures 12537. Eachaperture 12537 fluidly communicates withchannel 12538. -
FIG. 34 is a lateral cross-sectional view ofocular implant 12526 taken along section line C-C shown in the previous Figure.Ocular implant 12526 comprises a body having a firstmajor side 12530 and a secondmajor side 12532. With reference toFIG. 34 , it will be appreciated thatbody 12528 curves around a longitudinal central axis 1248 so that firstmajor side 12530 comprises aconcave surface 12536 and secondmajor side 12532 comprises aconvex surface 12534. Theconcave surface 12536 ofbody 12528 defines alongitudinal channel 12538 having achannel opening 12539. As shown inFIG. 34 ,body 12528 has a circumferential extent that spans an angle C. In the embodiment ofFIG. 34 , angle C has a magnitude that is about one hundred eighty degrees. Some useful implants in accordance with the present detailed description comprise a body having a circumferential extend that spans an angle that is about one hundred eighty degrees. Some particularly useful implants in accordance with the present detailed description comprise a body having a circumferential extend that spans an angle that is equal to or less than one hundred eighty degrees. -
FIG. 35 is a plan view showing animplant 12526 in accordance with the present detailed description.Ocular implant 12526 ofFIG. 35 comprises abody 12528 that extends along a generally curved longitudinalcentral axis 12548. In the embodiment ofFIG. 35 ,body 12528 has a distal radius of curvature RD and a proximal radius of curvature RP. Each radius of curvature is represented with an arrow inFIG. 35 . Distal radius of curvature RD is represented by an arrow extending between a first lateralcentral axis 12576 and a distal portion of longitudinalcentral axis 12548. Proximal radius of curvature RP is represented by an arrow extending between a second lateralcentral axis 12578 and a proximal portion of longitudinalcentral axis 12548. In the embodiment ofFIG. 35 ,body 12528 ofocular implant 12526 has an at rest shape that is generally curved. This at rest shape can be established, for example, using a heat-setting process. -
FIG. 36A throughFIG. 36D are a series of plan views illustrating a method in accordance with the present detailed description.FIG. 36A is a plan view showing animplant 12426.Implant 12426 comprises abody 12428 defining a plurality ofopenings 12440.Openings 12440 include afirst opening 12442 and asecond opening 12444. -
FIG. 36B is a plan view showing anassembly 12408 includingimplant 12426.Assembly 12408 ofFIG. 36B may be created by placing acore 12406 in achannel 12438 defined byimplant 12426. Asheath 12420 may be placed aroundimplant 12426 andcore 12406. For example,core 12406 andimplant 12426 may be inserted into a lumen defined bysheath 12420. By way of another example,sheath 12420 may be slipped overimplant 12426 andcore 12406. -
FIG. 36C is a planview showing assembly 12408 disposed in Schlemm's canal SC. The wall W of Schlemm's canal SC comprises a plurality ofcells 1290. With reference toFIG. 36C , it will be appreciated thatsheath 12420 is disposed betweenimplant 12426 andcells 1290. A method in accordance with the present detailed description may include the step of advancing a distal end of a cannula through a cornea of the eye so that a distal portion of the cannula is disposed in the anterior chamber of the eye. The cannula may be used to access Schlemm's canal, for example, by piercing the wall of Schlemm's canal with a distal portion of the cannula. A distal portion ofsheath 12420 may be advanced out of a distal port of the cannula and into Schlemm's canal SC.Ocular implant 12426 may be disposed insidesheath 12420 while the distal portion ofsheath 12420 is advance into Schlemm's canal SC. - In the embodiment of
FIG. 36C ,ocular implant 12426 comprises a body defining a plurality ofopenings 12440. With reference toFIG. 36C , it will be appreciated thatopenings 12440 are covered bysheath 12420 and that a distal portion ofimplant 12426 may be advanced into Schlemm's canal whileopenings 12440 are covered bysheath 12420. Coveringopenings 12440 asimplant 12426 is advanced into Schlemm's canal SC may reduce the trauma inflicted oncells 1290 by the procedure. - In some useful embodiments,
sheath 12420 comprises a coating disposed on an outer surface thereof. The properties of the coating may be selected to further reduce the trauma inflicted oncells 1290 by the procedure. The coating may comprise, for example, a hydrophilic material. The coating may also comprise, for example, a lubricious polymer. Examples of hydrophilic materials that may be suitable in some applications include: polyalkylene glycols, alkoxy polyalkylene glycols, copolymers of methylvinyl ether and maleic acid poly(vinylpyrrolidone), poly(N-alkylacrylamide), poly(acrylic acid), poly(vinyl alcohol), poly(ethyleneimine), methyl cellulose, carboxymethyl cellulose, polyvinyl sulfonic acid, heparin, dextran, modified dextran and chondroitin sulphate. - In
FIG. 36C , the distal portion ofsheath 12420 is shown extending between a smaller, distal diameter and a larger, proximal diameter. In the embodiment ofFIG. 36C , the distal portion ofsheath 12420 has a generally tapered shape. The tapered transition of the distal portion ofsheath 12420 may create a nontraumatic transition that dilates Schlemm's canal SC assheath 12420 is advanced into Schlemm's canal SC. This arrangement may reduce the likelihood that skiving of wall W occurs assheath 12420 is advanced into Schlemm's canal SC. -
FIG. 36D is a planview showing implant 12426 disposed in Schlemm's canal SC. In the embodiment ofFIG. 36D ,openings 12440 defined bybody 12428 have been uncovered.Openings 12440 may be uncovered, for example, by movingsheath 12420 in a proximal direction relative toimplant 12426. In some applications, this may be accomplished by applying a proximal directed force tosheath 12420 while holdingimplant 12426 stationary.Implant 12426 may be held stationary, for example, by applying a distally directed reaction force onimplant 12426. In the embodiment ofFIG. 36 , a distally directed reaction force may be provided by pushing on a proximal end ofimplant 12426 with a push tube. - In the embodiment of
FIG. 36D ,core 12406 has been removedchannel 12438 defined byimplant 12426.Core 12406 may be withdrawn fromchannel 12438, for example, by movingcore 12406 in a proximal direction relative toimplant 12426. In some applications, this may be accomplished by applying a proximal directed force tocore 12406 while holdingimplant 12426 stationary.Implant 12426 may be held stationary, for example, by applying a distally directed reaction force onimplant 12426. -
FIG. 37A throughFIG. 37D are a series of section views illustrating a method in accordance with the present detailed description. The picture plane ofFIG. 37A extends laterally across Schlemm's canal SC and thetrabecular meshwork 12596 overlaying Schlemm's canal SC. In the embodiment ofFIG. 37A , the distal end of acannula 12502 has been positioned proximate Schlemm's canal SC. A method in accordance with the present detailed description may include the step of advancing the distal end ofcannula 12502 through the cornea of an eye so that a distal portion ofcannula 12502 is disposed in theanterior chamber 12594 of the eye. -
FIG. 37B is an additional section view showing Schlemm's canal SC shown in the previous Figure. InFIG. 37B , a distal portion of cannula 502 is shown extending through a wall W of Schlemm's canal SC andtrabecular meshwork 12596. Adistal port 12504 ofcannula 12502 fluidly communicates with Schlemm's canal in the embodiment ofFIG. 37B . -
FIG. 37C is an additional section view showing Schlemm's canal SC shown in the previous Figure. In the embodiment ofFIG. 37C , a distal portion of asheath 12520 is shown extending throughdistal port 12504 ofcannula 12502 and into Schlemm's canal SC. Methods in accordance with the present invention can be used to deliver animplant 12526 into Schlemm's canal SC. In these methods, a distal portion ofsheath 12520 and acore 12506 may be advanced out ofdistal port 12504 ofcannula 12502 and into Schlemm's canal SC.Ocular implant 12526 may be disposed insidesheath 12520 while the distal portion ofsheath 12520 is advanced into Schlemm's canal SC. -
FIG. 37D is an additional sectionview showing implant 12526 shown in the previous Figure. In the embodiment ofFIG. 37D ,sheath 12520,core 12506, andcannula 12502 have all been withdrawn from the eye.Implant 12526 is shown resting in Schlemm's canal SC inFIG. 37D . -
FIG. 38A andFIG. 38B are simplified plan views showing asheath 12720 in accordance with the present detailed description.FIG. 38A andFIG. 38B may be referred to collectively asFIG. 38 .Sheath 12720 ofFIG. 38 comprises aproximal portion 12750 defining alumen 12722 and adistal portion 12752 defining adistal aperture 12754. With reference toFIG. 38 , it will be appreciated thatlumen 12722 is generally larger thandistal aperture 12754. - In the embodiment of
FIG. 38A ,distal portion 12752 ofsheath 12720 comprises afirst region 12756, asecond region 12758, and afrangible connection 12760 betweenfirst region 12756 andsecond region 12758. InFIG. 38A , afirst slit 12764 defined bydistal portion 12752 is shown disposed betweenfirst region 12756 andsecond region 12758. In the embodiment ofFIG. 38A ,frangible connection 12760 comprises abridge 12762 extending acrossfirst slit 12764. With reference toFIG. 38A , it will be appreciated thatdistal portion 12752 defines a number of slits in addition tofirst slit 12764. - In the embodiment of
FIG. 38B ,frangible connection 12760 has been broken.Frangible connection 12760 may be selectively broken, for example, by movingsheath 12720 in a proximal direction relative to an implant disposed inlumen 12722 having a diameter larger than the diameters ofdistal opening 12754 anddistal portion 12752 ofsheath 12720. With reference toFIG. 38 , it will be appreciated thatdistal aperture 12754 becomes larger whenfrangible connection 12760 is broken. - In the embodiment of
FIG. 38 , the presence ofslit 12764 creates a localized line of weakness indistal portion 12752 ofsheath 12720. This localized line of weakness causesdistal portion 12752 to selectively tear in the manner shown inFIG. 38 . It is to be appreciated thatdistal portion 12752 may comprise various elements that create a localized line of weakness without deviating from the spirit and scope of the present detailed description. Examples of possible elements include: a skive cut extending partially through the wall ofdistal portion 12720, a series of holes extending through the wall ofdistal portion 12720, a pert cut, a crease, and a score cut. - In
FIG. 38 ,distal portion 12752 ofsheath 12720 is shown extending betweendistal opening 12754 andlumen 12722. In the embodiment ofFIG. 38 ,distal portion 12752 ofsheath 12720 has a blunt shape. The blunt shape ofdistal portion 12752 ofsheath 12720 may create a nontraumatic transition that dilates Schlemm's canal assheath 12720 is advanced into Schlemm's canal. This arrangement may reduce the likelihood that skiving of the canal wall occurs assheath 12720 is advanced into Schlemm's canal. - Various fabrication techniques may be used to fabricate the ocular implant. For example, the ocular implant can be fabricated by providing a generally flat sheet of material, cutting the sheet of material, and forming the material into a desired shape. By way of a second example, the ocular implant may be fabricated by providing a tube and laser cutting openings in the tube to form the ocular implant.
- The ocular implant of this invention can be fabricated from various biocompatible materials possessing the necessary structural and mechanical attributes. Both metallic and non-metallic materials may be suitable. Examples of metallic materials include stainless steel, tantalum, gold, titanium, and nickel-titanium alloys known in the art as Nitinol. Nitinol is commercially available from Memry Technologies (Brookfield, Conn.), TiNi Alloy Company (San Leandro, Calif.), and Shape Memory Applications (Sunnyvale, Calif.).
- The ocular implant may include one or more therapeutic agents. One or more therapeutic agents may, for example, be incorporated into a polymeric coating that is deposited onto the outer surfaces of the struts and spines of the ocular implant. The therapeutic agent may comprise, for example, an anti-glaucoma drug. Examples of anti-glaucoma drugs include prostaglandin analogs. Examples of prostaglandin analogs include latanprost.
- The implants of the present disclosure provide a treatment for glaucoma by combining the mechanism of trabecular meshwork (TM) bypass and Schlemm's canal (SC) dilation. The trabecular meshwork bypass is achieved through the openings, the longitudinal channel, and channel opening of the implants above, and Schlemm's canal dilation is achieved by supporting Schlemm's canal with the body of the implant itself.
- A comprehensive mathematical model was developed in this disclosure to evaluate changes in fluid dynamics of aqueous humor outflow induced by combinations of trabecular mesh bypass and/or Schlemm's canal dilation, and to predict how the changes would affect outflow facility. First, a control eye was modeled after an ex vivo human anterior segment perfusion model using typical dimensions for the eye and Schlemm's canal. This was done in order to validate the model parameters with experimental data. Next, two combinations of bypass and dilation were modeled using the dimensional parameters of implants with 8 mm and 16 mm lengths. The mathematical model was used to predict outflow facilities in control and experimental simulations.
- The mathematical model was developed to numerically simulate aqueous humor outflow based on the assumptions and physical principles that govern fluid flow. Schlemm's canal is modeled as a rectangular channel with width (w) and height (h), where h varies with the location (x) along the canal due to trabecular mesh deformation. The trabecular mesh is treated as an elastic membrane in the model. The ostia of collector channels (CC) are distributed uniformly along the outer wall of Schlemm's canal with the first collector channel located at x=0.6 mm or 0=6°. Collector channels are treated as individual sinks with flow rate, JCC (see the governing equation below). Schlemm's canal in the experimental simulations is modeled after either an 8 mm implant or 16 mm implant. The region of Schlemm's canal with an implant is also modeled as a rectangular channel but with width (wd) and height (hd) corresponding to the implant cross-sectional area.
- The height of Schlemm's canal (h) is intra-ocular pressure (IOP) dependent. The dependence is assumed to be linear:
-
h=h 0*(1−IOP−PSCE) (1) - Across the trabecular meshwork, the aqueous humor flux (JTM) is dependent on the trabecular mesh resistance (RTM) and is governed by:
-
- In these equations, Psc is the fluid pressure in the Schlemm's canal, E is the Young's modulus of the trabecular meshwork, h0 is the value of h when intra-ocular pressure=Psc, RTM is the trabecular meshwork's resistance to fluid flow, Q is the flow rate along the SC, μ is the viscosity of aqueous humor, xcc indicates locations of collector channel ostia in the Schlemm's canal, JCC is the flow rate in the collector channels, Pepi is the pressure in the episcleral veins, and RCC is the flow resistance of collector channels that may depend on xcc. Since Schlemm's canal is a ring-like channel, the boundary conditions at x=0 for Psc and Q are the same as those at x=L, where L is the circumferential length of Schlemm's canal.
- In simulations with an implant such as those described herein, a portion of Schlemm's canal is stretched open. The implant inlet is assumed to be a uni-directional fluid source with zero flow resistance Psc=IOP. The implant is modeled as a channel with three side walls, leaving the side facing the outer wall of Schlemm's canal open. For example,
FIGS. 7A-7B show an implant having three “walls” comprisingfirst strut 144,second strut 146, andspine 140 which leaves opening orchannel 124 open and facing Schlemm's canal when implanted. The wall of the implant facing the inner wall of Schlemm's canal (spine 140) contains several windows (or openings), which allow the aqueous humor to enter SC through the TM. - Two scaffold designs are investigated in this disclosure. One has a total length of 8 mm with 3 windows and 3 spines (shown in
FIGS. 2, 4, 11, 17, 19A -C, 30A-C, 32, 33A-C, 35); and another has a total length of 16 mm with 5 windows and 6 spines (shown inFIG. 6, 10, 21A ). Individual dimensions of 8 mm and 16 mm implants are shown in Table 2A and 2B, respectively. The governing equations for the region of SC without the scaffold and RTM in window regions are equal to control parameters listed in Section (a). In the spine regions,Equations 1 and 2 are replaced by h=hs and JTM=0, respectively. Equations 3 through 5 are unchanged, excepted that w and h are replaced with hd and wd, respectively. The boundary conditions are given as IOP=Psc at x=0 and Q=0 at x=L. Additionally, Psc and Q are continuous at the distal end of the scaffold. - The baseline values of the constants are given in Table 1.
-
TABLE 1 Universal Parameters Parameter Description Value h0 Intrinsic Height of SC 20 μm w Width of SC 230 μm L Length of SC 36 mm E Young's modulus of TM 30 mmHg ΔP IOP - Pepi 5 ≦ ΔP ≦ 30 mmHg NCC Number of CCs 30 RTM TM Resistance to Flow 9 cm mmHg/(μl/min) RCC Resistance to flow in CC 2.5*NCC mmHg/(μl/min) β Ratio of RCC in control 3 SC vs. SC with TM bypass μ Viscosity of AH 7.5 × 10−4 kg/(m sec) or 0.75 cP - Dimensions of the implants shown in Table 2A-2B are estimated based on the actual sizes except width.
-
TABLE 2A Geometric Parameters of 8 mm implant Parameter Description Value Aw Area of window region 17553 μm2 As Area of spine region 22955 μm2 Ain Area of inlet region 29841 μm2 hw Height of window region 76.3 μm hs Height of spine region 99.8 μm hin Height of inlet region 129.7 μm Lw Length of window region 1.1 mm Nw Number of windows 3 wd Width of device 230 μm Lin Length of inlet spine region 1.1 mm Ldev Length of device in SC 7.2 mm Ls Length of spine region 0.9 mm -
TABLE 2B Geometric Parameters of 16 mm implant Parameter Description Value Aw Area of window region 20994 μm2 As Area of spine region 32092 μm2 Ain Area of inlet region 29841 μm2 hw Height of window region 91.3 μm hs Height of spine region 139.5 μm hin Height of inlet region 129.7 μm Lw Length of window region 1 mm Nw Number of windows 5 wd Width of device 230 μm Lin Length of inlet spine region 1.1 mm Ldev Length of device in SC 15 mm Ls Length of spine region 1.5 mm - For simplicity, the width of all implants are assumed to be the same as that of the intact Schlemm's canal; and the height of each implant is calculated from the cross-sectional areas estimated for that device divided by wd. In Table 1, the viscosity of aqueous humor (μ) at 37° C. is assumed to be the same as that measured at 34° C., because μ is close to the viscosity of water which changes only slightly (˜6%) when the temperature is increased from 34° C. to 37° C. The pressure in the episcleral vein (Pepi) is close to zero in experiments involving ex vivo perfusion of whole eye or anterior segment, but approximately equal to 8 mmHg in live eyes. In order to apply conclusions obtained from this mathematical model to both types of studies, ΔP was varied between 5 and 30 mmHg, where ΔP=IOP−Pepi, instead of changing the absolute value of IOP. Implantation of a bypass causes a significant increase in the pressure in this region of Schlemm's canal and can lead to an increase in the diameter of collector channel ostia in the region. To account for diameter increase-induced decrease in outflow resistance in collector channels, a parameter, β, can be defined as the ratio of RCC with ostia in control Schlemm's canal versus that in dilated Schlemm's canal. The value of β, which is >1, depends on how the three-dimensional shape of the collector channel is changed due to Schlemm's canal dilation and pressure increase, which is unknown at present. If the collector channel is considered as a circular channel, and its diameter is uniformly increased by a factor of two, then β equals 16 for Newtonian fluid. However, it is likely that only the portion of the collector channel near its ostium is be dilated after device implantation. Thus, a baseline value of β is assumed to be three.
- In control simulations, with the frequent and uniform distribution of collector channel ostia in Schlemm's canal, the pressure difference between Schlemm's canal and episcleral venous pressure (Psc−Pepi) showed negligible variation. This resulted in negligible circumferential flow along Schlemm's canal. When the pressure drop between the anterior chamber and episcleral veins (ΔP) was fixed at different pressures, ranging from 5 to 30 mmHg, the shapes of these profiles varied only slightly although their magnitudes were increased significantly. Therefore, only the profiles at 10 mmHg are shown in this disclosure. The total sum of the flow rates through the collector channels per unit ΔP is defined as the outflow facility (C). The average C of the control eye was 0.198 μl/min/mmHg (Table 3). When ΔP is increased from 5 to 30 mmHg, C decreased slightly in the control simulation with TM intact, which falls within the range of experimental data of human eyes reported in the literature.
-
TABLE 3 Simulated Outflow Facility Simulation Average Outflow Facility Control 0.198 8 mm implant 0.438 16 mm implant 0.638 -
FIG. 39 illustrates the results of mathematical simulations of the 8 mm and 16 mm implants with frequent and uniform circumferential distribution of collector channels and an IOP of 10 mmHg. InFIG. 39 ,solid line 390 represents the Psc in Schlemm's canal of the eye with the 8 mm implant, and dashed-line 392 represents the Psc in Schlemm's canal of the eye with the 16 mm implant.Circles 394 illustrate the flow in the collector channels of the eye with the 8 mm implant, andtriangles 396 show the flow in the collector channels of the eye with the 16 mm implant. In the simulations, the pressure in the region of Schlemm's canal (Psc) with the implants was similar to IOP. Outside this region, Psc decreased exponentially, starting at the distal end of the implants, with the smallest level of Psc slightly greater than controls. - Consequently, the outflow rate through the collector channels (Jcc) was highest in the implant regions due to the high Psc and Schlemm's canal dilation-induced reduction in outflow resistance in these collector channels. Outside this region, the profile of Jcc matched the Psc profile and was similar for both implants. The collector channels in the scaffold regions contributed to a majority of the overall difference in flow rate through collector channels when compared to controls. The average C value for the 8 mm implant was 121% greater than controls with a C value of 0.438 μl/min/mmHg and the 16 mm implant was 46% greater than the 8 mm implant (222% greater than controls) with a C value of 0.638 μl/min/mmHg (Table 3 above). However, the 16 mm implant reached twice as many collector channels as the 8 mm implant but only gained 46% greater outflow despite the addition of 6 collector channels. This indicates that as the distance from the collector channels to the inlet increases, the benefit to outflow facility diminishes.
- Significant circumferential flow was observed adjacent to the trabecular meshwork bypass not seen in control simulations. The peak circumferential flow rate was 3.2 μl/min with the 8 mm implant and 5.7 μl/min with the 16 mm implant. The magnitude of the circumferential flow indicates a significant portion of the total outflow passed through the trabecular mesh bypass inlet. The circumferential flow rate peaked at the position of the bypass and decreased with a linear step pattern in the implant region. At the distal end of the scaffold, the circumferential flow rate decreased exponentially until it reached zero, as shown in
FIG. 40 , in whichline 490 illustrates flow in Schlemm's canal in the 8 mm implant andline 492 illustrates flow in Schlemm's canal in the 16 mm implant. The circumferential flow region correlates to the regions of increased Psc and Jcc for both the 8 mm and 16 mm implant. Throughout the first 90 degrees of Schlemm's canal, the 16 mm implant maintained a 2.415 μl/min flow difference versus the 8 mm implant. But when 150 degrees of Schlemm's canal is reached, the difference is reduced to only 0.526 μl/min, indicating a diminishing advantage with a longer length device. - Calculations of the percentage of total aqueous humor outflow through collector channels within an implant region indicate that the longer the implanted region the greater the percentage of total outflow (Table 4).
-
TABLE 4 Percent of Total Outflow Through Collector Channels in Schlemm's Canal regions with Implants Percent of Schlemm's Average Percent of Total Type of Implant Canal Occupied Outflow in Implant Region 8 mm implant 20% 54.5% 16 mm implant 40% 74.6% - The 8 mm implant occupied three clock-hours of Schlemm's canal (20% of Schlemm's canal length), however the collector channels in that region accounted for 54.5% of the total outflow in the eye. The 16 mm implant occupied five clock-hours of Schlemm's canal (42% of Schlemm's canal length) which accounted for 74.6% of the total outflow. These results indicate that a significant portion of total outflow is diverted into the implant area and drains out collector channels adjacent to the implant. The more collector channels adjacent to the implant the larger a percentage of total outflow. Likewise, a segmental variation of the collector channel patency would make the outflow facility results dependent on implant location.
- Theoretical in vivo glaucoma scenarios were designed to simulate how different ocular implants could improve outflow in eyes with increased trabecular meshwork resistance (RTM) and reduced collector channel outflow capacity in the hemisphere of the implant. Three scenarios were simulated in Table 5, with fixed conventional outflow rate of 1.5 μL/min 27, 28 and Pepi of 10 mmHg.
-
TABLE 5 Theoretical Glaucoma Scenarios RTM Collector Channels in Theoretical Scenario (mmHg/μl/min) Implant Hemisphere Normal 2.12 Zero Blocked Glaucoma Case # 16.34 50% Blocked Glaucoma Case #2 8.78 75% Blocked - The first scenario was a normal eye, which assumed RTM to be 2.12 mmHg/4/min and no blocked collector channels. The second scenario assumed RTM to be 6.34 mmHg/4/min and 50% of the collector channels in the implanted hemisphere to be uniformly blocked including the collector channels at the trabecular mesh bypass. The third scenario assumed RTM to be 8.78 mmHg/4/min and 75% of the collector channels in the implanted hemisphere to be uniformly blocked including the collector channel at the trabecular meshwork bypass. Simulation results showed that in the control eye without implant, the intra-ocular pressures under these scenarios were 17, 25 and 30 mmHg, respectively, and based on the Goldmann equation, the corresponding outflow facilities were 0.214, 0.100 and 0.075 μL/min/mmHg, respectively. Implantation of the 8 mm implant would improve the simulated outflow facility to 0.450, 0.240 and 0.171 μL/min/mmHg, or reduce IOPs to 13.3, 16.3 and 18.8 mmHg, respectively. When compared to the control simulations, the 8 mm implant resulted in IOP reductions of 22%, 35% and 37%, respectively.
- The model shows the effects of trabecular meshwork bypass and Schlemm's canal dilation on outflow facility and subsequent IOP reduction. In analysis of the dilation length, increasing the dilated portion of Schlemm's canal from the bypass improved outflow facility. But, at a certain distance from the bypass there was diminished improvement. This indicates that dilation near the bypass creates circumferential flow from the bypass which allows more collector channels to be utilized.
- Fluid dynamic mathematical modeling of scaffolding ocular implants as described herein shows that bypassing the trabecular meshwork increases the pressure within Schlemm's canal, and increases circumferential flow rate, and the flow rate into collector channels adjacent to the trabecular meshwork bypass. The larger bypass size creates a larger increase in the circumferential flow when compared with controls. Dilation of Schlemm's canal adjacent to the trabecular meshwork bypass increases the pressure in Schlemm's canal in the area of dilation which further increases the circumferential flow. Increasing the length of dilation increases the number of collector channels accessed by the implant, however, there was diminishing improvement in circumferential flow and flow rate into collector channels over a distance of approximately one quadrant in the eye beyond the region with the implant. When trabecular meshwork resistance was increased and collector channels were closed segmentally to simulate glaucoma, the dependence on the location of trabecular meshwork bypass to collector channels and the dilation length of Schlemm's canal was more pronounced.
- While exemplary embodiments of the present invention have been shown and described, modifications may be made, and it is therefore intended in the appended claims to cover all such changes and modifications which fall within the true spirit and scope of the invention.
Claims (31)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/012,544 US20170360609A9 (en) | 2007-09-24 | 2016-02-01 | Methods and devices for increasing aqueous humor outflow |
US16/552,211 US11744734B2 (en) | 2007-09-24 | 2019-08-27 | Method of implanting an ocular implant |
US16/828,054 US12016796B2 (en) | 2007-09-24 | 2020-03-24 | Methods and devices for increasing aqueous humor outflow |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/860,318 US7740604B2 (en) | 2007-09-24 | 2007-09-24 | Ocular implants for placement in schlemm's canal |
US12/236,225 US8734377B2 (en) | 2007-09-24 | 2008-09-23 | Ocular implants with asymmetric flexibility |
US22415809P | 2009-07-09 | 2009-07-09 | |
US12/833,863 US8425449B2 (en) | 2009-07-09 | 2010-07-09 | Ocular implants and methods for delivering ocular implants into the eye |
US13/865,770 US9211213B2 (en) | 2009-07-09 | 2013-04-18 | Ocular implants and methods for delivering ocular implants into the eye |
US14/246,363 US9039650B2 (en) | 2007-09-24 | 2014-04-07 | Ocular implants with asymmetric flexibility |
US201562110293P | 2015-01-30 | 2015-01-30 | |
US14/691,267 US9610196B2 (en) | 2007-09-24 | 2015-04-20 | Ocular implants with asymmetric flexibility |
US14/932,658 US10406025B2 (en) | 2009-07-09 | 2015-11-04 | Ocular implants and methods for delivering ocular implants into the eye |
US15/012,544 US20170360609A9 (en) | 2007-09-24 | 2016-02-01 | Methods and devices for increasing aqueous humor outflow |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/691,267 Continuation-In-Part US9610196B2 (en) | 2007-09-24 | 2015-04-20 | Ocular implants with asymmetric flexibility |
US14/932,658 Continuation-In-Part US10406025B2 (en) | 2007-09-24 | 2015-11-04 | Ocular implants and methods for delivering ocular implants into the eye |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/552,211 Continuation US11744734B2 (en) | 2007-09-24 | 2019-08-27 | Method of implanting an ocular implant |
US16/828,054 Division US12016796B2 (en) | 2007-09-24 | 2020-03-24 | Methods and devices for increasing aqueous humor outflow |
Publications (2)
Publication Number | Publication Date |
---|---|
US20160220417A1 true US20160220417A1 (en) | 2016-08-04 |
US20170360609A9 US20170360609A9 (en) | 2017-12-21 |
Family
ID=56552713
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/012,544 Abandoned US20170360609A9 (en) | 2007-09-24 | 2016-02-01 | Methods and devices for increasing aqueous humor outflow |
US16/552,211 Active 2030-05-14 US11744734B2 (en) | 2007-09-24 | 2019-08-27 | Method of implanting an ocular implant |
US16/828,054 Active 2030-08-02 US12016796B2 (en) | 2007-09-24 | 2020-03-24 | Methods and devices for increasing aqueous humor outflow |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/552,211 Active 2030-05-14 US11744734B2 (en) | 2007-09-24 | 2019-08-27 | Method of implanting an ocular implant |
US16/828,054 Active 2030-08-02 US12016796B2 (en) | 2007-09-24 | 2020-03-24 | Methods and devices for increasing aqueous humor outflow |
Country Status (1)
Country | Link |
---|---|
US (3) | US20170360609A9 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9855167B2 (en) | 2012-03-20 | 2018-01-02 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US9931243B2 (en) | 2011-12-19 | 2018-04-03 | Ivantis, Inc. | Delivering ocular implants into the eye |
US10299958B2 (en) | 2015-03-31 | 2019-05-28 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US10314742B2 (en) | 2006-06-26 | 2019-06-11 | Sight Sciences, Inc. | Intraocular implants and methods and kits therefor |
US10363168B2 (en) | 2011-06-14 | 2019-07-30 | Ivantis, Inc. | Ocular implants for delivery into the eye |
US10406030B2 (en) | 2010-02-05 | 2019-09-10 | Sight Sciences, Inc. | Intraocular implants and related kits and methods |
US10492949B2 (en) | 2009-07-09 | 2019-12-03 | Ivantis, Inc. | Single operator device for delivering an ocular implant |
US10537474B2 (en) | 2008-03-05 | 2020-01-21 | Ivantis, Inc. | Methods and apparatus for treating glaucoma |
US20200170839A1 (en) * | 2017-08-03 | 2020-06-04 | Carl Zeiss Meditec Ag | Apparatus for influencing an intraocular pressure |
US10709547B2 (en) | 2014-07-14 | 2020-07-14 | Ivantis, Inc. | Ocular implant delivery system and method |
WO2021007559A1 (en) * | 2019-07-10 | 2021-01-14 | Anand Doraiswamy | Eye stents and delivery systems |
US11504270B1 (en) | 2019-09-27 | 2022-11-22 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US11712369B2 (en) | 2012-11-28 | 2023-08-01 | Alcon Inc. | Apparatus for delivering ocular implants into an anterior chamber of the eye |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9603741B2 (en) | 2000-05-19 | 2017-03-28 | Michael S. Berlin | Delivery system and method of use for the eye |
US20170360609A9 (en) | 2007-09-24 | 2017-12-21 | Ivantis, Inc. | Methods and devices for increasing aqueous humor outflow |
US8425449B2 (en) | 2009-07-09 | 2013-04-23 | Ivantis, Inc. | Ocular implants and methods for delivering ocular implants into the eye |
US9358156B2 (en) | 2012-04-18 | 2016-06-07 | Invantis, Inc. | Ocular implants for delivery into an anterior chamber of the eye |
ES2962607T3 (en) | 2015-08-14 | 2024-03-20 | Alcon Inc | Eye implant with pressure sensor |
WO2017106517A1 (en) | 2015-12-15 | 2017-06-22 | Ivantis, Inc. | Ocular implant and delivery system |
JP2022538906A (en) | 2019-07-01 | 2022-09-06 | マイケル エス. バーリン, | Image guided method and apparatus for glaucoma surgery |
CA3202776A1 (en) | 2021-01-11 | 2022-07-14 | Wayne A. Noda | Systems and methods for viscoelastic delivery |
CN113679508A (en) * | 2021-08-25 | 2021-11-23 | 温州医科大学附属眼视光医院 | Implant for increasing aqueous humor outflow and production method of implant |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6494857B1 (en) * | 1998-09-02 | 2002-12-17 | Thomas Neuhann | Device for improving in a targeted manner and/or permanently ensuring the ability of the aqueous humor to pass through the trabecular meshwork |
US20090082860A1 (en) * | 2007-09-24 | 2009-03-26 | Schieber Andrew T | Ocular Implants with Asymmetric Flexibility |
Family Cites Families (466)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US703296A (en) | 1901-06-15 | 1902-06-24 | Arnold Nueesch | Cattle-probe. |
US1601709A (en) | 1924-01-28 | 1926-10-05 | Anderson Windom Edward | Retainable needle construction for syringes |
US2716983A (en) | 1952-10-08 | 1955-09-06 | Abbott Lab | Piercing needle |
US3071135A (en) | 1960-01-27 | 1963-01-01 | Mfg Process Lab Inc | Hollow needle |
US3788327A (en) | 1971-03-30 | 1974-01-29 | H Donowitz | Surgical implant device |
US3884236A (en) | 1971-10-28 | 1975-05-20 | Mikhail M Krasnov | Method of glaucoma treatment |
US3811442A (en) | 1972-03-23 | 1974-05-21 | A Maroth | Hypodermic syringe holder and applicator |
US3948271A (en) | 1972-11-07 | 1976-04-06 | Taichiro Akiyama | Drain for the eardrum and apparatus for introducing the same |
US3858577A (en) | 1974-04-05 | 1975-01-07 | Univ Southern California | Fiber optic laser light delivery system |
US3982541A (en) | 1974-07-29 | 1976-09-28 | Esperance Jr Francis A L | Eye surgical instrument |
US4037604A (en) | 1976-01-05 | 1977-07-26 | Newkirk John B | Artifical biological drainage device |
US4273109A (en) | 1976-07-06 | 1981-06-16 | Cavitron Corporation | Fiber optic light delivery apparatus and medical instrument utilizing same |
US4134405A (en) | 1977-01-10 | 1979-01-16 | Smit Julie A | Catheter and intestine tube and method of using the same |
EP0030210B1 (en) | 1979-11-28 | 1984-08-29 | Lasag Ag | Observation device for eye-treatment |
NO147900C (en) | 1981-03-12 | 1983-07-06 | Finn Skjaerpe | MICROSURGICAL INSTRUMENT. |
JPS589111U (en) | 1981-07-07 | 1983-01-21 | 住友電気工業株式会社 | laser scalpel |
US4457757A (en) | 1981-07-20 | 1984-07-03 | Molteno Anthony C B | Device for draining aqueous humour |
US4428746A (en) | 1981-07-29 | 1984-01-31 | Antonio Mendez | Glaucoma treatment device |
US4497319A (en) | 1981-10-28 | 1985-02-05 | Nippon Infrared Industries Co., Ltd. | Laser irradiating apparatus |
US4633866A (en) | 1981-11-23 | 1987-01-06 | Gholam Peyman | Ophthalmic laser surgical method |
US4583539A (en) | 1982-01-12 | 1986-04-22 | Cornell Research Foundation, Inc. | Laser surgical system |
US4461294A (en) | 1982-01-20 | 1984-07-24 | Baron Neville A | Apparatus and process for recurving the cornea of an eye |
US4470407A (en) | 1982-03-11 | 1984-09-11 | Laserscope, Inc. | Endoscopic device |
US4548205A (en) | 1982-10-27 | 1985-10-22 | Armeniades C D | Ophthalmic instrument for measuring intraocular fluid pressure |
US4551129A (en) | 1983-04-08 | 1985-11-05 | Coleman D Jackson | Technique and apparatus for intraocular and microsurgery including lighter-irrigator hypodermic tube |
WO1985003217A1 (en) | 1984-01-30 | 1985-08-01 | Schlegel Hans Joachim | Apparatus for perforating the front wall of the phacocyst of the eye of a living being |
US4559942A (en) | 1984-02-29 | 1985-12-24 | William Eisenberg | Method utilizing a laser for eye surgery |
US4558698A (en) | 1984-03-01 | 1985-12-17 | Dell Lawrence W O | Laser canaliculostomy eye-treatment |
US4671273A (en) | 1984-03-19 | 1987-06-09 | Lindsey Ernest J | Laser hand piece, for use in opthalmic, plastic, and ear, nose, and throat surgery |
US4538608A (en) | 1984-03-23 | 1985-09-03 | Esperance Jr Francis A L | Method and apparatus for removing cataractous lens tissue by laser radiation |
AU590198B2 (en) | 1984-06-28 | 1989-11-02 | Neil Howard Joseph | Aqueous humour drainage device |
US4580559A (en) | 1984-07-24 | 1986-04-08 | Esperance Francis A L | Indirect ophthalmoscopic photocoagulation delivery system for retinal surgery |
US4994060A (en) | 1984-09-17 | 1991-02-19 | Xintec Corporation | Laser heated cautery cap with transparent substrate |
US4722350A (en) | 1984-09-21 | 1988-02-02 | Armeniades C D | Ophthalmic instrument for measuring intraocular fluid pressure |
US4566438A (en) | 1984-10-05 | 1986-01-28 | Liese Grover J | Fiber-optic stylet for needle tip localization |
US4660546A (en) | 1984-11-07 | 1987-04-28 | Robert S. Herrick | Method for treating for deficiency of tears |
US4658816A (en) | 1984-11-14 | 1987-04-21 | Concept Incorporated | Lighted canaliculus intubation sets |
US4604087A (en) | 1985-02-26 | 1986-08-05 | Joseph Neil H | Aqueous humor drainage device |
US5034010A (en) | 1985-03-22 | 1991-07-23 | Massachusetts Institute Of Technology | Optical shield for a laser catheter |
US4689040A (en) | 1985-04-29 | 1987-08-25 | Thompson Robert J | Tip for a phacoemulsification needle |
US4601713A (en) | 1985-06-11 | 1986-07-22 | Genus Catheter Technologies, Inc. | Variable diameter catheter |
US4699140A (en) | 1985-07-10 | 1987-10-13 | Iolab Corporation | Instrument for inserting an intraocular lens |
US4770654A (en) | 1985-09-26 | 1988-09-13 | Alcon Laboratories Inc. | Multimedia apparatus for driving powered surgical instruments |
US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US4791927A (en) | 1985-12-26 | 1988-12-20 | Allied Corporation | Dual-wavelength laser scalpel background of the invention |
NZ215409A (en) | 1986-03-07 | 1989-02-24 | Anthony Christopher Be Molteno | Implant for drainage of aqueous humour in glaucoma |
US4722724A (en) | 1986-06-23 | 1988-02-02 | Stanley Schocket | Anterior chamber tube shunt to an encircling band, and related surgical procedure |
US4826478A (en) | 1986-06-23 | 1989-05-02 | Stanley Schocket | Anterior chamber tube shunt to an encircling band, and related surgical procedure |
US4919130A (en) | 1986-11-07 | 1990-04-24 | Nestle S.A. | Tool for inserting compressible intraocular lenses into the eye and method |
US4729373A (en) | 1986-12-18 | 1988-03-08 | Peyman Gholam A | Laser-powered surgical device with a vibrating crystalline tip |
US4846172A (en) | 1987-05-26 | 1989-07-11 | Berlin Michael S | Laser-delivery eye-treatment method |
US4886488A (en) | 1987-08-06 | 1989-12-12 | White Thomas C | Glaucoma drainage the lacrimal system and method |
DE3726524A1 (en) | 1987-08-10 | 1989-02-23 | Fresenius Ag | HAEMOGLOBIN DETECTOR |
US4880000A (en) | 1987-12-15 | 1989-11-14 | Iolab Corporation | Lens insertion instrument |
US4934363A (en) | 1987-12-15 | 1990-06-19 | Iolab Corporation | Lens insertion instrument |
US4876250A (en) | 1988-10-31 | 1989-10-24 | Alcon Laboratories, Inc. | Methods for controlling ocular hypertension with angiostatic steroids |
US4936825A (en) | 1988-04-11 | 1990-06-26 | Ungerleider Bruce A | Method for reducing intraocular pressure caused by glaucoma |
US4934809A (en) | 1988-06-24 | 1990-06-19 | Volk Donald A | Lens positioning device for indirect biomicroscopy of the eye |
US4861341A (en) | 1988-07-18 | 1989-08-29 | Woodburn Robert T | Subcutaneous venous access device and needle system |
DE3831141A1 (en) | 1988-09-13 | 1990-03-22 | Zeiss Carl Fa | METHOD AND DEVICE FOR MICROSURGERY ON EYE BY LASER RADIATION |
US5371078A (en) | 1988-10-31 | 1994-12-06 | Alcon Laboratories, Inc. | Angiostatic steroids and methods and compositions for controlling ocular hypertension |
US5990099A (en) | 1988-10-31 | 1999-11-23 | Alcon Laboratories, Inc. | Angiostatic agents and methods and compositions for controlling ocular hypertension |
US4946436A (en) | 1989-11-17 | 1990-08-07 | Smith Stewart G | Pressure-relieving device and process for implanting |
US5092837A (en) | 1989-12-20 | 1992-03-03 | Robert Ritch | Method for the treatment of glaucoma |
US4968296A (en) | 1989-12-20 | 1990-11-06 | Robert Ritch | Transscleral drainage implant device for the treatment of glaucoma |
US5180362A (en) | 1990-04-03 | 1993-01-19 | Worst J G F | Gonio seton |
US5129895A (en) | 1990-05-16 | 1992-07-14 | Sunrise Technologies, Inc. | Laser sclerostomy procedure |
US5127901A (en) | 1990-05-18 | 1992-07-07 | Odrich Ronald B | Implant with subconjunctival arch |
US5178604A (en) | 1990-05-31 | 1993-01-12 | Iovision, Inc. | Glaucoma implant |
US5547468A (en) | 1990-07-12 | 1996-08-20 | University Of Miami | Instruments for use in performing gel injection adjustable keratoplasty |
US5254112A (en) | 1990-10-29 | 1993-10-19 | C. R. Bard, Inc. | Device for use in laser angioplasty |
US5290267A (en) | 1991-01-17 | 1994-03-01 | Fresenius Ag | Hypodermic needle |
US5722970A (en) | 1991-04-04 | 1998-03-03 | Premier Laser Systems, Inc. | Laser surgical method using transparent probe |
US5454796A (en) | 1991-04-09 | 1995-10-03 | Hood Laboratories | Device and method for controlling intraocular fluid pressure |
US6007511A (en) | 1991-05-08 | 1999-12-28 | Prywes; Arnold S. | Shunt valve and therapeutic delivery system for treatment of glaucoma and methods and apparatus for its installation |
US5300020A (en) | 1991-05-31 | 1994-04-05 | Medflex Corporation | Surgically implantable device for glaucoma relief |
US5359685A (en) | 1991-06-21 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Focusing tips for optical fibers |
US5770592A (en) | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
US5360399A (en) | 1992-01-10 | 1994-11-01 | Robert Stegmann | Method and apparatus for maintaining the normal intraocular pressure |
US5190552A (en) | 1992-02-04 | 1993-03-02 | Kelman Charles D | Slotted tube injector for an intraocular lens |
US5213569A (en) | 1992-03-31 | 1993-05-25 | Davis Peter L | Tip for a tissue phacoemulsification device |
ATE211008T1 (en) | 1992-04-10 | 2002-01-15 | Surgilight Inc | DEVICE FOR PERFORMING EYE SURGERY |
US5246452A (en) | 1992-04-13 | 1993-09-21 | Impra, Inc. | Vascular graft with removable sheath |
US5273056A (en) | 1992-06-12 | 1993-12-28 | Alcon Laboratories, Inc. | Use of combinations of viscoelastics during surgery |
US5613972A (en) | 1992-07-15 | 1997-03-25 | The University Of Miami | Surgical cutting heads with curled cutting wings |
US5643250A (en) | 1992-08-07 | 1997-07-01 | O'donnell, Jr.; Francis E. | Laser probe hand piece |
DE4226476C1 (en) | 1992-08-10 | 1993-08-12 | Hans Dr.Med. 3015 Wennigsen De Haindl | |
US5772597A (en) | 1992-09-14 | 1998-06-30 | Sextant Medical Corporation | Surgical tool end effector |
US5383926A (en) | 1992-11-23 | 1995-01-24 | Children's Medical Center Corporation | Re-expandable endoprosthesis |
WO1994021196A2 (en) | 1993-03-18 | 1994-09-29 | C.R. Bard, Inc. | Endovascular stents |
US5676669A (en) | 1993-04-30 | 1997-10-14 | Colvard; Michael | Intraocular capsular shield |
US5458615A (en) | 1993-07-06 | 1995-10-17 | Advanced Cardiovascular Systems, Inc. | Stent delivery system |
WO1995003010A1 (en) | 1993-07-23 | 1995-02-02 | Cook Incorporated | A flexible stent having a pattern formed from a sheet of material |
US5993438A (en) | 1993-11-12 | 1999-11-30 | Escalon Medical Corporation | Intrastromal photorefractive keratectomy |
US5702402A (en) | 1994-04-29 | 1997-12-30 | Allergal | Method and apparatus for folding of intraocular lens |
US5445637A (en) | 1993-12-06 | 1995-08-29 | American Cyanamid Company | Method and apparatus for preventing posterior capsular opacification |
WO1995029737A1 (en) | 1994-05-03 | 1995-11-09 | Board Of Regents, The University Of Texas System | Apparatus and method for noninvasive doppler ultrasound-guided real-time control of tissue damage in thermal therapy |
FR2721499B1 (en) | 1994-06-22 | 1997-01-03 | Opsia | Trabeculectomy implant. |
US6102045A (en) | 1994-07-22 | 2000-08-15 | Premier Laser Systems, Inc. | Method and apparatus for lowering the intraocular pressure of an eye |
US5704907A (en) | 1994-07-22 | 1998-01-06 | Wound Healing Of Oklahoma | Method and apparatus for lowering the intraocular pressure of an eye |
JP3573531B2 (en) | 1994-08-03 | 2004-10-06 | 鐘淵化学工業株式会社 | Microcatheter |
US5814062A (en) | 1994-12-22 | 1998-09-29 | Target Therapeutics, Inc. | Implant delivery assembly with expandable coupling/decoupling mechanism |
US5811453A (en) | 1994-12-23 | 1998-09-22 | Alcon Laboratories, Inc. | Viscoelastic compositions and methods of use |
US5607966A (en) | 1994-12-23 | 1997-03-04 | Alcon Laboratories, Inc. | Esters and amides of non-steroidal anti-inflammatory carboxylic acids which may be used as anti-oxidants, 5-lipoxygenase inhibitors and non-steroidal anti-inflammatory prodrugs |
US5738676A (en) | 1995-01-03 | 1998-04-14 | Hammer; Daniel X. | Laser surgical probe for use in intraocular surgery |
WO1996020742A1 (en) | 1995-01-06 | 1996-07-11 | Wong Vernon G | Improve eye implant for relief of glaucoma |
US5792103A (en) | 1995-02-03 | 1998-08-11 | Schwartz; Daniel M. | Viscosurgical method and apparatus |
US5792099A (en) | 1995-02-14 | 1998-08-11 | Decamp; Dennis | Syringe and cannula for insertion of viscoelastic material into an eye and method of using same |
US7892226B2 (en) | 1995-03-20 | 2011-02-22 | Amo Development, Llc. | Method of corneal surgery by laser incising a contoured corneal flap |
US5501274A (en) | 1995-03-29 | 1996-03-26 | Halliburton Company | Control of particulate flowback in subterranean wells |
US5575780A (en) | 1995-04-28 | 1996-11-19 | Saito; Yoshikuni | Medical hollow needle and a method of producing thereof |
US5626558A (en) | 1995-05-05 | 1997-05-06 | Suson; John | Adjustable flow rate glaucoma shunt and method of using same |
IL113723A (en) | 1995-05-14 | 2002-11-10 | Optonol Ltd | Intraocular implant |
US5968058A (en) | 1996-03-27 | 1999-10-19 | Optonol Ltd. | Device for and method of implanting an intraocular implant |
EP0957949B1 (en) | 1995-05-14 | 2004-08-04 | Optonol Ltd. | Intraocular implant, delivery device, and method of implantation |
US5536259A (en) | 1995-07-28 | 1996-07-16 | Medisystems Technology Corp | Hypodermic cannula |
US7655002B2 (en) | 1996-03-21 | 2010-02-02 | Second Sight Laser Technologies, Inc. | Lenticular refractive surgery of presbyopia, other refractive errors, and cataract retardation |
US5807302A (en) | 1996-04-01 | 1998-09-15 | Wandel; Thaddeus | Treatment of glaucoma |
US5865831A (en) | 1996-04-17 | 1999-02-02 | Premier Laser Systems, Inc. | Laser surgical procedures for treatment of glaucoma |
US5948427A (en) | 1996-04-25 | 1999-09-07 | Point Medical Corporation | Microparticulate surgical adhesive |
BR9709071A (en) | 1996-05-09 | 2000-01-11 | Itos Innovatite Technology In | the system additionally includes a cataract removal device (crd) (204) to fragment the cataract while it is frozen by the cryomanipulator. the crd includes a drilling unit (230) having a rotary drilling blade (246) for fragmenting the cataract and a housing having suction and irrigation ducts (256). a method of using the system includes freezing-grabbing and cataract fragmentation followed by irrigation and aspiration of the fluid and cataract fragments with the crd and / or the cryomanipulator. |
US6328747B1 (en) | 1996-05-09 | 2001-12-11 | Itos Innovative Technology In Ocular Surgery, Ltd. | Method and a system for performing cataract surgery |
AUPO394496A0 (en) | 1996-11-29 | 1997-01-02 | Lions Eye Institute | Biological microfistula tube and implantation method and apparatus |
US5895831A (en) | 1996-12-04 | 1999-04-20 | Uop Llc | Solid catalyst alkylation process |
GB9700390D0 (en) | 1997-01-10 | 1997-02-26 | Biocompatibles Ltd | Device for use in the eye |
US5713844A (en) | 1997-01-10 | 1998-02-03 | Peyman; Gholam A. | Device and method for regulating intraocular pressure |
US5736491A (en) | 1997-01-30 | 1998-04-07 | Texaco Inc. | Method of improving the fuel economy characteristics of a lubricant by friction reduction and compositions useful therein |
DE19705815C2 (en) | 1997-02-15 | 1999-02-11 | Heidelberg Engineering Optisch | Medical device for microsurgery on the eye |
US5893837A (en) | 1997-02-28 | 1999-04-13 | Staar Surgical Company, Inc. | Glaucoma drain implanting device and method |
US5911732A (en) | 1997-03-10 | 1999-06-15 | Johnson & Johnson Interventional Systems, Co. | Articulated expandable intraluminal stent |
US6050970A (en) | 1997-05-08 | 2000-04-18 | Pharmacia & Upjohn Company | Method and apparatus for inserting a glaucoma implant in an anterior and posterior segment of the eye |
US6002480A (en) | 1997-06-02 | 1999-12-14 | Izatt; Joseph A. | Depth-resolved spectroscopic optical coherence tomography |
DE19728069C1 (en) | 1997-07-01 | 1999-02-11 | Acritec Gmbh | Device for measuring intraocular pressure |
EP0898947A3 (en) | 1997-08-15 | 1999-09-08 | GRIESHABER & CO. AG SCHAFFHAUSEN | Method and apparatus to improve the outflow of the aqueous humor of an eye |
JPH1156897A (en) | 1997-08-18 | 1999-03-02 | Koken Co Ltd | Collagen ophthalmologic surgery assisting agent |
US5997531A (en) | 1998-01-29 | 1999-12-07 | Cardiodyne, Inc. | User actuated laser energy device and procedure for forming a channel within tissue |
US6083193A (en) | 1998-03-10 | 2000-07-04 | Allergan Sales, Inc. | Thermal mode phaco apparatus and method |
US6099521A (en) | 1998-05-26 | 2000-08-08 | Shadduck; John H. | Semiconductor contact lens cooling system and technique for light-mediated eye therapies |
US6319274B1 (en) | 1998-06-22 | 2001-11-20 | John H. Shadduck | Devices and techniques for light-mediated stimulation of trabecular meshwork in glaucoma therapy |
US6591838B2 (en) | 1998-07-06 | 2003-07-15 | Scimed Life Systems, Inc. | Implant system and method for bulking tissue |
AU5339099A (en) | 1998-08-05 | 2000-02-28 | Keravision, Inc. | Corneal implant with migration preventer |
DE69927936T2 (en) | 1998-08-17 | 2006-06-29 | Mitsubishi Pharma Corp. | PREVENTIVA / MEDIUM FOR GLAUCOMA TREATMENT |
US6241721B1 (en) | 1998-10-09 | 2001-06-05 | Colette Cozean | Laser surgical procedures for treatment of glaucoma |
US6447520B1 (en) | 2001-03-19 | 2002-09-10 | Advanced Medical Optics, Inc. | IOL insertion apparatus with IOL engagement structure and method for using same |
US6146375A (en) | 1998-12-02 | 2000-11-14 | The University Of Michigan | Device and method for internal surface sclerostomy |
US6371904B1 (en) | 1998-12-24 | 2002-04-16 | Vivant Medical, Inc. | Subcutaneous cavity marking device and method |
US7578828B2 (en) | 1999-01-15 | 2009-08-25 | Medtronic, Inc. | Methods and devices for placing a conduit in fluid communication with a target vessel |
ATE290821T1 (en) | 1999-02-04 | 2005-04-15 | Integ Inc | NEEDLE FOR BODY FLUID TEST KIT |
JP3492543B2 (en) | 1999-03-15 | 2004-02-03 | 金子工業有限会社 | Injection needle and its manufacturing method |
US6709465B2 (en) | 1999-03-18 | 2004-03-23 | Fossa Medical, Inc. | Radially expanding ureteral device |
US7214229B2 (en) | 1999-03-18 | 2007-05-08 | Fossa Medical, Inc. | Radially expanding stents |
US20050119601A9 (en) | 1999-04-26 | 2005-06-02 | Lynch Mary G. | Shunt device and method for treating glaucoma |
EP1173123A1 (en) | 1999-04-26 | 2002-01-23 | Mary G. Lynch | Trabeculotomy device and method for treating glaucoma |
US6699210B2 (en) | 1999-04-27 | 2004-03-02 | The Arizona Board Of Regents | Glaucoma shunt and a method of making and surgically implanting the same |
CA2372149A1 (en) | 1999-05-03 | 2000-11-09 | Dean F. Carson | Methods and devices for placing a conduit in fluid communication with a target vessel |
DE19920615A1 (en) | 1999-05-05 | 2000-12-07 | Tui Laser Ag | Device for treating glaucorn of the eye |
US6858034B1 (en) | 1999-05-20 | 2005-02-22 | Scimed Life Systems, Inc. | Stent delivery system for prevention of kinking, and method of loading and using same |
US6221078B1 (en) | 1999-06-25 | 2001-04-24 | Stephen S. Bylsma | Surgical implantation apparatus |
US8246671B2 (en) | 1999-08-09 | 2012-08-21 | Cardiokinetix, Inc. | Retrievable cardiac devices |
JP4085351B2 (en) | 1999-09-14 | 2008-05-14 | ドクタージャパン株式会社 | Epidural anesthesia needle |
US20090028953A1 (en) | 1999-12-10 | 2009-01-29 | Yamamoto Ronald K | Method of treatment using microparticulate biomaterial composition |
US20020072673A1 (en) | 1999-12-10 | 2002-06-13 | Yamamoto Ronald K. | Treatment of ocular disease |
US6726676B2 (en) | 2000-01-05 | 2004-04-27 | Grieshaber & Co. Ag Schaffhausen | Method of and device for improving the flow of aqueous humor within the eye |
US6375642B1 (en) | 2000-02-15 | 2002-04-23 | Grieshaber & Co. Ag Schaffhausen | Method of and device for improving a drainage of aqueous humor within the eye |
US6471666B1 (en) | 2000-02-24 | 2002-10-29 | Steven A. Odrich | Injectable glaucoma device |
US6398809B1 (en) | 2000-04-12 | 2002-06-04 | Bausch & Lomb Incorporated | Intraocular lens |
US7708711B2 (en) | 2000-04-14 | 2010-05-04 | Glaukos Corporation | Ocular implant with therapeutic agents and methods thereof |
US20050049578A1 (en) | 2000-04-14 | 2005-03-03 | Hosheng Tu | Implantable ocular pump to reduce intraocular pressure |
US20040111050A1 (en) | 2000-04-14 | 2004-06-10 | Gregory Smedley | Implantable ocular pump to reduce intraocular pressure |
US20050277864A1 (en) | 2000-04-14 | 2005-12-15 | David Haffner | Injectable gel implant for glaucoma treatment |
US6638239B1 (en) | 2000-04-14 | 2003-10-28 | Glaukos Corporation | Apparatus and method for treating glaucoma |
US20020143284A1 (en) | 2001-04-03 | 2002-10-03 | Hosheng Tu | Drug-releasing trabecular implant for glaucoma treatment |
US7867186B2 (en) | 2002-04-08 | 2011-01-11 | Glaukos Corporation | Devices and methods for treatment of ocular disorders |
US20030060752A1 (en) | 2000-04-14 | 2003-03-27 | Olav Bergheim | Glaucoma device and methods thereof |
US6533768B1 (en) | 2000-04-14 | 2003-03-18 | The Regents Of The University Of California | Device for glaucoma treatment and methods thereof |
US8679089B2 (en) | 2001-05-21 | 2014-03-25 | Michael S. Berlin | Glaucoma surgery methods and systems |
DE60131273T2 (en) | 2000-05-19 | 2008-08-28 | Michael S. Beverly Hills Berlin | LASER APPLICATION SYSTEM AND METHOD FOR EYE-USE |
US9603741B2 (en) | 2000-05-19 | 2017-03-28 | Michael S. Berlin | Delivery system and method of use for the eye |
JP3364654B2 (en) | 2000-05-31 | 2003-01-08 | 独立行政法人産業技術総合研究所 | Virtual form generation apparatus and generation method |
US6394979B1 (en) | 2000-06-09 | 2002-05-28 | Inviro Medical Devices Ltd. | Cannula for use with a medical syringe |
CA2407953A1 (en) | 2000-06-19 | 2001-12-27 | Glaukos Corporation | Stented trabecular shunt and methods thereof |
AT410781B (en) | 2000-07-20 | 2003-07-25 | Joma Kunststoffwerk Und Warenh | CONTAINER CLOSURE |
USD444874S1 (en) | 2000-07-31 | 2001-07-10 | Allergan Sales, Inc. | Self instill twist housing eye drop dispenser |
US6699211B2 (en) | 2000-08-22 | 2004-03-02 | James A. Savage | Method and apparatus for treatment of glaucoma |
FR2813521B1 (en) | 2000-09-01 | 2003-06-13 | Ioltechnologie Production | GLAUCOME DRAIN |
US6730056B1 (en) | 2000-09-21 | 2004-05-04 | Motorola, Inc. | Eye implant for treating glaucoma and method for manufacturing same |
US6962573B1 (en) | 2000-10-18 | 2005-11-08 | Wilcox Michael J | C-shaped cross section tubular ophthalmic implant for reduction of intraocular pressure in glaucomatous eyes and method of use |
WO2002036052A1 (en) | 2000-11-01 | 2002-05-10 | Glaukos Corporation | Glaucoma treatment device |
US6533764B1 (en) | 2000-11-06 | 2003-03-18 | Allergan, Inc. | Twist housing apparatus for instilling a medication into an eye |
DE10062478A1 (en) | 2000-12-14 | 2002-07-04 | Glautec Ag | Glaucoma treatment device |
US6544208B2 (en) | 2000-12-29 | 2003-04-08 | C. Ross Ethier | Implantable shunt device |
US6881198B2 (en) | 2001-01-09 | 2005-04-19 | J. David Brown | Glaucoma treatment device and method |
EP1353617A2 (en) | 2001-01-18 | 2003-10-22 | The Regents Of The University Of California | Minimally invasive glaucoma surgical instrument and method |
US6692524B2 (en) | 2001-01-19 | 2004-02-17 | Georges Baikoff | Techniques and implants for correcting presbyopia |
US6863667B2 (en) | 2001-01-29 | 2005-03-08 | Intralase Corp. | Ocular fixation and stabilization device for ophthalmic surgical applications |
US6989007B2 (en) | 2001-02-21 | 2006-01-24 | Solx, Inc. | Devices and techniques for treating glaucoma |
US6713081B2 (en) | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
US20020133168A1 (en) | 2001-03-16 | 2002-09-19 | Smedley Gregory T. | Applicator and methods for placing a trabecular shunt for glaucoma treatment |
JP3310270B1 (en) | 2001-03-28 | 2002-08-05 | 宮子 鎌田 | Medical injection needle and method of manufacturing the same |
US6666841B2 (en) | 2001-05-02 | 2003-12-23 | Glaukos Corporation | Bifurcatable trabecular shunt for glaucoma treatment |
EP1418868B1 (en) | 2001-04-07 | 2008-03-26 | Glaukos Corporation | Glaucoma stent for glaucoma treatment |
US7488303B1 (en) | 2002-09-21 | 2009-02-10 | Glaukos Corporation | Ocular implant with anchor and multiple openings |
US6981958B1 (en) | 2001-05-02 | 2006-01-03 | Glaukos Corporation | Implant with pressure sensor for glaucoma treatment |
US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
DE10118933A1 (en) | 2001-04-18 | 2002-11-14 | Glautec Ag | Glaucoma treatment device |
AT409586B (en) | 2001-04-26 | 2002-09-25 | Clemens Dr Vass | Implant draining aqueous humor from anterior chamber of eye into Schlemm's channel, includes fixation plate for stabilization on sclera |
US7678065B2 (en) | 2001-05-02 | 2010-03-16 | Glaukos Corporation | Implant with intraocular pressure sensor for glaucoma treatment |
US6533769B2 (en) | 2001-05-03 | 2003-03-18 | Holmen Joergen | Method for use in cataract surgery |
AU2002305400A1 (en) | 2001-05-03 | 2002-11-18 | Glaukos Corporation | Medical device and methods of use for glaucoma treatment |
DE60239868D1 (en) | 2001-06-12 | 2011-06-09 | Univ Johns Hopkins Med | RESERVOIR DEVICE FOR INTRAOCULAR DRUG DELIVERY |
US6802827B2 (en) | 2001-06-26 | 2004-10-12 | Stig O. Andersson | Hypodermic implant device |
US8267995B2 (en) | 2001-08-03 | 2012-09-18 | David Castillejos | Method and intra sclera implant for treatment of glaucoma and presbyopia |
JP2005525835A (en) | 2001-08-16 | 2005-09-02 | ジーエムピー ヴィジョン ソルーションズ インコーポレイテッド | Improved short circuit device and improved short circuit method for treating glaucoma |
US7331984B2 (en) | 2001-08-28 | 2008-02-19 | Glaukos Corporation | Glaucoma stent for treating glaucoma and methods of use |
US7027233B2 (en) | 2001-10-12 | 2006-04-11 | Intralase Corp. | Closed-loop focal positioning system and method |
US20030097151A1 (en) | 2001-10-25 | 2003-05-22 | Smedley Gregory T. | Apparatus and mitochondrial treatment for glaucoma |
US20050041200A1 (en) | 2001-11-07 | 2005-02-24 | Darren Rich | Gonioscopy assembly |
US7163543B2 (en) | 2001-11-08 | 2007-01-16 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
US20030093084A1 (en) | 2001-11-13 | 2003-05-15 | Optonol Ltd. | Delivery devices for flow regulating implants |
JP4303116B2 (en) | 2001-11-21 | 2009-07-29 | アイサイエンス コーポレイション | Ophthalmic microsurgery device |
US20030105456A1 (en) | 2001-12-04 | 2003-06-05 | J.T. Lin | Apparatus and methods for prevention of age-related macular degeneration and other eye diseases |
US6770093B2 (en) | 2002-01-23 | 2004-08-03 | Ophtec B.V. | Fixation of an intraocular implant to the iris |
WO2003073968A2 (en) | 2002-02-28 | 2003-09-12 | Gmp Vision Solutions, Inc. | Device and method for monitoring aqueous flow within the eye |
US20060200113A1 (en) * | 2002-03-07 | 2006-09-07 | David Haffner | Liquid jet for glaucoma treatment |
US7186232B1 (en) | 2002-03-07 | 2007-03-06 | Glaukoa Corporation | Fluid infusion methods for glaucoma treatment |
US7951155B2 (en) | 2002-03-15 | 2011-05-31 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
US20030229303A1 (en) | 2002-03-22 | 2003-12-11 | Haffner David S. | Expandable glaucoma implant and methods of use |
JP4339700B2 (en) | 2002-03-23 | 2009-10-07 | エーエムオー ディベロップメント, エルエルシー | System and method for improved material processing using laser beams |
US9301875B2 (en) | 2002-04-08 | 2016-04-05 | Glaukos Corporation | Ocular disorder treatment implants with multiple opening |
US20040147870A1 (en) | 2002-04-08 | 2004-07-29 | Burns Thomas W. | Glaucoma treatment kit |
US20040024345A1 (en) | 2002-04-19 | 2004-02-05 | Morteza Gharib | Glaucoma implant with valveless flow bias |
AU2003233300A1 (en) | 2002-05-29 | 2003-12-12 | University Of Saskatchewan Technologies Inc. | A shunt and method treatment of glaucoma |
US20070265582A1 (en) | 2002-06-12 | 2007-11-15 | University Of Southern California | Injection Devices for Unimpeded Target Location Testing |
US20030236483A1 (en) | 2002-06-25 | 2003-12-25 | Ren David H | Dual drainage ocular shunt for glaucoma |
US7133137B2 (en) | 2002-06-27 | 2006-11-07 | Visx, Incorporated | Integrated scanning and ocular tomography system and method |
JP2005532871A (en) | 2002-07-12 | 2005-11-04 | アイサイエンス サージカル コーポレイション | Ultrasonic interface connection device for tissue imaging |
AU2003256657A1 (en) | 2002-07-19 | 2004-02-09 | Yale University | Uveoscleral drainage device |
US7175660B2 (en) | 2002-08-29 | 2007-02-13 | Mitralsolutions, Inc. | Apparatus for implanting surgical devices for controlling the internal circumference of an anatomic orifice or lumen |
US7192412B1 (en) | 2002-09-14 | 2007-03-20 | Glaukos Corporation | Targeted stent placement and multi-stent therapy |
WO2004026347A2 (en) | 2002-09-17 | 2004-04-01 | Iscience Surgical Corporation | Apparatus and method for surgical bypass of aqueous humor |
US20050203542A1 (en) | 2002-09-18 | 2005-09-15 | Allergan, Inc. | Apparatus for delivery of ocular implants with reduced incidence of ocular adverse events |
CN1301692C (en) | 2002-09-18 | 2007-02-28 | 阿勒根公司 | Methods and apparatus for delivery of ocular implants |
US6899717B2 (en) | 2002-09-18 | 2005-05-31 | Allergan, Inc. | Methods and apparatus for delivery of ocular implants |
US6992765B2 (en) | 2002-10-11 | 2006-01-31 | Intralase Corp. | Method and system for determining the alignment of a surface of a material in relation to a laser beam |
US20040087886A1 (en) | 2002-10-30 | 2004-05-06 | Scimed Life Systems, Inc. | Linearly expandable ureteral stent |
US6702790B1 (en) | 2002-10-31 | 2004-03-09 | Chauncey F. Ross | Hypodermic needle |
WO2004045474A1 (en) | 2002-11-15 | 2004-06-03 | Gmp Cardiac Care, Inc. | Rail stent |
US20040098124A1 (en) | 2002-11-19 | 2004-05-20 | Freeman Jerre M. | Elongate scleral implants for the treatment of eye disorders such as presbyopia and glaucoma |
US20040116909A1 (en) | 2002-12-11 | 2004-06-17 | Ceramoptec Industries Inc. | Multipurpose diode laser system for ophthalmic laser treatments |
AU2003289010A1 (en) | 2002-12-13 | 2004-07-09 | Terumo Kabushiki Kaisha | Needle body for medical use and liquid-introducing tool |
US20040122380A1 (en) | 2002-12-19 | 2004-06-24 | Utterberg David S. | Blunt cannula with bent tip |
CA2513705A1 (en) | 2003-01-21 | 2004-08-05 | Carmel Pharma Ab | A needle for penetrating a membrane |
AT413332B (en) | 2003-01-23 | 2006-02-15 | Clemens Dr Vass | DRAINAGE IMPLANT FOR THE DISPOSAL OF CHAMBER WATER FROM THE FRONT EYE CHAMBER IN THE EPISCLERAL VEINS |
US20040216749A1 (en) | 2003-01-23 | 2004-11-04 | Hosheng Tu | Vasomodulation during glaucoma surgery |
RU2361552C2 (en) | 2003-02-18 | 2009-07-20 | Хампар КАРАГЕОЗЯН | Ways and devices for drainage of liquids and ophthalmotonus pressure dropping |
US8012115B2 (en) | 2003-02-18 | 2011-09-06 | S.K. Pharmaceuticals, Inc. | Optic nerve implants |
WO2005105197A2 (en) | 2003-02-28 | 2005-11-10 | Gmp Vision Solutions, Inc. | Indwelling shunt device and methods for treating glaucoma |
USD490152S1 (en) | 2003-02-28 | 2004-05-18 | Glaukos Corporation | Surgical handpiece |
US20050043722A1 (en) | 2003-08-22 | 2005-02-24 | Lin J. T. | Methods and apparatus for treatment of eye disorders using articulated-arm-coupled ultraviolet lasers |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20040193095A1 (en) | 2003-03-29 | 2004-09-30 | Shadduck John H. | Implants for treating ocular hypertension, methods of use and methods of fabrication |
US20040193262A1 (en) | 2003-03-29 | 2004-09-30 | Shadduck John H. | Implants for treating ocular hypertension, methods of use and methods of fabrication |
US20040199171A1 (en) | 2003-04-04 | 2004-10-07 | Takayuki Akahoshi | Phacoemulsification needle |
US6942343B2 (en) | 2003-04-07 | 2005-09-13 | Arkadiy Farberov | Optical device for intraocular observation |
CA2522956C (en) | 2003-04-16 | 2012-07-10 | Iscience Surgical Corporation | Opthalmic microsurgical instruments |
US20040225250A1 (en) | 2003-05-05 | 2004-11-11 | Michael Yablonski | Internal shunt and method for treating glaucoma |
EP1638508B1 (en) | 2003-06-16 | 2014-08-13 | Solx, Inc. | Shunt for the treatment of glaucoma |
US20060069340A1 (en) | 2003-06-16 | 2006-03-30 | Solx, Inc. | Shunt for the treatment of glaucoma |
US7147650B2 (en) | 2003-10-30 | 2006-12-12 | Woojin Lee | Surgical instrument |
US7291125B2 (en) | 2003-11-14 | 2007-11-06 | Transcend Medical, Inc. | Ocular pressure regulation |
US6929664B2 (en) | 2003-12-05 | 2005-08-16 | Fossa Medical, Inc. | Open lumen stents |
WO2005055873A2 (en) | 2003-12-05 | 2005-06-23 | Innfocus, Llc | Improved glaucoma implant device |
US9254213B2 (en) | 2004-01-09 | 2016-02-09 | Rubicon Medical, Inc. | Stent delivery device |
KR20060130648A (en) | 2004-01-12 | 2006-12-19 | 아이싸이언스 인터벤셔날 코포레이션 | Injector for viscous materials |
EP1715799A4 (en) | 2004-01-22 | 2010-06-02 | Solx Inc | Glaucoma treatment method |
SG183072A1 (en) | 2004-01-23 | 2012-08-30 | Iscience Surgical Corp | Composite ophthalmic microcannula |
US20050250788A1 (en) | 2004-01-30 | 2005-11-10 | Hosheng Tu | Aqueous outflow enhancement with vasodilated aqueous cavity |
US20060173399A1 (en) | 2005-02-01 | 2006-08-03 | Rodgers M S | MEMS flow module with pivoting-type baffle |
US7468051B2 (en) | 2004-03-02 | 2008-12-23 | Boston Scientific Scimed, Inc. | Occlusion balloon catheter with external inflation lumen |
EP1732484B1 (en) | 2004-03-26 | 2017-08-16 | Molteno Ophthalmic Ltd. | Ophthalmic implant for treating glaucoma |
US20080058704A1 (en) | 2004-04-29 | 2008-03-06 | Michael Hee | Apparatus and Method for Ocular Treatment |
US20100173866A1 (en) | 2004-04-29 | 2010-07-08 | Iscience Interventional Corporation | Apparatus and method for ocular treatment |
ZA200609408B (en) | 2004-04-29 | 2008-02-27 | Iscience Interventional Corp | Apparatus and method for surgical enhancement of aqueous humor drainage |
CA2564840A1 (en) | 2004-04-29 | 2005-11-17 | Michael Hee | Apparatus and method for ocular treatment |
US7704246B2 (en) | 2004-04-30 | 2010-04-27 | Connor Christopher S | Shielded intraocular probe for improved illumination or therapeutic application of light |
US8685435B2 (en) | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US8673341B2 (en) | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
WO2005110280A2 (en) | 2004-05-07 | 2005-11-24 | Valentx, Inc. | Devices and methods for attaching an endolumenal gastrointestinal implant |
US20050279369A1 (en) | 2004-06-21 | 2005-12-22 | Lin J T | Method and apparatus for the treatment of presbyopia and glaucoma by ciliary body ablation |
WO2006005038A2 (en) | 2004-06-28 | 2006-01-12 | Optimedica Corporation | Method and device for optical ophthalmic therapy |
WO2006014484A2 (en) | 2004-07-02 | 2006-02-09 | Surmodics, Inc. | Methods and devices for the treatment of ocular conditions |
WO2006015016A2 (en) | 2004-07-30 | 2006-02-09 | Massachusetts Eye And Ear Infirmary | Photodynamic therapy and compositions for treating ocular glaucoma |
US20060032507A1 (en) | 2004-08-11 | 2006-02-16 | Hosheng Tu | Contrast-enhanced ocular imaging |
US7584756B2 (en) | 2004-08-17 | 2009-09-08 | Amo Development, Llc | Apparatus and method for correction of aberrations in laser system optics |
US20060173397A1 (en) | 2004-11-23 | 2006-08-03 | Hosheng Tu | Ophthalmology implants and methods of manufacture |
US20060129141A1 (en) | 2004-12-10 | 2006-06-15 | Lin J T | Treatment of eye disorders using articulated-arm coupled ultraviolet lasers |
US20120010702A1 (en) | 2004-12-16 | 2012-01-12 | Iscience Interventional Corporation | Ophthalmic implant for treatment of glaucoma |
WO2006066103A2 (en) | 2004-12-16 | 2006-06-22 | Iscience Interventional Corporation | Ophthalmic implant for treatment of glaucoma |
US20060154981A1 (en) | 2005-01-12 | 2006-07-13 | Alcon, Inc. | Method of reducing intraocular pressure and treating glaucoma |
US20060167421A1 (en) | 2005-01-21 | 2006-07-27 | Radius International Ltd. Partnership | Catheter with insert-molded tip |
US20060167466A1 (en) | 2005-01-21 | 2006-07-27 | Vaclav Dusek | Intraocular lens inserter system components |
US20060178674A1 (en) | 2005-02-08 | 2006-08-10 | Mcintyre John | Surgical apparatus having configurable portions |
AR054647A1 (en) | 2005-02-21 | 2007-07-11 | Maldonado Bas Arturo | DEVICE FOR WATER HUMOR DRAINAGE IN GLAUCOMA CASES |
US7641627B2 (en) | 2005-02-23 | 2010-01-05 | Camras Carl B | Method and apparatus for reducing intraocular pressure |
US20060217741A1 (en) | 2005-03-28 | 2006-09-28 | Ghannoum Ziad R | Irrigation tip |
US20060224146A1 (en) | 2005-03-30 | 2006-10-05 | Lin J T | Method and system for non-invasive treatment of hyperopia, presbyopia and glaucoma |
US20060259021A1 (en) | 2005-05-12 | 2006-11-16 | Lin J T | Diode-laser-pumped ultraviolet and infrared lasers for ablation and coagulation of soft tissue |
CN101198301A (en) | 2005-05-18 | 2008-06-11 | 苏尔莫迪克斯公司 | Insertion instrument for non-linear medical devices |
US20060264971A1 (en) | 2005-05-18 | 2006-11-23 | Takayuki Akahoshi | Intraocular lens injection nozzle |
DE102005027355A1 (en) | 2005-06-13 | 2006-12-14 | Femtotechnologies Gmbh | Method for processing an organic material |
FR2887153B1 (en) | 2005-06-20 | 2008-04-04 | Alain Villette | INJECTION NEEDLE |
US8629161B2 (en) | 2005-06-21 | 2014-01-14 | Kowa Co., Ltd. | Preventive or remedy for glaucoma |
US20090043365A1 (en) | 2005-07-18 | 2009-02-12 | Kolis Scientific, Inc. | Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma |
EP1924306A2 (en) | 2005-09-16 | 2008-05-28 | BG Implant, Inc. | Glaucoma treatment devices and methods |
US8496628B2 (en) | 2005-09-30 | 2013-07-30 | Erskine Medical Llc | Needle-based medical device including needle guide |
US20070093794A1 (en) | 2005-10-14 | 2007-04-26 | Qi Wang | Device, system and method for dual-path ophthalmic device |
BRPI0617414A2 (en) | 2005-10-14 | 2011-07-26 | Alcon Inc | Method for treating primary and secondary forms of glaucoma |
US7611507B2 (en) | 2005-10-24 | 2009-11-03 | Amo Development Llc | Disposable patient interface |
US20070106200A1 (en) | 2005-11-08 | 2007-05-10 | Brian Levy | Intraocular shunt device and method |
US20070121120A1 (en) | 2005-11-16 | 2007-05-31 | Schachar Ronald A | Apparatus and method for measuring scleral curvature and velocity of tissues of the eye |
US8251963B2 (en) | 2005-12-08 | 2012-08-28 | Boston Scientific Scimed, Inc. | Flexible needle |
US8721656B2 (en) | 2006-01-17 | 2014-05-13 | Transcend Medical, Inc. | Glaucoma treatment device |
EP3338743A1 (en) | 2006-01-17 | 2018-06-27 | Novartis Ag | Drug delivery treatment device |
US20070173791A1 (en) | 2006-01-20 | 2007-07-26 | Intralase Corp. | System for ophthalmic laser surgery |
US7942894B2 (en) | 2006-01-31 | 2011-05-17 | Codman & Shurtleff, Inc. | Embolic device delivery system |
US20070202186A1 (en) | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
US9402714B2 (en) | 2006-03-06 | 2016-08-02 | Amo Development, Llc | Method of transplanting a cornea |
US20070219541A1 (en) | 2006-03-14 | 2007-09-20 | Intralase Corp. | System and method for ophthalmic laser surgery on a cornea |
JP2007244671A (en) | 2006-03-16 | 2007-09-27 | Fujifilm Corp | Blood collecting needle, injection needle, winged needle, test kit and blood collection kit |
US7522642B2 (en) | 2006-03-29 | 2009-04-21 | Amo Development Llc | Method and system for laser amplification using a dual crystal Pockels cell |
US8057463B2 (en) | 2006-04-07 | 2011-11-15 | Amo Development, Llc. | Adaptive pattern correction for laser scanners |
US20070293807A1 (en) | 2006-05-01 | 2007-12-20 | Lynch Mary G | Dual drainage pathway shunt device and method for treating glaucoma |
EP2123240A1 (en) | 2006-05-18 | 2009-11-25 | STAAR Japan Inc. | Insertion device for intraocular lens and method for manufacturing a lens-containing insertion device |
US7458953B2 (en) | 2006-06-20 | 2008-12-02 | Gholam A. Peyman | Ocular drainage device |
US7909789B2 (en) | 2006-06-26 | 2011-03-22 | Sight Sciences, Inc. | Intraocular implants and methods and kits therefor |
US20120123316A1 (en) | 2010-11-15 | 2012-05-17 | Aquesys, Inc. | Intraocular shunts for placement in the intra-tenon's space |
US8663303B2 (en) | 2010-11-15 | 2014-03-04 | Aquesys, Inc. | Methods for deploying an intraocular shunt from a deployment device and into an eye |
US8974511B2 (en) | 2010-11-15 | 2015-03-10 | Aquesys, Inc. | Methods for treating closed angle glaucoma |
US8308701B2 (en) | 2010-11-15 | 2012-11-13 | Aquesys, Inc. | Methods for deploying intraocular shunts |
US8852256B2 (en) | 2010-11-15 | 2014-10-07 | Aquesys, Inc. | Methods for intraocular shunt placement |
AU2007269259B2 (en) | 2006-06-30 | 2012-05-31 | Aquesys Inc. | Methods, systems and apparatus for relieving pressure in an organ |
US20090069786A1 (en) | 2006-07-05 | 2009-03-12 | Medical Research Products-B, Inc. | Medical apparatus and method for facilitating the management of long term tunneled conduits |
CA3094881A1 (en) | 2006-07-11 | 2008-01-17 | Refocus Group, Inc. | Scleral prosthesis for treating presbyopia and other eye disorders and related devices and methods |
US20080027519A1 (en) | 2006-07-28 | 2008-01-31 | Guerrero John M | Method of treatment of ocular compartment syndromes |
US20100262174A1 (en) | 2006-08-11 | 2010-10-14 | The Regents Of The University Of California | Microsurgery for Treatment of Glaucoma |
US7887532B2 (en) | 2006-09-05 | 2011-02-15 | Amo Development, Llc. | System and method for resecting corneal tissue using non-continuous initial incisions |
US20080082088A1 (en) | 2006-09-05 | 2008-04-03 | Intralase Corp. | System and method for resecting corneal tissue |
CA2668954C (en) | 2006-11-10 | 2020-09-08 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US8075552B2 (en) | 2006-11-20 | 2011-12-13 | Amo Development Llc. | System and method for preparation of donor corneal tissue |
KR20090102810A (en) | 2006-12-26 | 2009-09-30 | 큐엘티 플러그 딜리버리, 인코포레이티드 | Drug delivery implants for inhibition of optical defects |
US7575322B2 (en) | 2007-05-11 | 2009-08-18 | Amo Development Llc. | Auto-alignment and auto-focus system and method |
US8956419B2 (en) | 2007-05-14 | 2015-02-17 | Boston Scientific Scimed, Inc. | Open lumen stent |
US20080312661A1 (en) | 2007-06-12 | 2008-12-18 | Downer David A | Lens Injector Lumen Tip for Wound Assisted Delivery |
US8672870B2 (en) | 2007-07-17 | 2014-03-18 | Transcend Medical, Inc. | Ocular implant with hydrogel expansion capabilities |
US20090030381A1 (en) | 2007-07-23 | 2009-01-29 | Lind Casey J | Arced Hypodermic Needle |
US8475374B2 (en) | 2007-08-23 | 2013-07-02 | Purdue Research Foundation | Intra-occular pressure sensor |
US9456925B2 (en) | 2007-09-06 | 2016-10-04 | Alcon Lensx, Inc. | Photodisruptive laser treatment of the crystalline lens |
DE112008002383T5 (en) | 2007-09-06 | 2010-06-24 | LenSx Lasers, Inc., Aliso Viejo | Precise targeting of surgical photodisruption |
DK2865361T3 (en) | 2007-09-07 | 2019-07-08 | Mati Therapeutics Inc | TEA REPLACEMENTS AND RELATED PROCEDURES |
US20100324543A1 (en) | 2007-09-18 | 2010-12-23 | Kurtz Ronald M | Method And Apparatus For Integrating Cataract Surgery With Glaucoma Or Astigmatism Surgery |
US20170360609A9 (en) | 2007-09-24 | 2017-12-21 | Ivantis, Inc. | Methods and devices for increasing aqueous humor outflow |
US20090082862A1 (en) | 2007-09-24 | 2009-03-26 | Schieber Andrew T | Ocular Implant Architectures |
US7740604B2 (en) | 2007-09-24 | 2010-06-22 | Ivantis, Inc. | Ocular implants for placement in schlemm's canal |
US8425449B2 (en) | 2009-07-09 | 2013-04-23 | Ivantis, Inc. | Ocular implants and methods for delivering ocular implants into the eye |
ES2390315T3 (en) | 2007-11-02 | 2012-11-08 | Alcon Lensx, Inc. | Apparatus for improved postoperative ocular optical performance |
US8632526B2 (en) | 2007-11-07 | 2014-01-21 | Amo Development, Llc | System and method of interfacing a surgical laser with an eye |
US8142423B2 (en) | 2007-11-07 | 2012-03-27 | Amo Development, Llc. | System and method for incising material |
US20090118716A1 (en) | 2007-11-07 | 2009-05-07 | Intralase, Inc. | System and method for scanning a pulsed laser beam |
CA2705239C (en) | 2007-11-08 | 2018-09-25 | Alimera Sciences, Inc. | Ocular implantation device |
US8808222B2 (en) | 2007-11-20 | 2014-08-19 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
US8512404B2 (en) | 2007-11-20 | 2013-08-20 | Ivantis, Inc. | Ocular implant delivery system and method |
US8230866B2 (en) | 2007-12-13 | 2012-07-31 | Carl Zeiss Meditec Ag | Systems and methods for treating glaucoma and systems and methods for imaging a portion of an eye |
US20100331858A1 (en) | 2008-01-30 | 2010-12-30 | The Trustees Of Columbia University In The City Of New York | Systems, devices, and methods for robot-assisted micro-surgical stenting |
US8088150B2 (en) | 2008-02-04 | 2012-01-03 | Aleeva Medical Inc. | Device for disc shunt implantation and peri-shunt injection |
US8109896B2 (en) | 2008-02-11 | 2012-02-07 | Optonol Ltd. | Devices and methods for opening fluid passageways |
AU2009221859B2 (en) | 2008-03-05 | 2013-04-18 | Alcon Inc. | Methods and apparatus for treating glaucoma |
US20090247955A1 (en) | 2008-03-27 | 2009-10-01 | Iscience Interventional Corporation | Microliter injector |
EP2265314A4 (en) | 2008-04-02 | 2013-09-04 | Laurimed Llc | Methods and devices for delivering injections |
KR101572634B1 (en) | 2008-04-04 | 2015-12-01 | 포사이트 비젼4, 인크. | Therapeutic device for pain management and vision |
US9877973B2 (en) | 2008-05-12 | 2018-01-30 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
US8157568B2 (en) | 2008-05-22 | 2012-04-17 | Tsutomu Hara | Ophthalmologic model |
ES2640867T3 (en) | 2008-06-25 | 2017-11-07 | Novartis Ag | Eye implant with ability to change shape |
EP2334248A2 (en) | 2008-09-02 | 2011-06-22 | Medtronic Ablation Frontiers LLC | Irrigated ablation catheter system |
CA2745884C (en) | 2008-12-05 | 2017-08-01 | Ivantis, Inc. | Cannula for ocular implant delivery system |
CH700161A2 (en) | 2008-12-22 | 2010-06-30 | Grieshaber Ophthalmic Res Foun | IMPLANT FOR INTRODUCING into Schlemm's canal AN EYE. |
US8425473B2 (en) | 2009-01-23 | 2013-04-23 | Iscience Interventional Corporation | Subretinal access device |
US20100191177A1 (en) | 2009-01-23 | 2010-07-29 | Iscience Interventional Corporation | Device for aspirating fluids |
US8377122B2 (en) | 2009-01-28 | 2013-02-19 | Transcend Medical, Inc. | Ocular implant with stiffness qualities, methods of implantation and system |
US8337393B2 (en) | 2009-04-03 | 2012-12-25 | Transcend Medical, Inc. | Ocular implant delivery systems and methods |
EP3366326A1 (en) | 2009-04-17 | 2018-08-29 | Micell Technologies, Inc. | Stents having controlled elution |
WO2010132751A1 (en) | 2009-05-15 | 2010-11-18 | Iscience Interventional Corporation | Methods and apparatus for sub-retinal catheterization |
US20120078362A1 (en) | 2009-05-18 | 2012-03-29 | Dose Medical Corporation | Drug eluting ocular implant |
CA2766131C (en) | 2009-07-09 | 2017-10-24 | Ivantis, Inc. | Single operator device for delivering an ocular implant |
US8267925B2 (en) | 2009-07-29 | 2012-09-18 | Alcon Lensx, Inc. | Optical system for ophthalmic surgical laser |
US9504608B2 (en) | 2009-07-29 | 2016-11-29 | Alcon Lensx, Inc. | Optical system with movable lens for ophthalmic surgical laser |
US8920407B2 (en) | 2009-07-29 | 2014-12-30 | Alcon Lensx, Inc. | Optical system for ophthalmic surgical laser |
US8262647B2 (en) | 2009-07-29 | 2012-09-11 | Alcon Lensx, Inc. | Optical system for ophthalmic surgical laser |
US8951221B2 (en) | 2009-08-20 | 2015-02-10 | Grieshaber Ophthalmic Research Foundation | Method and device for the treatment of glaucoma |
AU2010310484A1 (en) | 2009-10-23 | 2012-05-10 | Ivantis, Inc. | Ocular implant system and method |
WO2011057283A1 (en) | 2009-11-09 | 2011-05-12 | Iscience Interventional Corporation | Expandable cannula for infusion of fluids |
KR101911960B1 (en) | 2010-01-22 | 2018-10-25 | 알러간, 인코포레이티드 | Intracameral sustained release therapeutic agent implants |
EP2531138B1 (en) | 2010-02-05 | 2016-11-30 | Sight Sciences, Inc. | Intraocular implants and related kits and methods |
WO2011106781A1 (en) | 2010-02-26 | 2011-09-01 | Iscience Interventional Corporation | Apparatus for enhancement of aqueous humor drainage from the eye |
US8337490B2 (en) | 2010-03-03 | 2012-12-25 | Wavelight Ag | Apparatus for movable and weight-compensating suspension of a focusing objective of a laser system |
EP2575715B1 (en) | 2010-05-27 | 2014-10-29 | Ellex-iScience, Inc. | Device for placing circumferential implant in schlemm's canal |
US8545430B2 (en) | 2010-06-09 | 2013-10-01 | Transcend Medical, Inc. | Expandable ocular devices |
US9510973B2 (en) | 2010-06-23 | 2016-12-06 | Ivantis, Inc. | Ocular implants deployed in schlemm's canal of the eye |
US8684743B2 (en) | 2010-07-23 | 2014-04-01 | Eye Care And Cure Pte. Ltd | Model human eye and face manikin for use therewith |
US20130267887A1 (en) | 2010-09-21 | 2013-10-10 | The Regents Of The University Of Colorado | Aqueous humor micro-bypass shunts |
BR112013009205A2 (en) | 2010-10-15 | 2016-07-26 | Iscience Interventional Corp | device for placement in the sclera of an eye, method for accessing the supracoroidal space of an eye, for accessing the subretinal space of an eye and for placing a hole within a scleral tract in one eye. |
EP2654715B1 (en) | 2010-11-24 | 2017-01-25 | Dose Medical Corporation | Drug eluting ocular implant |
EP2651334B1 (en) | 2010-12-17 | 2018-06-20 | Abbott Medical Optics Inc. | Ophthalmic lens, and its manufacturing method, having at least one rotationally asymmetric diffractive structure |
US9033963B2 (en) | 2011-04-10 | 2015-05-19 | Fs-Eye, Llc | Systems and methods to deliver photodisruptive laser pulses into tissue layers of the anterior angle of the eye |
EP2517619B1 (en) | 2011-04-27 | 2013-05-22 | Istar Medical | Improvements in or relating to glaucoma management and treatment |
US20120283557A1 (en) | 2011-05-05 | 2012-11-08 | Berlin Michael S | Methods and Apparatuses for the Treatment of Glaucoma using visible and infrared ultrashort laser pulses |
US8657776B2 (en) | 2011-06-14 | 2014-02-25 | Ivantis, Inc. | Ocular implants for delivery into the eye |
US9254225B2 (en) | 2011-07-20 | 2016-02-09 | Bruce B. Becker | Punctal plug inserter and method |
CN103917202B (en) | 2011-09-14 | 2016-06-29 | 弗赛特影像5股份有限公司 | Eye insert apparatus and method |
US8851676B2 (en) | 2011-10-21 | 2014-10-07 | Transcend Medical, Inc. | Gonio lens system with stabilization mechanism |
WO2013069018A2 (en) | 2011-11-11 | 2013-05-16 | Opr Group Ltd. | Ocular implant with intraocular fluid pressure regulation |
US9610195B2 (en) | 2013-02-27 | 2017-04-04 | Aquesys, Inc. | Intraocular shunt implantation methods and devices |
US8765210B2 (en) | 2011-12-08 | 2014-07-01 | Aquesys, Inc. | Systems and methods for making gelatin shunts |
US9808373B2 (en) | 2013-06-28 | 2017-11-07 | Aquesys, Inc. | Intraocular shunt implantation |
US8852136B2 (en) | 2011-12-08 | 2014-10-07 | Aquesys, Inc. | Methods for placing a shunt into the intra-scleral space |
US8663150B2 (en) | 2011-12-19 | 2014-03-04 | Ivantis, Inc. | Delivering ocular implants into the eye |
US9101444B2 (en) | 2012-01-12 | 2015-08-11 | Innfocus, Inc. | Method, surgical kit and device for treating glaucoma |
DE102012200411A1 (en) | 2012-01-12 | 2013-07-18 | Geuder Ag | Device for use in glaucoma surgery |
US20130182223A1 (en) | 2012-01-17 | 2013-07-18 | John Wardle | Suspended goniolens system |
ES2842454T3 (en) | 2012-03-20 | 2021-07-14 | Sight Sciences Inc | Eye delivery systems |
CA2868341C (en) | 2012-03-26 | 2021-01-12 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US9504603B2 (en) | 2012-04-02 | 2016-11-29 | Ocuject, Llc | Intraocular delivery devices and methods therefor |
US9358156B2 (en) | 2012-04-18 | 2016-06-07 | Invantis, Inc. | Ocular implants for delivery into an anterior chamber of the eye |
US9241832B2 (en) | 2012-04-24 | 2016-01-26 | Transcend Medical, Inc. | Delivery system for ocular implant |
US20160063898A1 (en) | 2014-08-26 | 2016-03-03 | Bioniko Consulting Llc | Ophthalmic surgical simulation system |
ES2633185T3 (en) | 2012-09-17 | 2017-09-19 | Novartis Ag | Expandable eye implant devices |
EP2900186B1 (en) | 2012-09-28 | 2016-11-16 | Doci Innovations GmbH | Implant for treating glaucoma |
DE102012221350A1 (en) | 2012-11-22 | 2014-05-22 | Universität Rostock | Eye implant of eye implant arrangement for treating and monitoring glaucoma disease in eye, has pressure sensors that are provided in casing to detect intraocular pressure at eye, such that supply or disconnection of pump is effected |
US10617558B2 (en) | 2012-11-28 | 2020-04-14 | Ivantis, Inc. | Apparatus for delivering ocular implants into an anterior chamber of the eye |
US9730638B2 (en) | 2013-03-13 | 2017-08-15 | Glaukos Corporation | Intraocular physiological sensor |
US9592151B2 (en) | 2013-03-15 | 2017-03-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US8939906B2 (en) | 2013-03-18 | 2015-01-27 | National Chiao Tung University | Wireless intraocular pressure monitoring device, and detecting module thereof |
ITMI20130783A1 (en) | 2013-05-13 | 2014-11-14 | Asag | IMPROVED IMPLANTABLE DRAINAGE VALVE IN THE PATIENT EYE FOR THE TREATMENT OF GLAUCOMA |
ES2762585T3 (en) | 2013-05-21 | 2020-05-25 | Alcon Inc | Flow promotion eye implant device and methods |
US20150057583A1 (en) | 2013-08-24 | 2015-02-26 | Alcon Research, Ltd. | Trabecular meshwork stimulation device |
US9795503B2 (en) | 2013-10-18 | 2017-10-24 | Rodolfo Alfredo PEREZ GROSSMANN | Method and apparatus for trabeculectomy and suprachoroidal shunt surgery |
BR122020011777B1 (en) | 2013-11-14 | 2022-01-25 | AqueSys, Inc | Insertion device for the treatment of glaucoma |
US10137034B2 (en) | 2013-11-26 | 2018-11-27 | Novartis Ag | Pressure-sensing vitrectomy surgical systems and methods |
JP6546194B2 (en) | 2013-12-06 | 2019-07-17 | アラーガン、インコーポレイテッドAllergan,Incorporated | Anterior chamber implant for treating ocular conditions |
US9289123B2 (en) | 2013-12-16 | 2016-03-22 | Verily Life Sciences Llc | Contact lens for measuring intraocular pressure |
EP3060180A4 (en) | 2014-02-24 | 2017-09-13 | National University of Singapore | An ocular drainage device and method of manufacturing thereof |
EP3677229A1 (en) | 2014-05-29 | 2020-07-08 | Glaukos Corporation | Implants with controlled drug delivery features |
DE102014212457A1 (en) | 2014-06-27 | 2015-12-31 | Implandata Ophthalmic Products Gmbh | Implant for the determination of intraocular pressure |
US10213107B2 (en) | 2014-07-01 | 2019-02-26 | Injectsense, Inc. | Methods and devices for implantation of intraocular pressure sensors |
US10709547B2 (en) | 2014-07-14 | 2020-07-14 | Ivantis, Inc. | Ocular implant delivery system and method |
US20170251921A1 (en) | 2014-10-20 | 2017-09-07 | The Regents Of The University Of California | Optical intraocular sensor and sensing method |
EP3270765B1 (en) | 2015-03-20 | 2020-05-06 | Glaukos Corporation | Gonioscopic devices |
ES2962607T3 (en) | 2015-08-14 | 2024-03-20 | Alcon Inc | Eye implant with pressure sensor |
WO2017030902A2 (en) | 2015-08-14 | 2017-02-23 | Camras Vision Inc. | Apparatus and method for reducing intraocular pressure |
WO2017062347A1 (en) | 2015-10-05 | 2017-04-13 | Massachusetts Eye And Ear Infirmary | Measurement of intraocular pressure |
KR20170058811A (en) | 2015-11-19 | 2017-05-29 | 글라우코스 코포레이션 | Delivery device systems and implants for treating glaucoma |
WO2017095825A1 (en) | 2015-11-30 | 2017-06-08 | California Institute Of Technology | System and method for measuring intraocular pressure |
WO2017106517A1 (en) | 2015-12-15 | 2017-06-22 | Ivantis, Inc. | Ocular implant and delivery system |
US20170209045A1 (en) | 2016-01-26 | 2017-07-27 | California Institute Of Technology | System and method for intraocular pressure sensing |
US20190038463A1 (en) | 2016-01-28 | 2019-02-07 | Aq Biomed, Llc | Ophthalamic implant for reduction of intraocular pressure in glaucomatous eyes and method of use |
CA3202776A1 (en) | 2021-01-11 | 2022-07-14 | Wayne A. Noda | Systems and methods for viscoelastic delivery |
-
2016
- 2016-02-01 US US15/012,544 patent/US20170360609A9/en not_active Abandoned
-
2019
- 2019-08-27 US US16/552,211 patent/US11744734B2/en active Active
-
2020
- 2020-03-24 US US16/828,054 patent/US12016796B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6494857B1 (en) * | 1998-09-02 | 2002-12-17 | Thomas Neuhann | Device for improving in a targeted manner and/or permanently ensuring the ability of the aqueous humor to pass through the trabecular meshwork |
US20090082860A1 (en) * | 2007-09-24 | 2009-03-26 | Schieber Andrew T | Ocular Implants with Asymmetric Flexibility |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11389328B2 (en) | 2006-06-26 | 2022-07-19 | Sight Sciences, Inc. | Intraocular implants and methods and kits therefor |
US11865041B2 (en) | 2006-06-26 | 2024-01-09 | Sight Sciences, Inc. | Intraocular implants and methods and kits therefor |
US10314742B2 (en) | 2006-06-26 | 2019-06-11 | Sight Sciences, Inc. | Intraocular implants and methods and kits therefor |
US10398597B2 (en) | 2006-06-26 | 2019-09-03 | Sight Sciences, Inc. | Intraocular implants and methods and kits therefor |
US10537474B2 (en) | 2008-03-05 | 2020-01-21 | Ivantis, Inc. | Methods and apparatus for treating glaucoma |
US11918514B2 (en) | 2009-07-09 | 2024-03-05 | Alcon Inc. | Single operator device for delivering an ocular implant |
US10492949B2 (en) | 2009-07-09 | 2019-12-03 | Ivantis, Inc. | Single operator device for delivering an ocular implant |
US11166847B2 (en) | 2010-02-05 | 2021-11-09 | Sight Sciences, Inc. | Intraocular implants and related kits and methods |
US10406030B2 (en) | 2010-02-05 | 2019-09-10 | Sight Sciences, Inc. | Intraocular implants and related kits and methods |
US10363168B2 (en) | 2011-06-14 | 2019-07-30 | Ivantis, Inc. | Ocular implants for delivery into the eye |
US11135088B2 (en) | 2011-12-19 | 2021-10-05 | Ivantis Inc. | Delivering ocular implants into the eye |
US9931243B2 (en) | 2011-12-19 | 2018-04-03 | Ivantis, Inc. | Delivering ocular implants into the eye |
US11116660B2 (en) | 2012-03-20 | 2021-09-14 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US10857027B2 (en) | 2012-03-20 | 2020-12-08 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US10888453B2 (en) | 2012-03-20 | 2021-01-12 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US10179066B2 (en) | 2012-03-20 | 2019-01-15 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US9855167B2 (en) | 2012-03-20 | 2018-01-02 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US11951037B2 (en) | 2012-03-20 | 2024-04-09 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US11617679B2 (en) | 2012-03-20 | 2023-04-04 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US11344447B2 (en) | 2012-03-20 | 2022-05-31 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US11389327B2 (en) | 2012-03-20 | 2022-07-19 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US9895258B2 (en) | 2012-03-20 | 2018-02-20 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US11471324B2 (en) | 2012-03-20 | 2022-10-18 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US11712369B2 (en) | 2012-11-28 | 2023-08-01 | Alcon Inc. | Apparatus for delivering ocular implants into an anterior chamber of the eye |
US10709547B2 (en) | 2014-07-14 | 2020-07-14 | Ivantis, Inc. | Ocular implant delivery system and method |
US11090188B2 (en) | 2015-03-31 | 2021-08-17 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US11872158B2 (en) | 2015-03-31 | 2024-01-16 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US10299958B2 (en) | 2015-03-31 | 2019-05-28 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US11826283B2 (en) * | 2017-08-03 | 2023-11-28 | Carl Zeiss Meditec Ag | Apparatus for influencing an intraocular pressure |
US20200170839A1 (en) * | 2017-08-03 | 2020-06-04 | Carl Zeiss Meditec Ag | Apparatus for influencing an intraocular pressure |
WO2021007559A1 (en) * | 2019-07-10 | 2021-01-14 | Anand Doraiswamy | Eye stents and delivery systems |
US11504270B1 (en) | 2019-09-27 | 2022-11-22 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US11857460B2 (en) | 2019-09-27 | 2024-01-02 | Sight Sciences, Inc. | Ocular delivery systems and methods |
Also Published As
Publication number | Publication date |
---|---|
US20170360609A9 (en) | 2017-12-21 |
US20200222238A1 (en) | 2020-07-16 |
US12016796B2 (en) | 2024-06-25 |
US20190380874A1 (en) | 2019-12-19 |
US11744734B2 (en) | 2023-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US12016796B2 (en) | Methods and devices for increasing aqueous humor outflow | |
US11504275B2 (en) | Methods and apparatus for treating glaucoma | |
US9610196B2 (en) | Ocular implants with asymmetric flexibility | |
EP2649970B1 (en) | Ocular implants and methods | |
US9402767B2 (en) | Ocular implant architectures | |
EP2194941B1 (en) | Ocular implants | |
US9351874B2 (en) | Methods and apparatus for delivering ocular implants into the eye | |
US8337509B2 (en) | Methods and apparatus for delivering ocular implants into the eye | |
AU2016203606B2 (en) | Ocular implants and methods | |
AU2014200768B2 (en) | Ocular implants and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: IVANTIS, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EUTENEUER, CHARLES L.;REEL/FRAME:042791/0487 Effective date: 20080430 Owner name: IVANTIS, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SCHIEBER, ANDREW T.;REEL/FRAME:042791/0345 Effective date: 20160201 |
|
STCV | Information on status: appeal procedure |
Free format text: ON APPEAL -- AWAITING DECISION BY THE BOARD OF APPEALS |
|
STCV | Information on status: appeal procedure |
Free format text: BOARD OF APPEALS DECISION RENDERED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: AMENDMENT / ARGUMENT AFTER BOARD OF APPEALS DECISION |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |
|
AS | Assignment |
Owner name: ALCON INC., SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:IVANTIS, INC.;REEL/FRAME:061161/0697 Effective date: 20220719 |